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Abstract 
Phosphorylation mediated inactivation of PTEN leads to multiple malignancies with increased 
severity. However, the consequence of such inactivation on downstream functions of PTEN are poorly 
understood.  Therefore, the objective of my thesis is to ascertain the molecular mechanisms by which PTEN 
phosphorylation drives lung cancer. PTEN phosphorylation at the C-terminal serine/threonine cluster 
abrogates its tumor suppressor function. Despite the critical role of the PTEN C-tail in regulating its 
function, the crystal structure of the C-tail remains unknown. Using bioinformatics and structural analysis, 
I determined that the PTEN C-tail is an intrinsically disordered region and is a hot spot for post-translational 
modifications (particularly phosphorylation) and protein-protein interactions. Evolutionary analysis of 
PTEN and its interacting proteins revealed that the PTEN C-tail has only recently evolved to acquire the 
ability to engage in a myriad of protein-protein interactions, resulting in its versatile functions. 
Replacement of the PTEN C-tail serine/threonine residues with alanines generated an artificial 
mutant, PTEN-4A, which remained “phospho-deficient” and therefore constitutively active. Interestingly, 
PTEN-4A suppressed cell proliferation and migration to a greater extent than PTEN-WT. PTEN-4A 
preferentially localized to the nucleus where it suppressed E2F-mediated transcription of cell cycle genes. 
PTEN physically interacted with the E2F1 protein and at E2F1-binding sites on chromatin, a likely 
mechanism for its transcriptional function. Further, deletion analysis on various PTEN domains revealed 
that the C2 domain of PTEN is indispensable for suppression of E2F-related genes. Systematic 
transcriptional promoter-reporter assays identified disease-associated C2 domain mutations that lose their 
ability to suppress E2F-mediated transcription, supporting the concept that these mutations are oncogenic 
in patients. Consistent with my findings, I observed increased level of PTEN phosphorylation and reduced 
nuclear PTEN levels in lung cancer patient samples.  
 xix 
 
Further, to determine whether the enhanced growth-suppressive properties of PTEN-4A may be 
due to differential protein-protein interactions, I performed a comparative proteomic profiling of PTEN-
WT and PTEN-4A interactomes using the SILAC methodology. Galectin-1 was identified as a candidate 
protein that binds preferentially to PTEN-WT and inhibits its tumor suppressive function. Taken together, 
the various tumor suppressive mechanisms of PTEN-4A may be harnessed therapeutically as adjunctive 
cancer therapy. Use of small molecule inhibitors that hinder PTEN C-tail phosphorylation is a plausible 
approach to activate PTEN function to reduce tumor burden.   
 
 1 
  
 
 
 
Chapter 1: Introduction 
 
Note to Readers: Portions of this chapter have been previously published in “Uversky, V.N., Dave, V., 
Iakoucheva, L.M., Malaney, P., Metallo, S.J., Pathak, R.R., and Joerger, A.C. 2014. Pathological 
Unfoldomics of Uncontrolled Chaos: Intrinsically Disordered Proteins and Human Diseases. Chemical 
Reviews 114:6844-6879”, and has been included with permission from the publisher.  
 
Introduction to Lung Cancer 
 Lung cancer refers to tumors arising from the respiratory epithelium lining the bronchi, bronchioles 
and alveoli. In the United States, lung cancer is the second most frequently diagnosed cancer in men and 
women after prostate and breast cancer, respectively. However, lung cancer accounts for more deaths than 
any other cancer both in men and women. Approximately 160,000 Americans die of lung cancer each year 
and the number of deaths due to lung cancer is greater than that of breast, prostate, colon and pancreatic 
cancer combined (Figure 1.1) (1). Cigarette smoking is the greatest risk factor for the development of lung 
cancer (2). Other risk factors include exposure to secondhand smoke, asbestos, radon and heavy metals (3). 
The greatest challenge facing lung cancer therapy is early diagnosis.  In fact, only 16% of lung cancers are 
diagnosed at a local stage wherein the five-year survival rates are at 55% (1). Absence of symptoms in early 
stages of the disease and high cost of screening tests has precluded early diagnosis (4). Consequently, the 
overall five-year survival rate for lung cancer is at a dismal 17% (1).  It is estimated that by 2020 the annual 
economic burden for lung cancer will be at USD 15 billion (5).  
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Figure 1.1: Lung cancer is the Cancer with the Highest Mortality Rate in the US. Lung cancer causes 
more deaths than prostate, breast, pancreatic and colon cancer combined, in the US. 
 
Histological Subtypes of Lung Cancer 
 Histologically, lung cancer is divided into two subtypes: Non-small cell lung cancer (NSCLC) and 
Small cell lung cancer (SCLC), which forms the basis for therapy (Figure 1.2). NSCLC accounts for 85% 
of all lung cancers. Given the incidence of NSCLC, the present work will largely focus on this histological 
subtype. NSCLC is sub-divided into adenocarcinoma, squamous cell carcinoma and large cell carcinoma. 
Adenocarcinoma, which is rarely associated with smoking, originates in the peripheral lung (6). In contrast, 
squamous cell carcinoma has a centri-lobar  origin around the bronchi (6). Large cell carcinomas are usually 
poorly differentiated epithelial tumors that can neither be classified as squamous or adenocarcinomas (6). 
SCLC is the most aggressive lung cancer subtype, which is associated with smoking, and therefore 
originates at  the bronchus (6).  Consequently, the five-year survival rate for SCLC is at 5% compared to 
21% for NSCLC (1). Given the diverse location and histological characteristics of SCLC and NSCLC, 
treatment strategies differ.  
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Figure 1.2: Histological Subtypes of Lung Cancer. 
 
Treatment Strategies for Lung Cancer 
The lung tumor stage and histological subtype dictates treatment modality. Surgical resection is the 
method of choice in early stage NSCLC, in addition to chemotherapy/radiotherapy as required. For late 
stage NSCLC, where surgery is not feasible, multiple combinations of chemotherapy, targeted agents and 
immunotherapy are used (7). The choice of the targeted agent usually depends on the actionable molecular 
target observed in individual tumors, such as EGFR or ALK mutations (7). For SCLC, usual treatment 
regimens consist of a combination of chemotherapy and radiotherapy (8). Molecularly targeted therapy and 
immunomodulatory agents are increasingly used in the treatment of SCLC (9, 10).  
 
Genetic Landscape of Lung Tumors 
 Driver mutations are distinct in SCLC and NSCLC. Comprehensive genomic characterization of 
NSCLC has allowed for personalized molecular targeted therapy. However, the aggressive nature of SCLC 
has precluded surgical resection, thereby limiting genomic analysis and subsequent personalized therapy 
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for SCLC (11, 12). The most frequently inactivated genes in SCLC are tumor suppressors p53, RB and to 
a lesser extent PTEN, that are either lost or mutated (11, 13-17). Other mutations in Ras family regulators, 
chromatin modifying enzymes, SOX family members, receptor tyrosine kinases, DNA repair genes, PI3K 
and NOTCH pathways have been reported (11, 13). Driver mutations for NSCLC (specifically for 
adenocarcinomas) with their incidence rates are depicted in Figure 1.3 (7). 
 
 
Figure 1.3: Driver Mutations in Lung Adenocarcinomas. 
 
Role of PTEN in Lung Cancer 
 Phosphatase and Tensin Homolog (PTEN) is a tumor suppressor that negatively regulates the 
proliferative PI3K/AKT pathway (Figure 1.4) (18). PTEN is required for normal lung branching 
morphogenesis. Loss of PTEN in the lung epithelium is associated with hyperplastic lesions in the airways 
(19, 20). Cigarette smoking, which is a risk factor for lung cancer, reduces PTEN levels in the airways (21). 
Despite the critical role of PTEN in the lung, it is not frequently mutated in lung cancer. PTEN 
loss/inactivating mutations are seen in ~10% of SCLC and PTEN mutations are very rarely observed in  
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NSCLC (17). However, aberrant PI3K/AKT activity is almost ubiquitous in NSCLC tumors. The aberrant 
PI3K/AKT signaling may be attributed to loss of PTEN function due to loss of its expression/activity, which 
is frequently observed in 40-70% of NSCLC cases (22-27). Loss of PTEN function occurs via several 
genomic and non-genomic mechanisms, including promoter hypermethylation, miRNAs and post-
translational modifications (PTMs), as discussed below. Loss of PTEN expression in EGFR mutant 
adenocarcinomas renders them resistant to standard TKI therapy (28). Further, mutant KRAS enhances 
PTEN degradation at the protein level, accelerating oncogenesis (29). Given the clinical relevance of PTEN 
and the PI3K/AKT pathway in lung cancer therapy, my thesis focuses on elucidating the role of PTEN 
phosphorylation as a non-genomic mechanism of PTEN inactivation in lung cancer.   
 
Introduction to PTEN 
 The PTEN gene was independently discovered by two groups in 1997 while investigating 
chromosome 10q23, a chromosomal location that frequently showed loss of heterozygosity in advanced 
stage cancers. The gene was named MMAC (mutated in multiple advanced cancers) or PTEN (phosphatase 
and tension homolog deleted on chromosome 10). The protein product of the PTEN gene shared sequence 
homology with the protein tyrosine phosphatase (PTP) superfamily and a cytoskeletal protein tensin. 
Consequently, PTEN was characterized as a dual lipid and protein phosphatase which is a non-redundant 
negative regulator of the PI3K/AKT pathway (Figure 1.4) (30). The most extensively studied tumor 
suppressive function of PTEN is its lipid phosphatase activity. PTEN dephosphorylates the secondary 
messenger PIP3 to PIP2, thereby depleting cellular PIP3, which is critical for AKT activation. As a protein 
phosphatase, PTEN dephosphorylates several molecules such as FAK, CREB, RAB7 and IRS1 amongst 
others to regulate oncogenic signaling (31-34). PTEN also has several phosphatase-independent functions, 
particularly in the nucleus (35). Besides its role in cancer, PTEN signaling plays an important role in 
neurological diseases such as autism (36). 
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Figure 1.4: PTEN Inhibits the PI3K/AKT Pathway. PTEN is a non-redundant negative regulator of the 
PI3K/AKT pathway. PTEN, through its lipid phosphatase activity, dephosphorylates PIP3 to PIP2. The 
cellular depletion of PIP3 prevents AKT activation thereby inhibiting oncogenic signaling through the 
pathway. 
 
 Germline mutations in PTEN causes PTEN Hamartoma Tumor Syndrome (PHTS), increasing the 
susceptibility of incidence to breast, thyroid and endometrial cancer in carriers (37). Mutations in PTEN 
are also observed in Autism-Spectrum Diseases (ASD) (36). While in cancers, PTEN mutations are not 
frequent (38). However, several non-genomic mechanisms exert a tight control on PTEN levels/activity. 
Consequently, deregulated PTEN levels are often pathogenic (39). Indeed, experiments in PTEN 
hypomorphic mouse models that express different levels of PTEN show a tissue-specific sensitivity to 
tumor initiation and progression (40). For example, lymph nodes and mammary glands are sensitive to 
small decreases in PTEN expression; a 20% decrease in PTEN levels is sufficient to generate tumors. While 
other tissues, such as the prostate, require a more profound reduction of PTEN for tumor initiation to occur 
(40). These observations led to the development of the "continuum model of tumor suppression" to explain 
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the consequences of PTEN reduction in cancer. Unlike the two-hit hypothesis, wherein both alleles of a 
tumor suppressor gene must be inactivated to cause tumor initiation, the continuum model proposes that 
subtle changes in the tumor suppressor dosage may cause tumors without the loss/mutation of even one 
allele (40). PTEN level/activity is controlled via several non-genomic mechanisms that are often altered in 
diseases, warranting a thorough understanding of the non-genomic mechanisms regulating PTEN functions. 
To this end, my thesis focuses on phosphorylation as a molecular mechanism that inactivates PTEN in lung 
cancer. 
 
PTEN Structure 
PTEN consists of (a) the N-terminal phosphatidylinositol 4,5-bisphosphate (PIP2) binding module 
(PBM), which allows PTEN to anchor to the membrane (its site of action) via PIP2 molecules; (b) the dual-
specificity lipid and protein phosphatase domain (PD), which contains a conserved catalytic motif 
HCKAGKGR; (c) the C2 domain, consisting of positively charged residues that help PTEN to associate 
with phosphatidylserine residues in the plasma membrane; and (d) the C-terminal region (C-tail) 
(Figure 1.5), which regulates membrane association and stability via multiple phosphorylation events. The 
C-terminal tail also consists of a PDZ-binding domain (PDZ-bd) which helps PTEN to bind to several PDZ 
domain containing proteins. The three-dimensional structure and in-depth structural analysis of PTEN is 
presented in Chapter 2.  
 
 
Figure 1.5: PTEN domain structure. The PBM and C2D play a crucial role in the membrane recruitment 
of PTEN. The PD contains a dual protein and lipid phosphatase motif and is responsible for the catalytic 
activity of PTEN. The C-tail controls PTEN stability, activity and sub-cellular localization via 
phosphorylation and other PTMs. The PDZ-binding domain is part of the C-tail and helps PTEN form 
complexes with PDZ domain containing proteins. 
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PTEN Proteoforms 
 The PTEN gene and corresponding protein identified in 1997 is considered to be the canonical form 
of the protein consisting of 403 amino acids. Several translational isoforms of the PTEN protein have 
recently been identified. These PTEN isoforms are translated from the same mRNA, but from different 
upstream non-canonical initiation start codons, resulting in a different N-terminal extension for each 
isoform (41). These isoforms include: PTEN-L (173 amino acid extension), PTEN-M (146 amino acid 
extension), PTEN-N (131 amino acid extension) and PTEN-O (72 amino acid extension) (41). The PTEN-
M isoform is the most abundant alternate isoform of PTEN and retains the phosphatase activity of PTEN 
(41). PTEN-L, the longest PTEN proteoform, is a constitutively active phosphatase and has been shown to 
have secretory and cell penetrating properties, making it an attractive candidate for protein delivery to 
restore PTEN function in tumor cells (42-46). PTEN-L also localizes to the mitochondria where it regulates 
energy metabolism (47). PTEN-L levels were found to be reduced in breast cancer and renal cell carcinoma 
(42, 43). However, the feasibility of PTEN-L protein for therapy and functional relevance of the other 
PTEN isoforms in various diseases remain to be determined.  
 
PTEN Sub-cellular Localization 
 Most research on PTEN has focused on its lipid phosphatase activity at the plasma membrane. 
However recently, the role of PTEN in different sub-cellular localizations, other than the membrane, has 
been defined. PTEN has now emerged as a master regulator of the cell cycle and chromosomal stability in 
the nucleus. The nuclear import of PTEN and details on its nuclear functions are provided below. PTEN is 
also found in the endoplasmic reticulum (ER), mitochondria and mitochondria-associated membranes 
(MAMs) (48-51). In the mitochondria, PTEN regulates mitochondria-dependent apoptosis in the presence 
of reactive oxygen species (49, 51).  The PTEN-L isoform also localizes to the mitochondria where it 
regulates energy metabolism in a protein-phosphatase dependent manner (47). PTEN localizes to the ER 
and MAM where it regulates shuttling of Ca2+ ions from the ER to the mitochondria, thereby making the 
cell susceptible to Ca2+ mediated apoptosis (50). A recent paper by Naquib et al, demonstrates that a large 
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fraction of PTEN is bound to endosomes along microtubules in the cell and that PIP3 dephosphorylation 
occurs at the endosomes (52). This is in contrast to the classical model of PTEN activity wherein it localizes 
to the plasma membrane to antagonize PI3K/AKT signaling (52).  Further, the PTEN-L isoform is secreted 
and can re-enter adjacent cells (42). PTEN can also be exported outside the cells via exosomes (53, 54).  
 
Cellular PTEN Functions 
Cell Metabolism 
The use of transgenic mice carrying additional copies of PTEN have provided insight on how PTEN 
regulates metabolism via PI3K/AKT dependent and independent pathways (55). The PTEN overexpressing 
mice had improved insulin sensitivity compared to wild type mice while on a normal and high fat diet (56). 
The mice also showed reduced body weight, increased energy expenditure and reduced fat storage (55, 56). 
The increased energy expenditure could be attributed to an increase in mitochondrial oxidative 
phosphorylation and a simultaneous decrease in anaerobic glycolysis (anti-Warburg effect) (55, 56). The 
mice also had reduced glutamine uptake and metabolism (55). PTEN also controls lipid metabolism through 
a transcription factor MAF1 (57). In conclusion, PTEN mediated inhibition of glycolysis and glutaminolysis 
promotes a tumor-suppressive metabolic state. Further, its effect on energy expenditure and metabolism 
makes it an attractive therapeutic molecule for reducing obesity. 
 
Cell Polarity 
 PTEN regulates cell polarity via PIP3 dependent and independent mechanisms. The spatial 
organization of PIP2 in epithelial cells helps define the apical and basolateral surfaces (58). PTEN 
preferentially localizes to the apical surface, enriching the local PIP2 levels. This helps recruit annexin2, 
CDC42 and the Par/aPKC complex, which leads to lumen formation and the establishment of polarity (59, 
60). Therefore, loss of PTEN may disrupt the development of the apical surface and lumen leading to loss 
of epithelial characteristics. This may cause the cells to switch to a more invasive mesenchymal phenotype 
which is a hallmark of Epithelial-Mesenchymal Transition (EMT) (35, 38). PTEN interacts with several 
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PDZ containing proteins such as MAGI1b and PAR3 to regulate the formation of junctional complexes (61, 
62). 
 PTEN also plays a role in regulating planar cell polarity by regulating ciliogenesis in the trachea 
and ependyma. Dishevelled, when phosphorylated, promotes cilia disassembly (63). PTEN, thorough its 
protein phosphatase activity, maintains Dishevelled in a hypophosphorylated state, thereby regulating 
ciliary homeostasis (63). Consequently, aberrant ciliary function is observed in PHTS and autism, two 
diseases that are associated with PTEN mutations (63-65).  
 
Cancer Stem Cells 
PTEN plays a role in regulating cancer and normal stem cell function in various organs such as the 
bone marrow, intestine, brain and the lung. PTEN deletion within the lung epithelium of mice causes an 
increase in bronchioalveolar stem cells (BASCs) and pulmonary neuroendocrine cell hyperplasia, which 
are the precursors for lung adenocarcinomas and SCLC respectively (19, 20, 66). BMI1 is an oncogene that 
increases the self-renewal and numbers of BASCs and lung cancer stem cells (67). PTEN, through its 
inhibitory effects on BMI1, could potentially control the stem cell population in the adult lung (68). Within 
the bone marrow, PTEN regulates the function of adult  hematopoietic stem cells (HSCs) to ensure normal 
hematopoiesis and also prevents the generation of Leukemia Initiating Cells (LICs) that lead to the 
development of neoplasms (69, 70). In the brain, PTEN depletion causes an oncogenic transformation of 
human neural stem cells (NSCs) into glioblastoma stem-cells that give rise to aggressive intracranial tumors 
(71). In the intestine, PTEN is required for maintaining the dormant intestinal stem cells and also plays a 
role in stem cell regeneration after intestinal injury, such as that caused by radiation therapy (72). PTEN is 
also required to limit the cancer stem cell population in cutaneous squamous cell carcinomas (73).  
 
Nuclear PTEN Functions 
For several years after its discovery, most research efforts were focused on the function of PTEN 
at the plasma membrane. However, research over the last decade has uncovered several novel nuclear roles 
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of PTEN, most of which are independent of its lipid phosphatase activity. The functions of PTEN in the 
nucleus have been subdivided as follows. 
 
PTEN and Chromosomal Stability 
 PTEN plays an important role in regulating chromosomal integrity and DNA damage repair. The 
PTEN C-tail associates with a centromere protein called CENP-C to regulate centromeric stability. 
Consequently, loss of PTEN results in centromere breakage and instability (74). Further, transgenic mice 
that lack the PTEN C-tail region develop multiple spontaneous benign and malignant tumors (75). 
PTEN also plays a critical role in regulating DNA damage repair. PTEN loss results in spontaneous 
double-stranded breaks (DSBs). Upon exposure to DNA damaging agents, PTEN interacts with chromatin 
to regulate Rad51 and Rad52 expression to facilitate DNA damage repair (74, 76). ATM mediated PTEN 
phosphorylation also plays a role in the DNA damage response (77). PTEN is required for nucleotide 
excision repair upon DNA damage due to UVB exposure. PTEN positively regulates DNA repair by 
increasing the transcription of a key nucleotide excision repair protein XPC (Xeroderma pigmentosum C) 
(78).  
Several recent papers have also highlighted the function of PTEN in efficient DNA replication. 
DNA often forms catenated duplexes at the end of replication in the G2 phases of the cell cycle. Improper 
decatenation delays the entry of cells into the M phase of the cell cycle and often results in chromosomal 
instability, a hallmark of cancer cells. PTEN regulates efficient DNA decatenation by physically associating 
with and stabilizing the decatenation enzyme DNA topoisomerase II (TOP2A). In contrast, PTEN deficient 
cells show several decatenation defects resulting in the formation of ultra-fine bridges in cells during 
anaphase (79). PTEN also associates with replication fork components to regulate the DNA replication 
process. DNA is most susceptible to breakage during the S phase of the cell cycle and several factors such 
as nucleotide deficiency and insufficient replication enzymes can cause replication stress. Under replication 
stress conditions, PTEN associates with and dephosphorylates a replication protein called MCM2 which 
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restricts replication fork progression thereby avoiding DNA replication defects and chromosomal instability 
(80).  
 
Transcriptional Functions of PTEN 
 While it is not very clear whether PTEN can directly bind to DNA, it is associated with multiple 
protein complexes comprising of several transcription factors, histones and chromatin remodelers to 
regulate transcription in the nucleus (31, 81-83). PTEN, through its protein phosphatase activity, 
dephosphorylates the transcription factor CREB and inhibits the transcription of CREB targets, thereby 
controlling cell proliferation (31). PTEN also inhibits the nuclear translocation and transcriptional activities 
of β-catenin in a caveolin-1 dependent manner to restrict cellular senescence bypass and metastasis (84). 
Chromatin remodeling factor BMI1 increases hTERT activity and reduces the expression of tumor 
suppressors p16INK4A and p14ARF. PTEN binds to BMI1 in a phosphatase independent manner and restrains 
its nuclear function (82). PTEN represses colon cancer progression by restricting paxillin transcription via 
inhibition of the transcription factor NFκB in a PI3K/AKT dependent manner (85). PTEN binds to and 
enhances the stability, DNA binding and hence transcriptional activity of p53 via phosphatase dependent 
and independent mechanisms (86). PTEN also regulates the transcription of several other genes that control 
functions other than those involved in oncogenesis. PTEN physically binds to the SRF transcription factor 
and at SRF responsive elements on chromatin to regulate smooth muscle cell differentiation (83). PTEN, 
through its protein phosphatase activity, positively regulates the function of the transcription factor MTF1 
in response to metal and oxidative stress (87). PTEN activates the transcription factor MAF1 to regulate 
lipid metabolism (57). Finally, at the global genomic level PTEN represses the transcription of RNA Pol 
III genes via its suppression of mTOR (88) and controls chromatin condensation by interacting with histone 
H1 (81). 
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Cell Cycle 
PTEN regulates several aspects of the cell cycle via AKT dependent and independent mechanisms 
(18, 89). PTEN enhances the E3 ligase activity of the APC/CDH1 complex which causes the proteasomal 
degradation of several cell cycle mediators, such as Cyclin A2, Cyclin B1, PLK1, Geminin and Aurora A 
through a phosphatase-independent mechanism (90). PTEN specifically inhibits the cell cycle at the G1/S 
and the G2/M transitions. RB is an important tumor suppressor that regulates transition through the G1 
phase of the cell cycle. PTEN therefore inhibits the G1 phase of the cell cycle by targeting molecules that 
inactivate RB. PTEN is known to inhibit Cyclin D1, Cyclin D3 and Cyclin E/CDK2 activity thereby leading 
to RB hypophosphorylation and activation (91-98). PTEN also increases the level of G1 phase cell cycle 
inhibitors p16, p21 and p27. Phosphorylation of PTEN contributes to its effect on the G2/M phase of the 
cell cycle. Dephosphorylated PTEN induces prometaphase arrest by interacting with and enhancing the 
nuclear retention of the Cyclin B1/CDK1 complex (99). Further, PTEN when phosphorylated at Ser380 by 
Plk1 associates with chromatin and is required for progression of cells through the mitotic phase. 
Consequently, a PTEN phosphorylation-deficient mutant causes mitotic exit (100). The effect of PTEN 
phosphorylation on the G1 phase of the cell cycle is however not known. Therefore, Chapter 3 of my thesis 
elucidates the effect of PTEN phosphorylation on the transcription of E2F1-regulated genes in the G1 phase 
of the cell cycle.  
 
PTEN Regulation 
Genomic Mechanisms 
PTEN Gene Mutations 
 Except for exon 9, which encodes the PTEN C-tail (101), PTEN mutations span the entire gene 
(Figure 1.6A). Complete allelic deletions of the PTEN gene and mutations in the PTEN promoter also occur 
frequently (102). 
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Epigenetic Regulation 
 The levels of PTEN are regulated by epigenetic modifications at the PTEN promoter level. 
Methylation of the PTEN promoter prevents transcription of its mRNA and results in reduced PTEN protein 
levels (Figure 1.6B). Hyper-methylation of the PTEN promoter, associated with reduction in PTEN 
expression, is frequently observed in several types of cancers (102), including lung cancer (103), indicating 
that PTEN deficiency either drives or exacerbates cancer phenotype.  
 
Transcriptional Regulation 
 PTEN expression is regulated by several transcription factors (35, 104) (Figure 1.6C). SALL4, 
SNAIL, ID1, EVI1, BMI1, c-JUN, PML/RARα, HES1, SLUG and SOX2 repress PTEN transcription, 
either directly or indirectly, by competitively preventing the binding of transcriptional activators to the 
PTEN promoter (35, 68, 105-113). Mitogen-activated protein kinase kinase-4 (MKK4), 17β-estradiol and 
insulin-like growth factor 1 (IGF1) suppress PTEN transcription via the NF-kB transcription factor (114-
116), while transforming growth factor beta (TGF-β) suppresses PTEN transcription by recruiting the 
SMAD transcription factors (104, 114, 117). OCT4 suppresses PTEN transcription through Sp1 and a high 
OCT4, low PTEN signature is associated with poor prognosis in lung cancer patients (118). JARID1B and 
Ataxin3 inhibit PTEN transcription by modulating histone modifications at the PTEN promoter (119, 120). 
Several of these inhibitory transcription factors are dysregulated in cancers, highlighting down-regulation 
of PTEN as a critical step in oncogenic cellular transformations (35). EGR1, IGF2, PPARγ, p53, SPRY2, 
CBF1, MAF1, TET1 and resistin, a cytokine, increase PTEN expression at the RNA level (121-129). 
Several naturally occurring compounds like phytoestrogens (found in soy), resveratrol (in red wine), 
quercetin and indole 3-carbinol (in broccoli) upregulate PTEN mRNA expression (104, 130-132) and have 
potential for use as chemo-preventive agents.  
 
 
 
 15 
  
Regulation of PTEN mRNA Levels via non-coding RNAs 
 Several non-coding RNAs, including microRNAs (miRNAs) regulate transcription of the PTEN 
gene (Figure 1.6D). miRNAs regulate PTEN expression and are frequently altered in cancers, autoimmune 
disorders, cardiovascular and metabolic diseases (35, 133).  These include miR-17~92, miR-19, miR-19b, 
miR-21, miR-22, miR-23b, miR-26a, miR-29b, miR-92a, miR-106b~25, miR-155, miR-214, miR-216a, 
miR-217, miR-221, miR-222, miR-301, miR-486, and miR494 amongst others (35, 133-148). In fact, 
several oncogenic molecules upregulate miRNA  expression to keep a check on cellular PTEN protein 
levels during tumorigenesis (35). 
 The PTENP1 pseudogene protects PTEN mRNA from miRNA inhibitory effects (Figure 1.6D). 
PTENP1 mRNA shares sequence homology with PTEN mRNA and therefore acts as a decoy by 
sequestering all miRNAs that suppress PTEN function (35, 149). Consistent with the role of PTENP1 in 
regulating PTEN expression levels, loss of PTENP1 is observed in breast and colon cancers (35, 149). 
 
Non-genomic Mechanisms 
Sub-cellular Localization of PTEN 
 PTEN localizes to several sub-cellular compartments, including the plasma membrane, cytosol, 
nucleus, mitochondria, MAMs, ER and exosomes. Cytosolic and membrane localization of PTEN is 
dictated by phosphorylation modifications in its C-tail region. Several PTEN-binding proteins, such as 
MAGI2, MAGI3, myosin V, caveolin, and MEK1, enhance its membrane binding (35, 150, 151).  
 PTEN lacks a canonical nuclear localization sequence. However, several nuclear transporters 
and post-translational modifications control its nuclear import. MVP, RAN, Importin α3 and Importin11 
are some of the known nuclear transporters for PTEN (152-155).Nuclear localization of PTEN is dictated 
by monoubiquitination modifications at residues Lys13 and Lys289 by the E3 ligase NEDD4-1 (104). 
Lysine residues, Lys13 and Lys289, are frequently mutated in Cowden syndrome, resulting in the nuclear 
exclusion of PTEN. Given the disease-associated aberrations in PTEN nuclear import and localization, 
nuclear PTEN levels have potential prognostic value in disease progression (35). Nuclear translocation of  
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Figure 1.6: Genomic Mechanisms of PTEN Regulation. (A) With the exception of Exon 9, which 
encodes for the PTEN C-tail, mutations occur along the entire length of the PTEN gene. (B) Promoter 
hypermethylation reduces transcription of the PTEN gene. (C) Several molecules increase PTEN 
transcription by directly interacting with the PTEN promoter or through histone modifications at the PTEN 
promoter. (D) PTEN mRNA levels are reduced by several miRNAs. PTENP1 is a PTEN pseudogene that 
acts as a sponge and scavenges PTEN targeting miRNA. Adapted with permission from Uversky et al, 
Copyright 2014 American Chemical Society (156). 
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PTEN by the E3 ligase XIAP and CHIP is less clear (157, 158). Monoubiquitinated cytoplasmic PTEN has 
several possible fates within the cell. Monoubiquitinated PTEN may be further ubiquitinated for 
proteasomal targeting and degradation, or it can shuttle between the nucleus and the cytoplasm or be 
deubiquitinated and exported from the nucleus (104). HAUSP (herpesvirus-associated ubiquitin-specific 
protease) deubiquitinates and exports PTEN from the nucleus. HAUSP overexpression is frequently seen 
in cancer (35). p63 is a transcription factor that belongs to the p53 gene family. A p63 splice variant, 
ΔNp63α, inhibits the nuclear translocation of PTEN by inhibiting NEDD4-mediated monoubiquitination 
of PTEN (159). In neurons, stimulation through the NMDA receptor causes PTEN Lys13 
monoubiquitination resulting in nuclear translocation (160). Ndfip1 and Rab5 enhance NEDD4-1 mediated 
PTEN ubiquitination resulting in its nuclear localization (161, 162). 
 PTEN sumoylation at Lys254 is required for its nuclear translocation and retention, an event 
that is dependent on PTEN phosphorylation by protein kinase ATM (163). Genotoxic stress and DNA 
damaging agents cause nuclear export of sumoylated PTEN (163), while oxidative stress inhibits nuclear 
export. PNUTS is an oncogene that allows tumor proliferation by sequestering PTEN in the nucleus. 
PNUTS-mediated nuclear localization of PTEN is independent of monoubiquitination (164).  
 Under conditions of oxidative stress, S6K phosphorylates PTEN at Ser380, which enhances its 
interaction with the deubiquitinase USP7 in the nucleus, leading to its nuclear export (165). In contrast, 
phosphorylation of Ser380 by Plk1 causes its association with chromatin which is required for the cell to 
progress through the M phase of the cell cycle (100). Dephosphorylation of PTEN at the serine/threonine 
cluster in its C-tail region allows for ubiquitination at Lys13 resulting in nuclear localization (166). Upon 
DNA damage, ATM phosphorylates PTEN at Ser113 which causes its nuclear localization (77).  
 Several other cellular cues and proteins regulate PTEN nuclear transport. For instance, 
sphingosine-1 phosphatase signaling promotes the nuclear export of PTEN by enhancing its association 
with a nuclear export protein Crm1 (167). Low cellular levels of ATP are also known to enhance PTEN 
nuclear accumulation (168). Taken together, several factors alter PTEN sub-cellular localization and PTEN 
mislocalization could potentially be pathogenic. 
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Degradation and Turnover of PTEN 
 Proteasomal degradation of PTEN is mediated via polyubiquitination catalyzed by E3 ligases 
NEDD4, XIAP, WWP2, MKRN1 and CHIP (Figure 1.7A). Upregulation of NEDD4 is observed in lung 
and breast cancer tissue samples and correlates inversely with PTEN protein levels (157). p34SE-1 
increases NEDD4 expression at both the mRNA and protein level, resulting in increased degradation of 
PTEN (169). NEDD4 mediated degradation of PTEN is inhibited by Rak through phosphorylation at 
Tyr336. Consistent with the role of Rak in regulating PTEN stability, loss of heterozygosity of the Rak 
gene has been observed in breast cancers (157). Similarly, the levels of CHIP negatively correlate with 
PTEN levels in human prostate cancer samples (158). Recently, Lys66 was found to be a major 
ubiquitylation site in PTEN that dominates over all other ubiquitylation sites in regulating PTEN stability 
(170). Several molecules such as TNSK1, TNKS2, NDFIP1, NDFIP2 affect PTEN ubiquitination and 
therefore affect its proteasomal degradation (171, 172). p53 is also known to reduce PTEN stability in 
cases of cellular proteasome dysfunction (173).  
 
Post-Translational Modifications (PTMs) 
 A variety of PTMs, including phosphorylation, ubiquitination, acetylation and oxidation, 
modulate PTEN activity (Figure 1.7B). Some of these regulatory PTMs are described below. 
 
Phosphorylation of PTEN 
 Phosphorylation is the major PTM that regulates PTEN activity and stability (Figure 1.8A and 
B). PTEN phosphorylation in the C2-domain and the C-terminal tail involves serine, threonine and tyrosine 
residues. Approximately 50% of phosphorylation modifications are clustered in the C-tail region. Casein 
kinase II phosphorylates Ser370, Ser380, Thr382, Thr383 and Ser385, increasing PTEN stability but 
decreasing its activity (discussed below) (174, 175). Ser380 is also phosphorylated by S6K under conditions 
of oxidative stress, resulting in the nuclear exclusion of PTEN (176). Ser362, Thr366 and Ser370 are 
phosphorylated by glycogen synthase kinase 3-beta (GSK3-β) (174, 177, 178). In addition, Plk3 
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Figure 1.7: Non-genomic mechanisms of PTEN regulation. (A) Several E3 ligases polyubiquitinate 
PTEN resulting in its proteasomal degradation. (B) PTEN function is heavily regulated by various post-
translational modifications. Adapted with permission from Uversky et al, Copyright 2014 American 
Chemical Society (156). 
 
phosphorylates PTEN at Thr366 and Ser370 (179). ATM phosphorylates PTEN at Ser113 and Thr398 to 
regulate the nuclear transport of PTEN (77, 163). Plk1 phosphorylates PTEN at Ser380, Thr382 and Thr383 
and the Ser380 phosphorylation event is critical for chromatin localization of PTEN during the M phase of 
the cell cycle (100). Plk1 can also phosphorylate PTEN at Ser385, which inhibits its polyubiquination but 
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decreases its catalytic activity. Phosphorylation of Ser385 by Plk1 also reduces PTEN monoubiquitination, 
thereby reducing its nuclear accumulation (180). PICT-1 enhances phosphorylation of PTEN at Ser380, 
thereby protecting it from degradation (174, 181). 
 
 
 
Figure 1.8: Phosphorylation as an Inactivation Mechanism for PTEN. (A) The PTEN protein, 
particularly the PTEN C-tail, undergoes several phosphorylation modifications. (B) Phosphorylation 
regulates the conformation of PTEN. PTEN when phosphorylated is present in its closed, inactive 
conformation wherein the C-tail occludes the PD and C2D. Upon dephosphorylation, PTEN adopts a more 
open conformation resulting in its membrane localization and activation. 
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 RhoA-associated protein kinase (ROCK) phosphorylates PTEN at Thr223, Ser229, T319 and 
T321, thereby modulating its intracellular localization during cell migration and chemotaxis (35, 182). A 
tyrosine kinase, Rak, phosphorylates PTEN on Tyr336 and down regulates ubiquitination by the E3 ligase 
NEDD4-1 (35, 183). Src kinase phosphorylates PTEN at Tyr240, Tyr336 and Tyr315. Phosphorylation at 
these sites upregulates the PI3K pathway through destabilization of PTEN (174, 184). IRβ physically binds 
to and phosphorylates PTEN at Tyr27 and Tyr174 (185). Therefore, the stability of PTEN is controlled 
differentially by the cytoplasmic level of various kinases involved in its phosphorylation.  
 Various cytokines and physiological stimuli also regulate PTEN phosphorylation. Leptin and 
TGF-β enhances phosphorylation at Ser380, Thr382, and Thr383 (174, 186, 187), while prostaglandin E2 
(PGE2) inhibits PTEN activity through phosphorylation at unknown serine residues (188). Estrogen 
signaling inactivates PTEN via phosphorylation to allow for oncogenic proliferation on endometrial cancer 
cells (189). Tissue ischemia alters PTEN phosphorylation, causing its inactivation and triggering a pro-
survival response via the PI3K/AKT pathway (174, 190).  H. pylori infection in the gut phosphorylates 
PTEN at Ser380, Thr382, Thr383 and inactivates it thereby promoting gastric cell survival (191). PTEN is 
also phosphorylated in intestinal stem cells upon nutrient deprivation to allow for a regenerative response 
(72).  
 Phosphorylation events at Ser380, Thr382, Thr383 and Ser385 within the PTEN C-tail region 
regulate PTEN activity and stability (Figure 1.8B). Upon phosphorylation, the C-tail folds onto the PTEN 
molecule and produces a “closed” conformation (192-194). Due to occlusion of its membrane-binding C2 
domain, the closed-form of PTEN shows reduced membrane binding and hence reduced phosphatase 
activity. However, the “closed” conformation of PTEN represents a more stable form of the protein (193-
195). Dephosphorylation of the aforementioned serine-threonine cluster induces the “open” conformation, 
which has greater membrane binding affinity and PIP3 phosphatase activity, albeit lower stability (193-
195). Therefore, phosphorylation at the PTEN C-tail cluster represents an inactivation mechanism which is 
the main focus of my thesis. 
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Acetylation of PTEN 
 PCAF, a histone acetyltransferase protein (HAT), acetylates PTEN at Lys125 and Lys128. 
Acetylation interferes with PTEN phosphatase activity because the modified residues are located within the 
catalytic cleft, which results in increased PI3K activity (174, 196). CBP acetyltransferase acetylates PTEN 
at Lys402, increasing its interaction with the PDZ-domain containing protein MAGI-2, which results in 
increased translocation of PTEN to cell junctions (174, 197). In the presence of HDAC inhibitors, PTEN is 
found to be acetylated at Lys163, a modification which reduces the PTEN tail body interaction causing its 
membrane translocation (198).  
 
Ubiquitination of PTEN 
 Mono- and polyubiquitination of PTEN causes nuclear translocation and proteasomal 
degradation, respectively. E3 ligases that cause proteasomal degradation of PTEN have been discussed 
above. RFP is a newly identified PTEN E3 ligase responsible for atypical polyubquitination of PTEN at 
multiple lysine residues within the C2 domain (199), inhibiting its phosphatase activity and thereby 
potentiating PI3K activity (199). K27-linked polyubiquitination of PTEN at Lys342 and Lys344 does not 
affect PTEN protein stability but suppresses its dimerization (200, 201).  
 
Oxidation and S-nitrosylation of PTEN 
 Oxidative stress inactivates PTEN by forming a disulfide bridge (between Cys71 and Cys124) 
within its catalytic pocket (202). PTEN shields itself from oxidative inactivation through a peroxidase 
enzyme called peroxiredoxin (174, 203), while thioredoxin regenerates catalytically active PTEN once it 
has been oxidized (204). S-nitrosylation of PTEN occurs at residues Cys83, Cys71 and Cys124, enhancing 
its degradation via ubiquitination (174, 205). Nitrosylation of PTEN is observed in early Alzheimer’s 
disease and animal models of cerebral ischemia (174).  
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Other PTEN Post-Translational Modifications 
 PTEN also undergoes sumoylation, ribosylation and lysine methylation. While ribosylation and 
methylation inhibit PTEN function, sumoylation is involved in the nuclear translocation of PTEN (163, 
172, 206). PTEN methylation at Lys349 regulates its role in DNA damage repair (207). 
 
Protein-Protein Interactions of PTEN 
 PTEN interacts with a number of proteins to control various cellular functions. A list of PTEN 
interacting proteins with their associated functions is presented in Table 1.1.  
 
Table 1.1: Protein Interacting Partners of PTEN. 
Function  Proteins involved  References 
     
Enhance PTEN activity, Prevent 
PTEN inactivation 
S1PR2, TLR4, AIF, ARR1, ARR2, , 
NDRG2, p85, PRDX, TRDX, 
p110α, p110β, NEP, TOB1 
(48, 208‐219) 
Inhibitors of PTEN activity  DJ‐1, MAN2C1, SMYD2, PLK1, 
CK2, TIMAP, ARR1, ARR2, PCAF, 
PNUTS, PREX2, RFP, SIPL1, 
TRDX, ER, IRβ 
(100, 164, 175, 189, 196, 199, 
206, 211, 220‐226) 
Enhance PTEN degradation  HSP70, HSP90, CHIP, TNKS1, 
TNKS2, WWP2, NEDD4‐1, 
MKRN1, NDFIP1, NDFIP2, XIAP, 
p53 
(158, 171‐173, 227‐230) 
Reduce PTEN degradation  UBC9, UBCH7, MC1R, 
USP13,CK2, PLK1, PICT1, 
MAGI2, NHERF1, p85, RAK, 
PFN1 
(100, 175, 181, 183, 215, 222, 
231‐237) 
PTEN membrane localization  NEP, CAV1, MAGI1, MAGI2, 
MAGI3, MYO5A, MYO5B, 
MYO5C, MEK, SUMO1, SUMO2, 
NHERF1, p85 
(61, 150, 151, 208, 215, 231, 
238‐244) 
PTEN nuclear localization  PLK1, CHIP, MVP, NEDD4‐1, 
NDFIP1, Crm, XIAP, USP7 
(100, 152, 158, 161, 222, 228, 
230, 245‐247) 
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Table 1.1 (continued): Protein Interacting Partners of PTEN. 
Function  Proteins involved  References 
     
Functions in the nucleus   APC3, APC4, APC5, APC7, AR, 
BMI1, CCNB1, CDH1, CDK1, 
CENPC, DLG1, EG5, H1, MTF1, 
p53, TOP2A, CREB, KLF4, 
MCM2, MYOCD, SRF, hnRNPC, 
HP1, RAD52, AKT, PLK1, p73, 
p300 
(31, 76, 79‐83, 86, 87, 90, 99, 
100, 222, 248‐257) 
Post‐translational modification 
of PTEN 
CK2, PLK1, SMDY2, CHIP, IRβ, 
MAST1, MAST2, MAST3, 
NEDD4‐1, PCAF, PICT1, RAK, 
RFP, SIPL1, STK11, TNKS1, 
TNKS2, WWP2, MKRN1, 
SUMO1, SUMO2, XIAP 
(100, 158, 172, 175, 181, 183, 
196, 199, 206, 222, 227‐230, 
232, 243, 244, 258, 259) 
Protein phosphatase substrates 
of PTEN 
Src, FAK1, RAB7, CREB, IRS1, 
KLF4, MCM2, DVL 
(31‐34, 63, 80, 253, 260‐262) 
Inhibition of oncogenic signaling 
pathways 
Cx43, EPHB1, MSP58, FAK1, 
AIB1, FBW7, MAGI1b, NHERF1, 
NHERF2, PDGFRβ, RAB7, 
SMAD2, SMAD3, EGFR, IRS1, 
NUDT16L1, PFN1, PXN, RNH1, 
Cbl, PREX2 
(32‐34, 61, 236, 260‐271) 
Neurological signaling  PSD95, HTR2C, DBN, DLG1, 
MAST2, MYO5A, MYO5B, 
MYO5C, NDFIP1 
(161, 241, 246, 247, 249, 250, 
272‐274) 
Miscellaneous  PTEN‐L, PAR3, IP3R, BAX, DVL, 
Cbl 
(47, 49, 50, 60, 63, 263, 275) 
Not known  FABP4, TFG, PTPN13, AFP, 
PPP1A,  CALU, IQGAP1 
(270, 276‐280) 
 
 
Summary  
 Lung cancer has the highest mortality rate amongst all cancers in the US. PTEN mutations do 
not occur very frequently in lung cancer. However, a large proportion of lung tumors have aberrantly 
activated PI3K/AKT signaling. This is attributed to several non-genomic mechanisms that down regulate 
PTEN expression/activity. Indeed, 40-70% of lung tumors show reduced PTEN expression. PTEN 
undergoes several PTMs that regulate its expression/activity levels. PTEN C-tail phosphorylation, a 
predominant modification of PTEN, plays an important role in regulating PTEN stability, sub-cellular 
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localization and catalytic activity.  Alterations in PTEN C-tail function could therefore potentially disrupt 
PTEN function. Consequently, my thesis focuses on the PTEN C-tail and how its phosphorylation serves 
as an inactivation mechanism for PTEN, particularly focusing on mechanisms driving lung cancer and 
interrogation of PTEN phosphorylation status in lung cancer patient samples. 
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CHAPTER 2: PTEN is an Intrinsically Disordered Protein 
 
Note to Readers: Portions of this chapter have been previously published in “Malaney, P., Pathak, R.R., 
Xue, B., Uversky, V.N., and Dave, V. 2013. Intrinsic disorder in PTEN and its interactome confers 
structural plasticity and functional versatility. Sci Rep 3:2035”, and has been included with permission from 
the publisher. 
 
Background 
 As discussed in chapter 1, the PTEN C-tail regulates the membrane localization, stability and 
catalytic activity of PTEN through various PTMs and PPIs. Despite the critical role of the C-tail in 
regulating PTEN function, its structure remains unknown. In this chapter, I have performed structural 
analyses on the PTEN C-tail to gain an insight into how it modulates PTEN function. 
 
Materials and Methods 
Disorder Analysis 
Disorder analysis for PTEN was  performed using the PONDR-FIT software (281). The software 
assigns a disorder score to each amino acid of the protein. Residues with disorder scores >0.5 were 
considered to be disordered.  
 
Compositional Analysis 
Compositional analysis for PTEN was performed using the Compositional Profiler Tool (282). 
Comparative analysis was performed for full-length PTEN, its ordered and disordered regions respectively. 
The analysis makes use of PDB Select 25 and DisProt as a database for ordered and disordered proteins, 
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respectively. Any change in amino acid levels for the query protein (i.e enrichment or depletion) over the 
average value (obtained from the databases) is expressed as (C-Corder)/Corder. C is the level of a particular 
amino acid in the query protein, which in this case is full-length PTEN, its ordered domain and the 
intrinsically disordered PTEN tail. Corder corresponds to the level of the same amino acid obtained from a 
database of ordered proteins (PDB Select 25). A similar profile for typical IDPs is obtained using the 
DisProt database.  
Further, a comparative compositional analysis was performed for the disordered and ordered 
regions of PTEN. Percentage frequency of a specific class of residues (i.e hydrophobic, polar, aromatic, 
structure breaking, cysteine and asparagine) is calculated for the ordered and disordered regions, 
respectively. The percentage frequency for the ordered region is calculated as ((No. of a given class of 
residues in the ordered region/Total number of amino acids in the ordered region) x 100). Similarly, the 
percentage frequencies are calculated for the disordered region.  
 
Mutational Analysis 
Mutation data for the PTEN protein was compiled from the Sanger Institute Catalogue of Somatic 
Mutations in Cancer (COSMIC). The number of observed mutations at every amino acid position is 
determined.  
In order to correlate the mutations in PTEN with its amino acid composition, I calculated the ratio 
of mutations in the different classes of residues used to define IDRs (hydrophobic, polar, aromatic, structure 
breaking, cysteine and asparagine) in the disordered vs ordered region. The ratio is calculated as: 
Ratio ൌ RdRo 
              Where, Rd is calculated as: 
Rd ൌ No. of	mutations	in	a	given	class	of	residue	in	the	disordered	regionNo. of	given	residues	in	disordered	region  
 
               Similarly, Ro is calculated as: 
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Ro ൌ No. of	mutations	in	a	given	class	of	residue	in	the	ordered	regionNo. of	given	residues	in	ordered	region  
 
Sequence Alignments for PTEN and its Interacting Proteins                                            
FASTA sequences for PTEN and its interacting proteins in various animal species were retrieved 
from UniProtKB. Sequence alignments were performed using Clustal Omega tool 
(http://www.ebi.ac.uk/Tools/msa/clustalo/). 
 
PTMs and PPIs of PTEN 
 PTMs and PPIs of PTEN were retrieved by a manual literature search. Only those proteins that are 
known to directly interact with specific PTEN domains are depicted. 
 
MoRF and ELM Prediction 
The MoRFPred algorithm (283) was used to identify MoRF regions within the PTEN protein, while 
the ELM software (284) was used to scan the PTEN protein for annotated ELMs.  
 
Results 
PTEN is an Intrinsically Disordered Protein 
Analysis of the two PTEN crystal structures deposited on PDB (1D5R, 5BZZ) revealed that only 
the structures of the PTEN phosphatase domain (PD) and membrane binding C2 domain (C2D) have been 
determined (Figure 2.1A and 2.1B). However, the structures of the N-terminus, the D-loop in the C2D and 
the 50 amino-acid C-tail remain undetermined (285, 286). The C-tail is of particular significance due to its 
ability to regulate PTEN membrane association, enzymatic activity and stability (193-195, 287). The lack 
of a crystal structure for the PTEN C-tail points to its structural flexibility and the possibility that the PTEN 
C-tail may be an intrinsically disordered region (IDR). IDRs are stretches of proteins that, due to their 
unique amino acid composition, are unable to adopt stable tertiary and/or secondary structures under 
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physiological conditions in-vitro. Proteins containing one or more IDRs are called Intrinsically Disordered 
Proteins (IDPs). To test the hypothesis that PTEN is an IDP, I utilized two disorder prediction software 
programs, PONDR-VLXT and PONDR-FIT (281, 288). My analysis revealed that PTEN has a highly 
disordered C-tail, encompassing amino acids 351–403 (Figure 2.1A and 2.1C). A PDZ-binding motif 
(amino acids 401–403) is part of the disordered region. The unique amino acid composition of IDRs dictates 
their structural plasticity (282, 288, 289). IDRs are enriched in polar and structure-breaking amino acid 
residues, depleted in hydrophobic and aromatic residues, and rarely contain Cys and Asn residues (282, 
288, 290). The disordered PTEN C-tail (AA 351–403) is enriched in polar  and structure breaking residues 
and is depleted in hydrophobic, aromatic  and Cys/Asn residues, indicating an ideal profile for the IDR 
(Figs. 2.2B and 2.2C). Further, compositional analysis of PTEN using the Composition Profiler (282) 
reveals that the disordered region in PTEN is enriched in polar residues (specifically H, T, D, S and E) and 
structure breaking residues (specifically P) but is depleted in all aromatic and hydrophobic residues in 
addition to  cysteine (Figure 2.2A), again exhibiting universal characteristics of IDPs. Taken together, I 
establish the PTEN C-tail as a functional IDR and classify PTEN as a new IDP. 
 
Low Mutability of PTEN IDR suggests Critical Biological Functions     
Mutations in PTEN are associated with several types of cancers (102). To correlate PTEN mutations to its 
structure, we analyzed all human PTEN mutations deposited in the COSMIC Database 
(http://www.sanger.ac.uk/genetics/CGP/cosmic/).  The disordered PTEN C-tail IDR shows unusually low 
mutability (~8-fold less) compared to any other 50 amino-acid stretch of PTEN (Figure 2.3A and 2.3B). To 
confirm our finding of the low mutability of the C-tail region, we also analyzed all human PTEN mutations 
deposited in the Human Gene Mutation Database (HGMD, http://www.hgmd.cf.ac.uk/ac/index.php) (291) 
cBioPortal for Cancer Genomics (292, 293) and the Roche Cancer Genome Database (294), which was 
consistent with mutational data derived from COSMIC database (101). The low mutability of the PTEN C-
tail can be explained through several plausible explanations. First, it is likely that mutations in the PTEN 
C-tail are deleterious, precluding their identification. Second, it is equally likely that mutations in individual  
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Figure 2.1: PTEN is an Intrinsically Disordered Protein. (A) Diagrammatic representation of PTEN 
structure. (B)  Crystal structure of PTEN. Only the phosphatase (in pink) and C2 domain (in blue) are 
amenable to crystallization (Source: RCSB Protein Data Bank, ID5R). (C) Disorder analysis of PTEN.  Any 
value above 0.5 indicates intrinsic disorder. The most prominent disordered regions in PTEN is located at 
the C-terminus.  
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Figure 2.2: PTEN has an Amino Acid Composition Characteristic of IDPs. (A) Composition profiling 
for full-length PTEN (in green), its ordered domain (in yellow) and its IDR (in red). The tool used is 
Composition Profiler (282). As shown in the graph, the disordered region in PTEN is enriched in polar 
residues (specifically H, T, D, S and E), structure breaking residues (specifically P) and is depleted of all 
hydrophobic residues, cysteine and all aromatic residues consistent with the definition of IDPs. (B) 
Histogram representing the percentage of hydrophobic, polar, aromatic, structure breaking, cysteine and 
asparagine residues in ordered vs. disordered regions. The disordered region has an amino acid composition 
in line with the definition of IDPs. (C) IDPs are enriched in polar (R, Q, S, T, E, K, D, H) and structure 
breaking (G, P) amino acids and are depleted in hydrophobic (I, L, V, M, A), aromatic (Y, W, F) and 
cysteine (C) and asparagine (N) residues. The amino acid sequence of PTEN highlights these classes of 
residues with their relative distribution. 
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residues within the IDR are well tolerated, as the evolutionary pressure may have shifted to maintaining 
global biophysical properties and structural malleability of the IDR to safeguard its critical function (295). 
Third, frameshift mutations frequently occur in the C2D resulting in loss of the C-tail (296). Fourth, 
mutations solely in the C-tail are not required to disrupt its function. Mutations in the PTEN body may 
affect the interaction of the PTEN body with the C-tail, which may have deleterious implications for PTEN 
function (297). Moreover, the PTEN C-tail IDR exhibits preferential mutations in aromatic residues 
compared to the ordered region (Figure 2.3C). The ratio of mutations in aromatic residues in the disordered 
to ordered region is much higher than any other class of residues (structure breaking, hydrophobic, polar, 
Cys and Asn), likely attributed to the structure-imparting property of aromatic residue (298). Specifically, 
aromatic residues within IDRs engage in stacking interactions, enhancing nucleation between distinct 
residues at functional protein-protein interaction interfaces (298). Thus, loss of this critical structural and 
functional property imparted by aromatic residues may be associated with a disease phenotype.  
 
The Disordered PTEN C-tail is a Hot-spot for PTMs  
Modifying enzymes readily dock on structurally flexible IDRs, making them a hot spot for PTMs 
(299-302). Consistently, as seen in Figure 1.7B, the PTEN C-tail undergoes several PTMs. While the PTEN 
C-tail is just one-third the size of the major two domains, PD or the C2D, it contributes to ~25% of total 
PTEN PTMs (Figure 2.4A and 2.4B).  
Phosphorylation is the most predominant PTM of the disordered PTEN C-tail. Intriguingly, 
regulatory cancer-associated proteins have twice as much disorder and undergo more frequent 
phosphorylation/dephosphorylation than other cellular proteins, as predicted by DISPHOS (a DISorder-
enhanced PHOSphorylation prediction software) (301), implicating a tight interconnection between protein 
phosphorylation and disorder.  Consistent with the function of PTMs in IDRs, clustering of Ser and Thr 
phosphorylation sites in the C-tail IDR regulates PTEN stability, sub-cellular localization and activity (195, 
287) (Figure 1.8A). Phosphorylation in the PEST [proline (P), glutamic acid (E), serine (S) and threonine 
(T)] domain within the C-tail IDR (amino acids 352 to 399) inhibits degradation of PTEN (174). CK2,  
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Figure 2.3: Low Mutability of the PTEN C-tail IDR. (A) The number of mutations observed in PTEN 
over its 403 amino acid stretch is plotted. Fewer mutations are observed in the tail region (in red), possibly 
indicating the deleterious nature of mutations in the functionally critical C-terminal region. [Source: Sanger 
Institute Catalogue of Somatic Mutations in Cancer (COSMIC)]. (B)  Number of mutations in every 
successive 50 amino-acid stretch of the PTEN protein. The last 50 amino-acid stretch, representing the tail 
region has at least one-eighth the number of mutations seen in any other 50 amino-acid stretch along PTEN, 
pointing to its critical function in cell homeostasis. (C) Correlation of mutations with the amino acid 
composition of PTEN. Compared to the other classes of residues, mutations in aromatic residues are much 
higher in the disordered region when compared to the ordered region.  
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GSK3-β and PLK3 phosphorylate Ser and Thr residues within the IDR, each providing a distinct function 
(174). MAST, LKB1 and CK1 kinases have also been implicated in PTEN phosphorylation. LKB1 modifies 
T383, while CKI modifies T366, S370 and S385(303). Indeed, our DISPHOS prediction for C-tail IDRs 
supports these experimental observations (Figure 2.4C). 
At the intramolecular level, phosphorylation at C-tail residues triggers a conformational change in 
PTEN, inhibiting its membrane association and, therefore, its lipid phosphatase activity (193-195, 304) 
(Figure 1.8B). The phosphorylated C-tail IDR folds onto the PD and C2 domains, giving rise to the “closed” 
conformation of PTEN that is incapable of interaction with the membrane (194, 287).  The “closed” form 
of PTEN is enzymatically inactive and cannot convert PIP3 to PIP2. Several interfaces on the PTEN-body 
are involved in this intramolecular interaction with the C-tail (194, 287, 297, 305).  
Further,  the phosphorylation events of PTEN occur in two independent cascades of ordered events, with 
the S380-S385 cluster being modified prior to the S361-370 cluster (303). Even within the two clusters, the 
phosphorylation events follow a specific pattern with a distributive kinetic mechanism. Not surprisingly,  
distributive kinetics is energetically favorable on protein domains that are highly disordered with multiple 
ensembles of flexible structures (303). Thus, the dynamic nature of these phosphorylation events is 
contingent to the inherent flexibility in the PTEN structure. 
 
 Intrinsic Disorder Drives the PPIs of PTEN 
Protein-Protein Interactions (PPIs) typically occur between conserved, structurally rigid regions of 
two or more proteins, particularly ordered proteins that display energetically favorable, highly-folded 
conformations. Intriguingly, IDPs lack tertiary structure, yet engage in PPIs, albeit with lower affinities, 
but  high specificity (290). The lack of structure within IDPs enhances their biophysical landscape, 
conferring them with the ability to attain structural complementarities required for PPIs. Since IDPs do not 
conform to a stable structure, they are less compact, providing a larger physical interface and energetic 
adaptability to interact with multiple proteins (290, 302). Thus, conditional folding within IDPs is  
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Figure 2.4: The PTEN C-tail IDR is a Hot-spot for PTMs. (A and B) The percentage of PTMs 
normalized to the length of the various domains in PTEN reveal that the PTEN C-tail is frequently modified 
via PTMs. (C) The DISPHOS phosphorylation site prediction software predicts more than 60% of 
experimentally validated PTEN phosphorylation sites in the C-tail.  
 
 
effectively utilized for interaction with a multitude of binding partners, enabling them to shuttle between 
several signaling cascades as efficient “cogs”, mediating and regulating PPIs (299, 302, 306-309). Indeed, 
we discovered that PTEN, being an IDP, interacted with more than 100 proteins (Table 1.1), which was 
 36 
  
determined upon a manual literature search. Of these 100 proteins, ~60 proteins had known PTEN 
interaction domains. Derivation of the PTEN primary interactome from these 60 proteins using Cytoscape 
(http://www.cytoscape.org/) indicated that the disordered PTEN C-tail region is responsible for 
approximately 37% of total PTEN interactions, despite being three times smaller than PD and C2D regions 
(Figure 2.5A, B and C) 
Further, disorder analysis on the entire PTEN primary interactome revealed that 51 proteins (>80 
%) were IDPs, of which 25 interacted with the C-tail IDR (Figure 2.6). This indicates that while the C-tail 
comprises of just ~12% of the PTEN protein, it binds half the number of IDPs, suggesting a high propensity 
for disorder-disorder (D-D)-type interactions.  
In order to study evolutionary conservation of the PTEN C-tail and its interactions across species, 
several sequence alignments were performed. Sequence alignment of the entire PTEN protein from 
different animal species shows a good conservation of the catalytic phosphatase domain, between 
vertebrates and invertebrates, with 100% sequence conservation for the dual specificity phosphatase 
catalytic motif HCKAGKGR (35) (Figure 2.7A). The C-tail shows good conservation in the vertebrate 
species, likely indicating the recent emergence of the function of PTEN C-tail region in regulating PTEN 
activity and enriching its PPI potential, translating to its versatile functions (Figure 2.7B). In order to 
examine the conservation across species for the PTEN C-tail interacting proteins, a literature search was 
conducted to identify experimentally verified domains/motifs involved in interaction with the C-tail. The 
domains involved in these interactions with the C-tail, for 13 representative proteins with relevant literature 
sources for these interactions, are presented in Table A1 (Appendix A). Subsequent sequence alignments 
for these 13 proteins Figure A1 (Appendix A) show sequence homology for the domains/motifs involved 
in interaction with the PTEN C-tail. These findings support the concept that the PTEN C-tail has evolved 
in vertebrates to incorporate features that allow it to interact with these proteins. 
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Figure 2.5: The Disordered PTEN C-tail Participates in Several PPIs. (A) Sixty-three proteins interact 
with known interfaces on PTEN. Proteins shown in pink interact with the phosphatase domain, those in 
blue interact with the C2 domain and those in orange interact with the disordered tail. (Visualization tool: 
Cytoscape). (B and C) The PTEN C-tail has a higher propensity for PPIs, where the percentage of PPIs 
(per amino acid) is over 50%. 
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Figure 2.6: Most Proteins within the PTEN Interactome are Highly Disordered. Approximately 80% 
of PTEN-interacting proteins within the primary interactome, particularly those that interact with the PTEN 
C-tail, are disordered, as indicated in red. The proteins within the interactome that are ordered are indicated 
in blue.  
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Figure 2.7: Recent Emergence of the PTEN C-tail in Evolutionary History. (A) The PTEN catalytic 
motif is conserved across several vertebrate and invertebrate species. (B) Sequence alignment of the PTEN 
protein for vertebrate and invertebrate animals indicates the recent emergence of the PTEN C-tail in 
vertebrate animals. Green color indicates sequence similarity while red indicates sequence dissimilar amino 
acid residues with respect to the human PTEN protein.  
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Modulation of PTEN PPIs by Linear Binding Motifs 
IDPs mediate PPIs via short linear amino acid sequences (~ 20 residues) called Molecular 
Recognition Elements (MoREs) or Molecular Recognition Features (MoRFs) (308, 310). MoRFs undergo 
disorder-to-order transitions upon binding and adopt thermodynamically stable, well-defined structures 
(310), increasing the propensity of IDPs to interact with a vast repertoire of proteins. MoRFs also display 
molecular recognition elements that capture the binding partner proteins with high specificity. These 
partner-dependent conformational differences are critical to imparting versatile binding properties to IDRs 
(308). 
Since the PTEN IDR engages in multiple PPIs, we tested the possibility for the existence of MoRFs. 
The MORFPred algorithm (283) revealed that PTEN contains major MoRF sites at amino acids 273–279, 
amino acids 339–347 (in close vicinity of the disordered C-tail) and amino acids 395–403 (part of the 
disordered C-tail) (Figure 2.8A).  The primary restriction of MoRFs to the PTEN C-tail IDR, or adjacent 
regions, indicates that these MoRFs directly participate in modulating PPI functions. However, mutational 
analysis within MoRFs is required to establish their active role in functional PPIs.  
PPIs are also facilitated by very short motifs (3–10 amino acids) called Short Linear Motifs (SLiMs) 
or Eukaryotic Linear Motifs (ELMs) (284, 311). Because of their short sequences, ELMs arise/disappear 
by simple point mutations, providing the evolutionary plasticity that the ordered protein domains lack. Thus, 
ELMs easily adapt to novel interactions in signaling pathways, where rapid assembly/disassembly of multi-
protein complexes is a prerequisite.  The frequent occurrence of ELMs in a typical proteome indicates their 
critical cellular functions. Consistent with this notion, a higher density of ELMs are observed in hub 
proteins and IDPs (284). Since ELMs have short sequences, they interact with low-affinity, however, they 
engage in highly cooperative binding in protein complexes, triggering productive signaling (284). 
Therefore, at increased intracellular local concentrations they competitively bind to mutually overlapping 
physiological targets of each other, as seen with PDZ, SH2 and PTB interaction domains found in cancer-
associated proteins and in IDRs (284, 311).  
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As PTEN contains a PDZ-binding motif within the IDR (Figure 2.1A and C), we probed for the 
existence and features of ELMs in PTEN using The Eukaryotic Linear Motif Resource (http://elm.eu.org). 
We identified 34 different classes of ELMs in PTEN that mediate PPIs.  Interestingly, the four ELMs that 
are most conserved (conservation score>0.75) occurred within the PTEN C-tail IDR, indicating its high 
level of functional/biological significance (Figure 2.8B). ELM functions are further modulated by post-
translational modifications, mainly by phosphorylation (284). Indeed, the PTEN IDR possesses eight 
phosphorylation sites (174, 303) (Figure 1.8A).  
 
Figure 2.8: Biochemical Features Modulating PTEN PPIs. (A) All of the major MoRFs (with a length 
greater than 5 residues) are observed in the vicinity of disordered regions indicating a positive correlation 
between intrinsic disorder and PPIs. (B) ELMs occurring in the disordered PTEN C-tail have been 
indicated. Interestingly, all of the motifs with a high conservation score (>0.75, indicated in red) are 
restricted to the C-tail IDR.  
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Conclusion 
The PTEN C-tail plays a crucial role in regulating PTEN stability, cellular localization and its 
enzymatic activity via various PTMs and PPIs. In spite of its critical function, determining the structure of 
the C-tail IDR remains challenging and is missing in both PTEN crystal structures deposited in PDB. In 
this chapter, I demonstrate that the PTEN C-tail is an intrinsically disordered region that undergoes frequent 
structural transitions, precluding its structural determination by crystallization. Further, I also demonstrate 
that most PTEN PPIs and PTMs are clustered in the C-tail region. Most PTEN interacting proteins are IDPs 
themselves, thereby enforcing the concept that PTEN engages in a myriad of disorder-disorder type 
interactions. Finally, sequence alignments demonstrate that the PTEN C-tail has recently emerged in 
evolutionary history and that its interacting proteins possess largely conserved PTEN binding motifs. Since 
PTEN C-tail phosphorylation is an important modification that controls PTEN function, the subsequent 
chapters focus on how PTEN phosphorylation regulates its nuclear function and its PPIs. 
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CHAPTER 3: A PTEN Conformer that Inhibits the Cell Cycle 
Background 
 Research over the last decade has established phosphorylation as an inactivation mechanism for 
PTEN (193-195). Although phosphorylation stabilizes the PTEN protein by preventing its ubiquitination 
and proteasomal degradation, it abrogates the ability of PTEN to bind to the cell membrane and inhibits its 
catalytic activity (192, 195, 297). As discussed in Chapter 1, PTEN C-tail phosphorylation triggers a 
conformational change resulting in an inactive closed form of the tumor suppressor that is unable to inhibit 
PI3K/AKT/mTOR signaling (192-194, 297). Several studies have utilized a constitutively active, 
phosphorylation deficient mutant to elucidate the impact of phosphorylation on PTEN function. The 
phospho-deficient mutant preferentially accumulates at the plasma membrane and is seven times more 
efficient at dephosphorylating PIP3, compared to the wild type PTEN (192, 194, 297). Enhanced nuclear 
accumulation of this phospho-deficient mutant has also been noted (166, 195, 312-315). However, the 
functional implications of the enhanced nuclear localization are largely yet to be determined. Within the 
nucleus, PTEN is known to inhibit cell cycle progression, specifically at the G1/S and G2/M transitions, by 
various phosphatase dependent and independent mechanisms (18, 92, 93, 97, 100, 316). The mechanism 
by which phosphorylation affects cell cycle specific functions of PTEN is an active area of research. PTEN 
phosphorylation by Plk1 is required for normal cell cycle progression through the mitosis (M) phase, while 
the phospho-deficient mutant of PTEN causes early mitotic exit in cells (100). However, the role of PTEN 
phosphorylation in the G1 phase of the cell cycle is yet to be determined. In this chapter, using a phospho-
deficient PTEN mutant, I delineate the role of PTEN in the G1 phase of the cell cycle. 
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Materials and Methods 
Plasmids 
 The 800 pSG5L-HA-PTEN WT, 977 pSG5L-HA-PTEN A4, 811 pSG5L-HA-PTEN C124S, 882 
pSG5L-HA-PTEN G129E, 878 pSG5L-HA-PTEN 1-353. 809 pCDNA3 GFP PTEN WT, and pCDNA3 
GFP PTEN A4 plasmids were a gift from Dr. William Sellers (Addgene plasmid #10750, #10753, #10744, 
#10746, #10765, #10759 and #10760) (30, 317). The 10-4 cyclin E promoter was a gift from Dr. Robert 
Weinberg (Addgene plasmid #8458) (318), -1748 human cyclin D1 promoter pGL3 basic was a gift from 
Dr. Frank McCormick (Addgene plasmid #32726) (319), pGL2-AN was a gift from Dr. William Kaelin 
(Addgene plasmid #20950) (320). E2F-Luc and HA-E2F1 plasmids were a gift from Dr. Srikumar 
Chellappan (H. Lee Moffitt Cancer Center and Research Institute) (321, 322). pIRES-Flag-PTEN WT was 
a gift from Dr. Lih-Yuan Lin (National Tsing Hua University, Taiwan) (87). pIRES-Flag-PTEN 4A was 
cloned in the lab by PCR amplification from the pIRES-Flag-PTEN WT plasmid. pSG5L-HA PTEN C124S 
4A, pSG5L-HA PTEN G129E 4A and pSG5L-HA PTEN d32 4A were engineered in the lab by PCR 
amplification from the parent plasmid pSG5L-HA-PTEN A4. pIRES-Flag PTEN WT and pIRES-Flag 
PTEN 4A were sub-cloned into the pLVX-tdTomato-C1 vector (Takara Bio USA Inc., Mountain View, 
CA) for assembly into lentiviruses. For PTEN deletion constructs (PBM-PD and C2D), the various 
deletions were PCR amplified and cloned into the pSG5L-HA vector. The deletion constructs were then 
sub-cloned into the pcDNA3-GFP vector (Life Technologies, Carlsbad, CA). PTEN truncation mutants 
Q214*, R233*, K260* and R335* were cloned in the pSG5L-HA vector using standard PCR amplification. 
PTEN point mutants P246L, F271S, D331G and P339L were cloned in the pSG5L-HA vector using nested 
PCR (323). All plasmids were verified by sequencing. Please see Table 3.1 for primer sequences. 
 
Cell culture and Stable Cell Line Generation 
 NCI-H1299 cells (ATCC® CRL-5803™, Manassas, VA) and HEK 293T cells (ATCC® CRL-
3216™, Manassas, VA), a gift from Dr. Mary Zhang (Wayne State University), were cultured in DMEM  
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(Dulbecco's Modified Eagle's medium, Sigma Aldrich,  St. Louis, MO) supplemented with 10% Fetal 
Bovine Serum (FBS), Antibiotic-antimycotic solution (final concentration 200 units/ml penicillin G, 200 
µg/ml streptomycin sulfate and 0.5 µg/ml amphotericin B, Sigma Aldrich, St. Louis, MO ) and Plasmocin 
(1.25 µg/ml, Invivogen, San Diego, CA). The cells were maintained in a humidified incubator with 5% CO2 
at 370 C.  
 The pLVX-TdTomato-C1-Flag-PTEN-WT and pLVX-TdTomato-C1-Flag-PTEN-4A constructs 
were assembled into viruses at the Viral Vector Core (University of Iowa). H1299 cells were infected with 
the lentiviruses at a MOI (Multiplicity of Infection) of 0.5 for a period of 8 hours. Polybrene was used at a 
concentration of 12 µg/ml to facilitate viral infection. 72 hours post-infection, the cells were treated with 
increasing concentrations of puromycin to identify the stable transformants. The cells were maintained at 5 
µg/ml of puromycin. 
 
Transfection and Luciferase-based Reporter Assays 
 Transient transfection with luciferase-based promoter-reporter plasmids and expression plasmids 
was performed in H1299 or HEK 293T cells using the PEI (Polyethylenimine) method (324, 325). Briefly, 
6-well plates at 50-60% confluence were co-transfected with 1µg of the luciferase constructs and varying 
amounts of different PTEN (or mutant PTEN) expression plasmids. The total amount of DNA was kept 
constant across wells using corresponding empty vector controls. 48 hours after transfection, luciferase 
activity was measured using the Synergy H4 Hybrid Reader (BioTek, Winooski, VT). The transfection 
efficiency was normalized across wells using 62.5 ng of pCMV β-galactosidase plasmid (Takara Bio USA 
Inc., Mountain View, CA) as described previously (326).  Data obtained represent the average of three 
transfection experiments, each carried out in triplicate and depicted as means ± S.E. unless stated otherwise.  
 
Protein Isolation, Co-immunoprecipitation Assays and Western Blots 
Whole cell extracts, to check for protein expression or for immunoprecipitation assays, were 
isolated using Pierce IP Lysis Buffer (Thermo Fisher Scientific, Waltham, MA; 25 mM Tris.HCl pH 7.4, 
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150 mM NaCl, 1% NP-40, 1 mM EDTA, 5% glycerol) supplemented with phosphatase and protease 
inhibitors (Sigma Aldrich, St. Louis, MO). Protein concentration was determined using Bradford Dye 
Reagent (BioRad, Hercules, CA). Nuclear proteins were isolated without using detergents as described 
previously (327). For immunoprecipitation (IP) assays, 300 µg-1 mg of protein was incubated with the 
desired antibody/beads overnight on a rotator. The beads/immuno-complex was then washed 3 times with 
the Lysis Buffer and boiled in 100 µl of 2X Laemmli Buffer containing 5% β-mercaptoethanol. The co-
immunoprecipitated (co-IPed) proteins released were analyzed by immunoblotting. Briefly, proteins were 
separated on a 12% SDS-PAGE gel and electroblotted to nitrocellulose membranes (0.45 μm; GE 
Healthcare, Pittsburgh, PA). Blots were blocked with 5% nonfat dry milk or bovine serum albumin in TBST 
buffer (10 mM Tris, pH 8,150 mM NaCl, 0.1% Tween 20) and incubated with corresponding primary 
antibodies. Peroxidase conjugated secondary antibodies were used at 1:10,000 concentration. Blots were 
developed by chemiluminescence (Thermo Fisher Scientific, Waltham, MA) and autoradiographed. The 
list of antibodies used, with their concentrations, is outlined in Table 3.2. 
 
Chromatin Immunoprecipitation Assays (ChIP) 
Chromatin was isolated from the PTEN-4A stable cell line using ChIP IT Express Magnetic 
Chromatin Immunoprecipitation kits (Active Motif, Carlsbad, CA) as per the manufacturer’s instructions. 
Briefly, the cells were fixed with formaldehyde, the chromatin was isolated and digested with micrococcal 
nuclease. The DNA was purified from an aliquot of the digestion mix to verify chromatin shearing. DNA 
present in the digestion mix was extracted and purified using a phenol:chloroform:isoamyl alcohol mixture 
(25:24:1, v/v). The DNA was precipitated with 100% ethanol and washed with 70% ethanol before 
dissolving it in 30 µl of water. 1.5 and 3 µgs of the purified DNA was run on a 3% agarose gel in 1X TAE 
(40mM Tris (pH 7.6), 20mM acetic acid, 1mM EDTA) to verify that efficient micrococcal nuclease 
digestion had occurred, resulting in DNA fragments ranging between 150-300 base-pairs. Once the 
chromatin shearing was verified, the original micrococcal nuclease digested cross-linked chromatin was 
immunoprecipitated overnight using Rabbit IgG, E2F1 and Flag antibodies (for PTEN ChIP) bound to 
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Protein G Magnetic beads. The immunoprecipitates were washed, reverse-cross linked and subjected to 
Proteinase K digestion. The released DNA was used to PCR-amplify GAPDH, cyclin D1 and cyclin E1 
genomic DNA derived from defined promoter regions. GAPDH promoter region served as a negative 
control. The primer sequences are listed in Table 3.1. 
 
Proliferation and Migration Assays 
Cell proliferation assays were performed using Cell Counting Kit-8 (Dojindo Molecular 
Technologies Inc., Rockville, MD). Parent H1299 cells, PTEN-WT and PTEN-4A stable cells were plated 
in 96-well plates at increasing density ranging from 400 to 1200 cells/well and cultured in DMEM growth 
medium as described above. The cells were then serum starved for 24 hours following which they were 
replenished with serum free medium alone or serum free medium containing 100 ng/ml of human 
recombinant leptin (R&D Systems Minneapolis, MN). 24 hours following leptin treatment, the final cell 
numbers were assessed by measuring absorbance at 450 nm.  
Parent H1299, PTEN-WT and PTEN-4A stable cells were grown on electric cell substrate 
impedance sensing (ECIS) 8-well plate arrays (8W1E; Applied Biophysics, Troy, NY) in above growth 
media. For proliferation assays, the impedance was measured using the ECIS system (Applied Biophysics, 
Troy, NY) at 1000 Hz for 7 days until the cells were completely confluent. For migration assays, the cells 
were wounded using an elevated field pulse of 1,400 mA at 32,000 Hz applied for 20 seconds, producing a 
uniform circular lesion of 250 mm in size, and wounds were tracked over a period of 12 hours. The 
impedance (Z) was measured at 16,000 Hz, normalized to its value at the initiation of data acquisition, and 
plotted as a function of time. Assays were performed in triplicates and reported as mean ± S.E. unless stated 
otherwise (p value≤ 0.05).  
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Table 3.1: Primer Sequences for Cloning and ChIP Assays. 
Primer Name Sequence 
PBM-PD-F TATATTGGATCCATGACAGCCATCATCAAAGAGATCG 
PBM-PD-R TATATTGAATTCTCATCTATAATCCAGATGATTCTTTAACAGGTA 
C2D-F TATATTGGATCCCCAGTGGCACTGTTGTTTCACAAG 
C2D-R TATATTGAATTCTCATGTTTTTGTGAAGTACAGCTTCACCTTA 
PTEN-Q214-R TATATTGAATTCCTAAGGATTGCAAGTTCCGCCACTGA 
PTEN-R233-R TATATTGAATTCTCATGTGGGTCCTGAATTGGAGG 
PTEN-K260-R TATATTGAATTCTTAGTGGAAGAACTCTACTTTGATATCACCACA 
PTEN-R335-R TATATTGAATTCTCAGTTGGCTTTGTCTTTATTTGCTTTGTC 
PTEN-P246L-P2 CACACACAGGTAACAACTGAGGG 
PTEN-P246L-P3 GAGTTCCCTCAGTTGTTACCTGTG 
PTEN-F271S-P2 TTACCCAAAAGTGAGACATTTTGTCC 
PTEN-F271S-P3 GACAAAATGTCTCACTTTTGGGTAAAT 
PTEN-D331G-P2 TATCGGTTGGCTTTGCCTTTATTTGCT 
PTEN-D331G-P3 AGCAAATAAAGGCAAAGCCAACCGA 
PTEN-P339L-R TATATTGAATTCTCATGTTTTTGTGAAGTACAGCTTCACCTTAAAA
TTTAG 
PTEN d32 4A-F TATATTGGATCCTATTGCTATGGGATTTCCTGCAGA 
PTEN d32 4A-R TATATTGAATTCTCAGACTTTTGTAATTTGTGTATGCTG 
GAPDH-ChIP-F  TACTAGCGGTTTTACGGGCG 
GAPDH-ChIP-R TCGAACAGGAGGAGCAGAGAGCGA 
Cyclin D1-ChIP-F ATGAAAACCGGACTACAGGGGCAACTC 
Cyclin D1-ChIP-R AAGATCAAAGCCCGGCAGAGAATGG 
Cyclin E1-ChIP-F CCGCCGTGTTTACATTCCACCCG 
Cyclin E1-ChIP-R ACAGGGCGGGGCCAAGTGACAG 
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Table 3.2: Details of Antibodies used. 
 
Results 
PTEN-4A is a more Potent Tumor Suppressor than PTEN-WT 
To study the effect of PTEN phosphorylation on its tumor suppressor function, a phosphorylation-deficient 
mutant was used. This mutant, designated as PTEN-4A, was generated by replacement of the serine-
threonine cluster (S380, T382, T383, S385) in the PTEN C-tail by alanine residues. A PTEN-deficient lung 
adenocarcinoma cell line, NCI-H1299, was used for all experiments. Lentiviral transduction was used to 
produce stable cell lines that either expressed Flag-tagged wild type form of PTEN (PTEN-WT) or the 
Flag-tagged phospho-deficient mutant of PTEN (PTEN-4A). Both forms of PTEN were stably expressed  
 
 
Antibody Catalog No. Concentration 
Flag (Rabbit, polyclonal) Sigma Aldrich, F7425 1:1000 
Flag M2 (mouse, monoclonal) Sigma Aldrich, F3165 1:1000 
GFP (Rabbit, polyclonal)  Abcam, ab290 1:1000 
GFP (mouse, monoclonal) Abcam, ab1218 1:1000 
HA (mouse, monoclonal) Thermo Fisher, 26183 1:1000 
PTEN (rabbit, monoclonal) Cell Signaling, 9559 1:1000 
PTEN (goat, polyclonal) Santa Cruz Biotechnology, sc-6818 1:200 
Lamin B1 Cell Signaling, 12586 1:1000 
β-Actin (mouse, monoclonal) Sigma Aldrich, A2228 1:1000 
β-Actin (rabbit, polyclonal) Sigma Aldrich, A5060 1:1000 
Rabbit secondary antibody Jackson  ImmunoResearch, 111-035-045 1:10,000 
Goat secondary antibody Sigma Aldrich, A5420 1:10,000 
Mouse secondary antibody Jackson  ImmunoResearch, 115-035-003 1:10,000 
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Figure 3.1: PTEN-4A is a more Potent Tumor Suppressor than PTEN WT. (A) Lentiviral transduction, 
followed by puromycin selection, was used to stably express Flag PTEN-WT and Flag PTEN-4A proteins 
in PTEN deficient NSCLC cell line H1299. The expression levels of both PTEN-WT and PTEN-4A 
proteins were similar. (B) PTEN-4A inhibited cell proliferation significantly more than PTEN-WT in a 
standard cell proliferation assays (i). Even in the presence of a proliferative signal such as leptin, PTEN-
4A remained a potent inhibitor of cell proliferation (ii). Data are derived from experiments performed in 
triplicates ± S.E.  (n=3,*p<0.05). (C) Cell proliferation assays on H1299, PTEN-WT and PTEN-4A cells 
measured by the ECIS method also revealed that PTEN-4A (black line) significantly suppressed cell 
proliferation as compared to PTEN-WT (pink line). (D) Likewise, PTEN-4A significantly inhibited the 
migratory potential of PTEN-4A (blue line) as compared to PTEN-WT (red line). 
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at similar levels in H1299 cells (Figure 3.1A). Proliferation assays were performed on H1299 parent cell 
line, PTEN-WT stable and PTEN-4A stable cell lines using colorimetric assay (Figure 3.1B) and the ECIS 
(Electric Cell-substrate Impedance Sensing) method (Figure 3.1C). I observed that PTEN-4A suppressed 
cell proliferation to a greater extent than PTEN-WT (Figure 3.1B (i) and 3.1C). The stable cell lines were 
then treated with a cytokine, leptin, which is known to signal through the PI3K/AKT pathway, causing cell 
proliferation (325). Leptin is also elevated in patient lung tumors (328, 329). Further, leptin is also known 
to induce PTEN phosphorylation, thereby inactivating it (330). Upon leptin treatment, I observed that cells 
expressing PTEN-WT proliferated at a rate similar to the PTEN-deficient parent H1299 cell line. However, 
cells expressing PTEN-4A proliferated at a lower rate, indicating that PTEN-4A can counter the 
proliferative effects of a cytokine like leptin (Figure 3.1B (ii)). I then performed migration assays in the 
stable cell lines and observed that the PTEN-4A expressing cells have the least migratory capacity 
compared to the PTEN-WT expressing cells or the parent H1299 cell line (Figure 3.1D). Therefore, the 
phospho-deficient PTEN mutant, PTEN-4A, is a more potent tumor suppressor compared to PTEN-WT.  
 
PTEN-4A Preferentially Localizes to the Nucleus 
Previous reports indicate that PTEN-4A exhibits increased membrane localization (194, 313, 315). 
However, given the emerging role of PTEN in the nucleus, I wanted to determine whether PTEN-4A 
exhibited a differential nuclear localization pattern compared to PTEN-WT. Therefore, I isolated nuclear 
proteins from the PTEN-WT and PTEN-4A expressing stable cell lines. I found that PTEN-4A 
preferentially localized to the nucleus (Figure 3.2A and 3.2B). My observations are consistent with other 
recent findings indicating that PTEN-4A preferentially localizes to the cell membrane and the nucleus in 
different cell types (166, 312-315). 
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Figure 3.2: PTEN-4A Preferentially Localizes to the Nucleus. (A) Total nuclear proteins isolated from 
PTEN-WT and PTEN-4A stable cells revealed that PTEN-4A preferentially localized to the nucleus as 
compared to PTEN-WT, as examined by immunoblotting with Flag antibodies. (B) Lamin B1, an 
exclusively nuclear protein, was used as a loading control and to normalize densitometric values obtained 
for PTEN-WT and PTEN-4A protein levels in the nucleus. PTEN-4A was approximately 2.5-fold higher 
in the nucleus than PTEN-WT. Data are derived from three independent experiments ± S.E. (n=3, *p<0.05). 
 
PTEN-4A Preferentially Inhibits E2F1-mediated transcription 
Several recent studies have described tumor suppressive functions of PTEN in the nucleus, 
including inhibition of the cell cycle at the G1 and G2/M phases  (18, 92, 93, 97, 100, 316). However, the 
effect of phosphorylation on this nuclear function of PTEN is not known. Several groups, including ours, 
have shown that the phospho-deficient mutant of PTEN, PTEN-4A, shows preferential nuclear localization 
(166, 312). Consistent with this, I observe that PTEN-4A selectively inhibits the transcription of several 
well established E2F1 regulated genes that are involved in the cell cycle (Figure 3.3A-E). The 
transcriptional potential of the E2F1-regulated gene promoter constructs: the artificial E2F1 reporter, native 
E2F1 promoter, cyclin E1 and cyclin D1, were assessed using luciferase–based promoter-reporter 
constructs co-expressed with plasmids transiently expressing PTEN-WT or PTEN-4A in H1299 cells 
(Figure 3.3H). The artificial E2F1 reporter, E2F-Luc, was used for all further experiments to understand 
the mechanistic role of PTEN in E2F1-mediated transcription. PTEN inhibits the PI3K/AKT pathway 
through its phosphatase activity (18). Therefore, I sought to determine whether the effect of PTEN on E2F1-
mediated transcription is dependent on its phosphatase activity using two PTEN mutants: C124S 4A (dual 
lipid and protein phosphatase dead mutant) and PTEN G129E 4A (lipid phosphatase dead mutant). It was 
observed that the lipid phosphatase activity of PTEN was critical for E2F1- mediated transcriptional  
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Figure 3.3: PTEN-4A Preferentially Inhibits E2F1-mediated Transcription. (A) Transcriptional assays 
on four E2F1-responsive promoter reporter constructs in H1299 cancer cells indicate that they are all 
activated by E2F1 expression. (B) PTEN-4A preferentially suppresses (3 fold greater suppression) the 
transcription from an artificial E2F1 reporter (E2F-Luc) compared to PTEN-WT. (C) PTEN-4A inhibits 
transcription of the native E2F1 promoter 2.5 fold more than PTEN-WT. (D) Both PTEN-WT and PTEN-
4A suppress cyclin E1-transcription. However, PTEN-4A inhibits transcription from the cyclin E1-
promoter approximately 2 fold more than PTEN-WT. (E) Both PTEN-WT and PTEN-4A suppress cyclin 
D1-transcription. However, PTEN-4A inhibits transcription from the cyclin D1-promoter 1.5 fold more 
than PTEN-WT. (F) As compared to PTEN-4A (lane 2), PTEN catalytic mutants, PTEN C124S 4A  (lane 
3) and PTEN G129E 4A (lane 4) cannot suppress E2F1 reporter activity. (G) A PTEN-4A construct lacking 
the nuclear localization sequence of PTEN (PTEN d32-4A) cannot suppress E2F1-mediated transcription 
(lanes 2 and 3). (H and I) All constructs show stable protein expression upon transient transfection. All 
data are represented from three independent experiments carried out in triplicate ± S.E. (*p value ≤0.05). 
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suppression (Figure 3.3F and 3.3H). These results indicate an AKT-dependent mechanism of PTEN’s effect 
on E2F1-mediated transcription.  
Next, I wanted to determine the relationship between the nuclear localization of PTEN-4A and its 
effect on transcriptional suppression of E2F1-regulated genes. PTEN does not possess a canonical nuclear 
localization sequence. However, the first 32 amino acids of PTEN are critical for its nuclear transport (154). 
A PTEN-4A mutant lacking the first 32 amino acids, PTEN d32-4A, was unable to suppress E2F1-mediated 
transcription (Figure 3.3G and 3.3I), indicating that nuclear localization of PTEN-4A is a prerequisite for 
its effect on E2F1-mediated transcription. My results indicate that PTEN-4A needs to be localized to the 
nucleus to suppress E2F1-mediated transcription in a phosphatase-dependent manner. 
 
The PTEN C2 Domain is Required for E2F1-mediated Transcriptional Suppression 
In order to determine which protein domains of PTEN might be critical for its transcriptional 
functions, I cloned and expressed PTEN deletion constructs and tested their transcriptional activities in 
luciferase-based transcriptional assays (Figure 3.4B). Using multiple PTEN deletion mutants, I observed 
that the C2 domain (C2D) is required for E2F1-mediated transcriptional suppression. Deletion of the C2D, 
as in the mutant PBM-PD (Figure 3.4A, lane 4), resulted in loss of transcriptional suppression. My results 
are consistent with recent findings that the C2D of PTEN contains a chromatin localization sequence and 
is responsible for several nuclear functions of PTEN (76). Results from Figures 3.3F and 3.4A indicate 
partial phosphatase-dependent and -independent mechanisms by which PTEN regulates E2F1-mediated 
transcription.  
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Figure 3.4: The PTEN C2 Domain is Required for E2F1-mediated Transcriptional Suppression. (A) 
PTEN-4A, PTEN 1-353 and PTEN C2 Domain (C2D) can suppress E2F1-mediated transcription as 
assessed on the artificial E2F1-responsive promoter (lanes 2, 3 and 5). However, the PTEN phosphatase 
domain mutant (PBM-PD), which lacks the C2D, cannot suppress transcriptional activity (lane 4). (B) All 
of the PTEN deletion constructs, PTEN 1-353, PBM-PD and C2D show stable protein expression upon 
transient transfection. (C) PTEN 1-353 inhibits E2F1-mediated transcription. Therefore, all subsequent 
C2D mutants were made in the PTEN 1-353 context to avoid confounding effects coming from variable 
phosphorylation status and intramolecular conformational closure of PTEN of C-tail in all mutants tested. 
(D) All of the analyzed PTEN truncation mutants lost their ability to suppress E2F1-mediated transcription 
as compared to the PTEN 1-353 construct (compare lane 1 to lanes 2, 3, 4 and 5). (E) PTEN C2D point 
mutants F271S and P339L cannot inhibit E2F1-mediated transcription when compared to PTEN 1-353 
(compare lane 1 to lanes 3 and 5). The point mutants P246L and D331G, however, retain their ability to 
suppress E2F1-mediated transcription (compare lane 1 to lanes 2 and 4). (F and G) The PTEN C2D 
truncation and deletion mutants maintain protein stability following transient transfection. All data are 
represented from three independent experiments carried out in triplicate ± S.E. (*p value ≤0.05). 
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Several disease-associated mutations occur in the PTEN C2 domain. To investigate whether these 
mutations affect transcriptional functions of PTEN, I cloned and expressed four point mutants (P246L, 
F271S, D331G and P339L) and four truncation mutants (Q214*, R233*, K260*, R335*) (Figure 3.4F and 
3.4G). To prevent any confounding results due to conformational changes modulated by the C-tail region, 
the point mutants were cloned without the PTEN C-tail region i.e, in the PTEN 1-353 background. The 
transcriptional activity of the point mutants were compared to the PTEN 1-353 construct (Figure 3.4C and 
3.4E). Transcriptional assays revealed that the two point mutants PTEN F271S and PTEN P339L cannot 
suppress E2F1 mediated transcription. Further, all the truncation mutants tested failed to suppress 
transcription of E2F1-regulated genes (Figure 3.4D). All of these truncation mutants lack a β-sheet 
encompassing amino acids 336-353, which may likely be required for the effect of PTEN on E2F1-mediated 
transcription. In summary, I identified disease-associated PTEN mutants that have lost their ability to 
suppress transcription of E2F1-regulated genes. The exact mechanism of this loss of function remains to be 
determined.  
 
PTEN-4A Physically Interacts with E2F1 Protein and at E2F1 DNA Binding Sites on Chromatin 
PTEN binds to several transcription factors, including Sp1, MTF1, CREB in the nucleus to regulate 
the expression of multiple genes (31, 87, 331). In order to determine whether PTEN physically associates 
with the E2F1 protein, I performed co-immunoprecipitation assays. Flag-tagged PTEN- WT or Flag-tagged 
PTEN-4A and HA-tagged E2F1 constructs were co-expressed in HEK 293T cells. Reciprocal 
immunoprecipitation experiments using HA and Flag co-IP revealed that E2F1 binds to both PTEN-WT 
and PTEN-4A (Figure 3.5A). To determine whether PTEN-4A can associate with E2F1- binding sites on 
chromatin, I performed Chromatin Immunoprecipitation (ChIP) assays. The ChIP assays were performed 
in the PTEN-4A stable cell line. My results indicate the presence of both E2F1 and PTEN-4A at E2F1-
binding sites on the cyclin D1 and cyclin E1 promoters (Figure 3.5B). Therefore, PTEN-4A physically 
interacts with the E2F1 protein and at E2F1-binding sites on DNA.  
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Figure 3.5: PTEN-4A Physically Interacts with E2F1 Protein and at E2F1 DNA Binding Sites on 
Chromatin. (A) Both PTEN-WT and PTEN-4A physically associate with the E2F1 protein in co- 
immunoprecipitation assays in HEK 293T cells in over-expression experiments (indicated by arrows).  (B) 
Chromatin-immunoprecipitation assays indicate that both PTEN-4A and E2F1 bind to E2F1 DNA-binding 
sites on chromatin at the cyclin D1 and cyclin E1 promoters in the PTEN-4A stable cell line.  
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Conclusion 
Since its discovery in 1997, substantial amount of research on PTEN has focused on its function as 
a lipid phosphatase at the cell membrane. Emerging evidence points to the versatile role of PTEN in 
different sub-cellular compartments where it regulates functions independent of its lipid phosphatase 
activity (35, 89). Supporting these findings, my data in this chapter demonstrates the role of PTEN in 
inhibiting the transcription of genes involved in the G1 phase of the cell cycle in the nucleus via phosphatase 
dependent and independent mechanisms. 
It is now known that PTEN can bind to several transcription factors (31, 87, 331), histones (81) and 
remodeling factors (82), including E2F1, to regulate the expression of genes. Recent findings suggest that 
the C2 domain of PTEN contains a chromatin localization sequence, indicative of a phosphatase 
independent mechanism in regulating transcription (76). However, whether PTEN can directly bind to DNA 
remains to be determined. Further, study of most disease associated PTEN lesions have focused on 
mutations in the catalytic pocket of PTEN that abrogate its enzymatic activity. However, in the present 
study, I have demonstrated that disease associated C2 domain mutations lose their ability to suppress E2F1-
mediated transcription.  Indeed, the exact mechanism of this loss of function is a potential area for research. 
Consistent with my results, several C2 domain mutants such as K289E have been shown to affect PTEN 
function, resulting in pathogenic signaling (332).  
In spite of its functional versatility, PTEN mutations are infrequent in cancers. However, several 
non-genomic mechanisms contribute to PTEN inactivation resulting in oncogenic transformation and 
progression. PTEN function and subcellular localization is frequently modulated by post translational 
modifications, particularly phosphorylation and ubiquitination (166, 194, 229, 312, 332). In this chapter, 
my experiments demonstrate that PTEN phosphorylation affects its nuclear localization and function in 
suppressing E2F1-mediated transcription. In the subsequent chapter, I test the hypothesis that 
phosphorylation alters the protein binding profile of PTEN.  
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CHAPTER 4: Defining the Protein Interactome of PTEN Conformers 
 
Background 
As discussed in Chapter 1, PTEN undergoes several PTMs that alter its stability, protein-protein 
interactions and sub-cellular localization. Phosphorylation is the most extensively studied PTM of PTEN. 
However, the global impact that phosphorylation has on the protein interactions of PTEN is yet to be 
determined. Phosphorylation induces a conformational change in PTEN resulting in the occlusion of the 
phosphatase and C2 domains by the C-tail region (192-194). Most known PTEN binding proteins associate 
with the C2 domain and C-tail (101). Therefore, the intra-molecular association triggered by 
phosphorylation could potentially mask the protein-binding interfaces of PTEN. Consistently, the 
unphosphorylated or a phospho-deficient PTEN mutant was found to have increased affinity for the PI3K 
regulatory subunit p85 and several PDZ domain containing proteins, such as MAGI-2 (214, 215, 239, 317).  
To assess the impact of PTEN phosphorylation on its ability to bind to proteins, I have performed SILAC 
(Stable Isotope Labelling by Amino Acids in Cell culture) based mass-spectrometry analysis on native 
PTEN (PTEN-WT) and its phospho-deficient mutant (PTEN-4A). The results of my analysis are outlined 
in this chapter. 
 
Materials and Methods 
Plasmids and Reagents 
pIRES-Flag-PTEN WT was a gift from Dr. Lih-Yuan Lin (National Tsing Hua University, Taiwan) 
(87). pIRES-Flag-PTEN 4A was cloned in the lab by PCR amplification from the pIRES-Flag-PTEN WT 
plasmid. pIRES-Flag PTEN WT and pIRES-Flag PTEN 4A were sub-cloned into the pLVX-tdTomato-C1 
vector (Takara Bio USA Inc., Mountain View, CA) for assembly into lentiviruses. pLX304 LGALS1 was 
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obtained from The ORFeome Collaboration (DNASU, Tempe, AZ) (333-335). All plasmids were verified 
by sequencing. Recombinant Galectin-1 was obtained from PeproTech (Rocky Hill, NJ). 
 
Cell Culture, Stable Cell Line Generation and Transfection 
NCI-H1299 cells (ATCC® CRL-5803™, Manassas, VA) and HEK 293T cells (ATCC® CRL-
3216™, Manassas, VA), a gift from Dr. Mary Zhang (Wayne State University), were cultured in DMEM  
(Dulbecco's Modified Eagle's medium, Sigma Aldrich, St. Louis, MO) supplemented with 10% Fetal 
Bovine Serum (FBS), Antibiotic-antimycotic solution (final concentration 200 units/ml penicillin G, 200 
µg/ml streptomycin sulfate and 0.5 µg/ml amphotericin B,  Sigma Aldrich, St. Louis, MO) and Plasmocin 
(1.25 µg/ml, Invivogen, San Diego, CA). The cells were maintained in a humidified incubator with 5% CO2 
at 370 C.  
 The pLVX-TdTomato-C1-Flag-PTEN-WT and pLVX-TdTomato-C1-Flag-PTEN-4A plasmids 
were assembled into lentiviruses at the Viral Vector Core (University of Iowa). H1299 cells were infected 
with the lentiviruses at a MOI (Multiplicity of Infection) of 0.5 for a period of 8 hours. Polybrene was used 
at a concentration of 12 µg/ml to facilitate viral infection. 72 hours post-infection, the cells were treated 
with increasing concentrations of puromycin to identify the stable transformants. The cell were maintained 
at 5 µg/ml of puromycin. 
Transient transfection with expression plasmids was performed in H1299 or HEK 293T cells using 
the PEI (Polyethylenimine) method (324, 325).  
 
Protein Isolation, Co-immunoprecipitation Assays and Western Blots 
To check for protein expression or for immunoprecipitation assays, whole cell extracts were 
prepared using Pierce IP Lysis Buffer (Thermo Fisher Scientific, Waltham, MA) containing 25 mM 
Tris.HCl pH 7.4, 150 mM NaCl, 1% NP-40, 1 mM EDTA and 5% glycerol supplemented with phosphatase 
and protease inhibitors (Sigma Aldrich, St. Louis, MO). Protein concentration was determined using 
Bradford Dye Reagent (BioRad, Hercules, CA). Nuclear proteins were isolated without using detergents as 
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described previously (327). For immunoprecipitation (IP) assays, 300 ug-1 mg of protein was incubated 
with the 3 ug of V5 antibody (see Table 4.1 for antibody details) overnight on a rotator. The beads/immuno-
complex was then washed 3 times with the Lysis Buffer and boiled in 100 µl of 2X Laemmli Buffer 
containing 5% β-mercaptoethanol. The co-immunoprecipitated (co-IPed) proteins released were analysed 
by immunoblotting. Briefly, proteins were separated on a 12% SDS-PAGE gel and electroblotted to 
nitrocellulose membranes (0.45 μm; GE Healthcare, Pittsburgh, PA). Blots were blocked with 5% nonfat 
dry milk or bovine serum albumin in TBST buffer (10 mM Tris, pH 8,150 mM NaCl, 0.1% Tween 20) and 
incubated with corresponding primary antibodies. Peroxidase conjugated secondary antibodies (see Table 
4.1) were used at 1:10,000 concentration. Blots were developed by chemiluminescence (Thermo Fisher 
Scientific, Waltham, MA) and autoradiographed. The list of antibodies used, with their concentrations, is 
outlined in Table 4.1. 
 
Silver Staining 
 Nuclear and cytoplasmic protein extracts were isolated from the parent H1299, PTEN-WT and 
PTEN-4A stable cell lines as above and subject to Flag immunoprecipitation. The Flag beads (Sigma 
Aldrich, St. Louis, MO) were blocked overnight with nuclear/cytoplasmic extracts from the parent H1299 
cells to avoid non-specific binding. The blocked beads were then washed with lysis buffer and were 
incubated with extracts from the PTEN-WT and PTEN-4A stable cell lines. The immunocomplexes were 
eluted using a 3X Flag peptide (150 ng/µl in a volume of 100 µl, Sigma Aldrich, St. Louis, MO).  Flag 
immunoprecipitates from nuclear and cytoplasmic extracts of parent H1299, PTEN-WT and PTEN-4A 
stable cells were run on a 0.75mm 10% SDS-PAGE gel. The gel was stained using the Proteosilver Silver 
stain kit (Sigma Aldrich, St. Louis, MO), as per manufacturer’s instructions. Briefly, the electrophoresed 
proteins in the gel were fixed in a fixing solution (50% ethanol, 10% acetic acid) for 40 minutes, washed 
with 30% ethanol followed by MilliQ water (EMD Millipore, Billerica, MA) for 10 minutes each. The gel 
was then incubated in the sensitizer solution for 10 minutes, washed twice with MilliQ water for 10 minutes 
each and equilibrated with silver solution for 10 minutes followed by a 1 minute wash in MilliQ water. The 
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gel was placed in a developer solution until bands of the desired intensity were visualized and the reaction 
stopped using ProteoSilver stop solution. The gel was visualized using the ChemiDoc MP Imaging system 
(BioRad, Hercules, CA) and stored in MilliQ water. 
 
Mass Spectrometry 
PTEN-WT and PTEN-4A stable cell lines were grown in DMEM (Sigma Aldrich, St. Louis, MO) 
labelled with light and heavy lysine and arginine, respectively. The cells were grown in the labelled media 
for 8 doublings, resulting in 94% isotopic incorporation as determined by tandem mass spectrometry 
(MS/MS). Since I observed a selective transcriptional suppression of G1 phase related genes by phospho-
deficient PTEN-4A in Chapter 3, the proteomics was performed for cells synchronized in G1 phase using 
lovastatin (7.5 µM, 24 hours) (336). Nuclear and cytoplasmic proteins isolated from PTEN-WT and PTEN-
4A stable cells were subject to Flag immunoprecipitation (IP) (Flag Affinity Beads, Sigma Aldrich, St. 
Louis, MO) followed by gentle elution using a 3X Flag peptide (150 ng/µl in a volume of 100 µl, Sigma 
Aldrich, St. Louis, MO). Eluted extracts from the PTEN-WT and PTEN-4A stable cell lines were mixed in 
a 1:1 ratio (by concentration of PTEN protein) and run on an SDS-PAGE gel followed by Coomassie 
staining using a Colloidal concentrate of Brilliant Blue G (Sigma Aldrich, St. Louis, MO) as per the 
manufacturer’s instructions. Briefly, the electrophoresed proteins in the gel were fixed in a Fixing solution 
(40% methanol, 7% glacial acetic acid in water) followed by staining with the Brilliant Blue Colloidal 
Concentrate overnight. Subsequently, the gel was destained using a destaining solution (25% methanol, 
10% glacial acetic acid in deionized water). The sample lanes from the Coomassie stained gel were excised 
into 5 slices and in-gel trypsinized to isolate peptides. These peptides were subjected to LC-MS/MS (Liquid 
chromatography, tandem mass spectrometry) at the Proteomics Core (H. Lee Moffitt Cancer Center and 
Research Institute, Tampa FL). Data were analyzed using the database SEQUEST. Metabolic labelling of 
amino acids resulted in a mass shift of 8 units for PTEN-WT and PTEN-4A interacting proteins 
respectively. Approximately 1100 nuclear and 700 cytoplasmic proteins were identified in the PTEN-
interactomes (false discovery rate ≤ 5%). A ratio of spectral intensities for proteins from PTEN-4A and the 
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PTEN-WT cell lines was calculated. Proteins that preferentially interact with PTEN-4A (ratio ≥ 1.5) and 
PTEN-WT (ratio ≤0.5) in the nucleus and cytoplasm are depicted on a heat map in Figure 4.3. The XLSTAT 
software was used to generate the heat map.  
 
Proliferation and Migration Assays 
Cell proliferation assays were performed using Cell Counting Kit-8 (Dojindo Molecular 
Technologies Inc., Rockville, MD). Parent H1299 cells, PTEN-WT and PTEN-4A stable cells were plated 
in 96-well plates at a density of 800 cells/well and cultured in DMEM growth medium as described above. 
The cells were then serum starved for 24 hours following which they were replenished with serum free 
medium alone or serum free medium containing 20 ng/ml of human recombinant Galectin-1. 24 hours 
following Galectin-1 treatment, the final cell numbers were assessed by measuring absorbance at 450 nm. 
The percentage change in cell numbers upon Galectin-1 treatment was calculated. 
For migration assays, parent H1299, PTEN-WT and PTEN-4A stable cells were transfected with 
an empty vector or a full-length V5-tagged Galectin-1 protein expressing plasmid. Forty hours after 
transfection, the cells were wounded using a 200µl pipette tip. The scratch was visualized at 0 and 16 hours 
after wounding. The area of the wound was calculated at these two time points for the cells and percent 
increase in migration was calculated. Assays were performed in triplicates and reported as mean ± S.E. 
unless stated otherwise (p value≤ 0.05).  
 
Table 4.1: Details of Antibodies used. 
Antibody Catalog No. Concentration
Flag (Rabbit, polyclonal) Sigma Aldrich, F7425 1:1000 
Flag M2 (mouse, monoclonal) Sigma Aldrich, F3165 1:1000 
β-Actin (mouse, monoclonal) Sigma Aldrich, A2228 1:1000 
β-Actin (rabbit, polyclonal) Sigma Aldrich, A5060 1:1000 
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Table 4.1 (continued): Details of Antibodies used. 
 
Results: 
PTEN-WT and PTEN-4A have a Differential Protein Binding Profile 
To test the hypothesis that PTEN-WT and PTEN-4A have a differential protein binding profile, I 
performed a preliminary silver stain experiment using the parent H1299, PTEN-WT and PTEN-4A stable 
cell lines. A schematic of the sample preparation is provided in Figure 4.1A. Nuclear and cytoplasmic Flag-
tag bound immunocomplexes from the H1299, PTEN-WT and PTEN-4A stable cells were run on an SDS-
PAGE gel and silver stained. The silver stained bands on the SDS-PAGE gel revealed that both PTEN-WT 
and PTEN-4A show unique proteins present in the nuclear and cytoplasmic interactomes, respectively, 
while parent H1299 cell nuclear extract does not bind to 3X-Flag-beads (Figure 4.1B (ii and iii)). Further, 
when nuclear interactomes for PTEN-WT and PTEN-4A are compared, the two PTEN variants bind to 
different proteins and/or have differential binding affinities for a given protein (Figure 4.1B (iv)). Having 
established that each interactome had a distinct protein profile, I sought to identify the differentially binding 
proteins to PTEN-WT and PTEN-4A proteins in the cytoplasm and the nucleus. To this end, I performed a 
SILAC-based mass-spectrometric analysis as described in Figure 4.2. Since we observe a role for PTEN in 
the G1 phase of the cell cycle in Chapter 3, cells for the mass spectrometric analysis were synchronized in 
the G1 phase using lovastatin. Proteins that differentially interact with PTEN-4A and PTEN-WT in the 
nucleus and cytoplasm are depicted on a heat map (Figure 4.3A). Several known PTEN binding proteins 
were detected, reinforcing the validity and strength of my proteomic analysis (Table 4.2). 
Antibody Catalog No. Concentration
V5 (rabbit, polyclonal) Sigma Aldrich, V8137 1:1000 
Phospho-Akt (Thr308) Cell Signaling,  1:1000 
Rabbit secondary antibodies Jackson  ImmunoResearch, 111-035-045 1:10,000 
Mouse secondary antibodies Jackson  ImmunoResearch, 115-035-003 1:10,000 
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Figure 4.1: PTEN-WT and PTEN-4A have a Differential Protein Binding Profile. (A) Schematic of 
sample preparation for silver stain experiments. (B) Silver stained gel shows that PTEN-WT and PTEN-
4A bind to different proteins in the cytoplasm and nucleus respectively (ii and iii). Further, when nuclear 
interactomes for PTEN-WT and PTEN-4A are compared, the two PTEN variants bind to different proteins 
and/or have differential binding affinities for a given protein (iv). The immunoprecipitated extracts from 
the control H1299 cells show no bands indicating the absence of any background and non-specific 
interacting proteins (v) 
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Figure 4.2: Schematic of Sample Generation for the LC/MS-MS Experiments. 
 
Differential Binding of Galectin-1 to PTEN-WT 
Of the differentially binding proteins, two members of the Galectin family, Galectin-1 and 
Galectin-7, were identified. Galectins are β-galactoside binding proteins that participate in a variety of 
processes such as cell proliferation, migration and cell adhesion (337-339). Particularly, Galectin-1 and 
Galectin-3, are implicated in several cancer subtypes as pro-metastatic molecules (340, 341). Galectin-1 is 
specifically upregulated in lung cancer (342), especially in cancer stem-like cells (343). Furthermore, 
Galectin-1 promotes lung cancer metastasis via integrin α6β4 and Notch1/Jagged2 signaling (344). 
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Figure 4.3: SILAC based Proteomics Reveals that PTEN-WT and PTEN-4A have a Differential 
Protein Binding Profile in the Nucleus and Cytoplasm. (A) The heat map illustrates that PTEN-WT and 
PTEN-4A have a different protein-interaction pattern in the nucleus and cytoplasm. Galectin-1 is identified 
as a candidate protein as it binds selectively to PTEN-WT (3 fold higher) as compared to PTEN-4A in the 
cytoplasm. (B) Galectin-1 preferentially binds to PTEN-WT (2.3 fold higher than PTEN-4A) as assessed 
in immunoprecipitation experiments in HEK 293T cells. Data are derived from experiments performed in 
triplicates ± S.E.  (n=3,*p<0.05). 
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Table 4.2: Known PTEN Binding Proteins Identified in this Study 
Cytoplasm Nucleus 
Heterogeneous nuclear ribonucleoproteins C1/C2 
(HNRNPC) 
Heterogeneous nuclear ribonucleoproteins C1/C2 
(HNRNPC) 
Major Vault Protein (MVP) Major Vault Protein (MVP) 
Thioredoxin (TRDX) Thioredoxin (TRDX) 
Peroxiredoxin1 (PRDX1) Peroxiredoxin1 (PRDX1) 
Ras-related nuclear protein (RAN) Ras-related nuclear protein (RAN)RAN 
Heat shock protein 90 Alpha (HSP-90α) Heat shock protein 90 Alpha (HSP-90α) 
Heat shock protein 90 Alpha (HSP-90β) Heat shock protein 90 Alpha (HSP-90β) 
Cyclin-dependent kinase 1 (CDK1) Cyclin-dependent kinase 1 (CDK1) 
Ras-related protein Rab7a Ras-related protein Rab7a 
Profilin Profilin 
 Parkinson Protein 7 (PARK7) 
 CK2α (Casein kinase 2 subunit alpha) 
 CK2β (Casein kinase 2 subunit beta) 
 DNA replication licensing factor (MCM2) 
 Drebrin 
 
Galectin-1 is also known to signal via the PI3K/AKT pathway (Figure 4.4A) (345, 346). Given the 
relevance of Galectin-1 in lung cancer and the PI3K/AKT cascade, I sought to examine the functional 
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relationship between PTEN and Galectin-1. In co-immunoprecipitation (Co-IP) experiments, Galectin-1 
was found to preferentially bind to PTEN-WT (2.3 fold higher) as compared to PTEN-4A (Figure 4.3B, 
indicated by arrow). This observation is consistent with our SILAC based proteomics data where spectral 
counts for Galectin-1 are 3 times higher for PTEN-WT (as compared to PTEN-4A) in the cytoplasm. These 
results suggest that Galectin-1 may bind to and attenuate PTEN-WT function, thereby asserting its 
oncogenic activity in cancer cells. 
 
Galectin-1 Binds to PTEN and Inhibits its Function in Proliferation and Migration Assays 
To test my hypothesis that Galectin-1 binds to and attenuates PTEN function, I performed 
proliferation and migration assays in parent H1299, PTEN-WT and PTEN-4A stable cell lines in the 
presence of Galectin-1 (Figure 4.4B and 4.4C). I observed that PTEN-4A suppressed the proliferative and 
migratory effect of Galectin-1 more than PTEN-WT. Therefore, it is plausible that Galectin-1 binds and 
sequesters PTEN-WT protein, thereby attenuating its inhibitory effect on cell growth and migration. The 
selective binding of Galectin-1 to PTEN-WT maybe at an interface that is unique to the conformation of 
the wild type protein, but is compromised/lost upon transition to the more open form of conformation of 
PTEN-4A. Whether PTEN binds directly to Galectin-1, and if so, the exact interfaces of PTEN-WT and 
PTEN-4A involved in the interaction remains to be determined. 
 
Conclusion 
Post-translational modifications modulate protein interactions of PTEN, which may influence its 
catalytic activity or sub-cellular localization. For instance, PTEN C-tail phosphorylation and acetylation 
prevents its interaction with PDZ domain containing proteins that allow for its membrane localization (197, 
239, 317).  Phosphorylation also inhibits the interaction of PTEN with β-arrestins that inhibit or activate 
the lipid phosphatase activity of PTEN, depending on upstream signals from the RhoA/ROCK pathway 
(211). Unphosphorylated PTEN also forms a complex with p85, the regulatory subunit of PI3K, an 
 70 
  
interaction that enhances the lipid phosphatase activity of PTEN, its membrane localization and stability, 
resulting in PI3K/AKT pathway inhibition (213, 214, 347).  
 
 
Figure 4.4: Physiological Relevance of the PTEN-Galectin-1 Complex. (A) Galectin-1 treatment 
increases phospho-AKT levels in HEK293T cells, indicating that it signals through the PI3K/AKT/mTOR 
pathway (B) Proliferation assays in the parent H1299, PTEN-WT and PTEN-4A stable cell lines indicate 
that the PTEN-4A stable cells proliferate the slowest (compared to the PTEN-WT stable and H1299 cells) 
on Galectin-1 treatment.  (C) Migration assays show that the PTEN-4A cells have the lowest migratory 
capability upon Galectin-1 treatment. These experiments indicate that Galectin-1 preferentially binds to and 
inhibits the tumor-suppressive function of PTEN-WT. Data are derived from experiments performed in 
triplicates ± S.E.  (n=3,*p<0.05). 
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Given the influence of phosphorylation on the protein interactions of PTEN, I used a SILAC based 
mass spectrometry technique to identify protein binding partners for PTEN-WT and its phospho-deficient 
mutant PTEN-4A. My data demonstrate that PTEN-WT and PTEN-4A have a differential protein binding 
profile, which may have implications for PTEN function. I identified Galectin-1 as a candidate protein that 
preferentially bound to PTEN-WT and inhibited its function in cell proliferation and migration assays. Our 
studies on differential binding of Galectin-1 to PTEN-WT opens up avenues to further study the role of 
PTEN phosphorylation and its influence on binding to Galectin-1.  
In summary, I have identified how PTEN phosphorylation and the associated conformational 
change acts as an important modulator of PTEN protein interactions. Given the importance of 
phosphorylation in regulating PTEN function in the nucleus and at the level of PPIs, as shown in chapter 3 
and 4, it would be essential to determine the phosphorylation status of PTEN in human patient samples. 
Therefore, in the next chapter, I assess the phosphorylation status of PTEN in human lung cancer samples 
to establish it as a bonafide PTEN inactivation mechanism with clinical implications.  
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CHAPTER 5: PTEN Status in Human Lung Cancer 
 
Background 
 PTEN mutations occur at a low frequency in lung cancer and are particularly predominant in small-
cell lung cancer (348-350). However, loss of PTEN expression, coupled with AKT activation, is frequently 
observed in lung cancer and is a predictor of poor prognosis (22-27). This loss of PTEN expression is 
attributed to several genomic and non-genomic mechanisms, such as promoter hyper-methylation (103, 
351), transcriptional suppression, suppression by miRNAs (352-356) and  lncRNAs amongst others (357-
359). Further, several factors such as protein mislocalization and post-translational modifications 
compromise PTEN function in tumors (357-359). In Chapter 3, biochemical and molecular biology methods 
were used to show how phosphorylation negatively impacts PTEN function in the nucleus to cause 
transcriptional suppression of E2F1-mediated genes. To determine the clinical relevance of my findings in 
Chapter 3, immuno-histological staining of tissue microarrays (TMA), containing patient lung tumor 
samples of different grades and histological subtypes, was performed. 
 
Materials and Methods 
Immunohistochemistry 
A TMA containing multiple types of lung cancer tissue (of varying grades), cancer adjacent and 
normal lung tissue was obtained from US Biomax (LC-2085a). The TMAs were stained with either an 
antibody to PTEN (6H.2, BioCare) or phospho-PTEN (pSer380/pThr382/pThr383, SAB4300044, Sigma 
Aldrich). Red chromogen or DAB was used as substrates for the PTEN and phospho-PTEN antibodies, 
respectively. Mayer’s hematoxylin was used as a counter stain. All staining was performed at the Tissue 
Core at H. Lee Moffitt Cancer Center and Research Institute (Tampa, FL). 
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Image and Statistical Analysis 
 The stained tissue cores in the TMA were analyzed to calculate percent positivity (percentage of 
the core that showed any and all expression of the protein). Quantitation of nuclear and cytoplasmic PTEN 
levels was done using an algorithm that extends the cells from the nucleus (identified by the hematoxylin 
stain) in a fixed distance in all directions. The TMAs were analyzed at the Analytical Microscopy Core at 
H. Lee Moffitt Cancer Center and Research Institute (Tampa, FL). Statistical analysis for the analyzed data 
was done using the IBM SPSS Software Suite. Outliers were removed using Tukey’s Test (360, 361) and 
significance was determined using Mann-Whitney Tests.  
 
Results 
PTEN Expression Levels are Reduced in Lung Cancer 
 Staining of a lung cancer TMA with a PTEN antibody revealed that lung tumors show a decreased 
level of PTEN compared to cancer-adjacent (CA) or normal lung tissue. Intriguingly, cancer-adjacent 
tissues show greater PTEN expression compared to normal lung tissue (Figure 5.1A). However, most of 
the PTEN in cancer-adjacent tissues is inactivated through phosphorylation (see Figure 5.2 below). Both 
non-small cell (adenocarcinoma, squamous carcinoma) and small-cell lung cancer tissues show reduced 
PTEN expression when compared to normal and cancer-adjacent tissues (Figure 5.1B). Further, the 
expression of PTEN was inversely correlated with tumor grade (Figure 5.1C).  
 
Nuclear PTEN Levels are Reduced in Lung Cancer 
 Nuclear and cytoplasmic levels of PTEN were determined using the TMA stained with the PTEN 
antibody. Lung tumor tissues showed a lower PTEN nuclear-to-cytoplasmic (N/C) ratio compared to 
cancer-adjacent or normal lung tissue (Figure 5.1D). The PTEN N/C ratio was reduced across all 
histological subtypes of lung cancer analyzed (Figure 5.1E) and decreased with increasing tumor grade 
(Figure 5.1F). These results are consistent with the critical role of PTEN in the nucleus, as identified in 
Chapter 4 and findings by others (31, 76, 80, 81, 99, 100, 163, 255, 362-366).  
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Figure 5.1: Total PTEN and Nuclear PTEN levels are Reduced in Human Lung Cancer Samples.              
(A) Total PTEN expression levels are reduced in tumor tissue compared to normal and cancer adjacent lung 
tissue, as quantitatively examined by histological staining of a tissue microarray (No. of samples: 137 
(tumor), 16 (normal), 13 (cancer-adjacent), *p<0.05). (B) Total PTEN expression levels are reduced in non-
small cell lung tumors (adenocarcinoma and squamous cell carcinomas) and in small-cell lung tumors (No. 
of samples: 60 (adenocarcinoma), 57 (squamous carcinoma), 18 (small-cell lung cancer), 16 (normal), 13 
(cancer-adjacent), *p<0.05). (C) Total PTEN expression levels decrease with increasing tumor grade (No. 
of samples: 87 (low and moderate grade), 31 (high grade), 16 (normal), 13 (cancer-adjacent), *p<0.05).  
(D) The nuclear to cytoplasmic ratio (N/C ratio) of PTEN levels is decreased in tumor tissue compared to 
normal and cancer adjacent lung tissue (No. of samples: 160 (tumor), 20 (normal), 10 (cancer-adjacent), 
*p<0.05). (E) PTEN N/C ratios are reduced in non-small cell lung tumors (adenocarcinoma and squamous 
cell carcinomas) and in small-cell lung tumors (No. of  samples: 66 (adenocarcinoma), 71 (squamous 
carcinoma), 22 (small cell lung cancer), 20 (normal), 10 (cancer-adjacent), *p<0.05). (F) PTEN N/C ratios 
decrease with increasing tumor grade (No. of samples: 96 (low and moderate grade), 37 (high grade), 20 
(normal), 10 (cancer-adjacent), *p<0.05). 
 75 
  
   
Figure 5.2: PTEN C-tail Phosphorylation is Increased in Human Lung Cancer. (A) Relative pPTEN 
expression levels are increased in tumor tissue compared to normal and cancer adjacent lung tissue (No. of 
samples: 136 (tumor), 14 (normal), 13 (cancer-adjacent), *p<0.05). (B) Relative pPTEN expression levels 
are increased in non-small cell lung tumors (adenocarcinoma and squamous cell carcinomas) and in small-
cell lung tumors (No. of samples: 59 (adenocarcinoma), 57 (squamous carcinoma), 18 (small-cell lung 
cancer), 14 (normal), 13 (cancer-adjacent), *p<0.05). (C and D) Relative pPTEN expression levels increase 
with increasing tumor grade (No. of samples: 87 (low and moderate grade), 31 (high grade), 14 (normal), 
13 (cancer-adjacent, *p<0.05). 
 
PTEN C-tail Phosphorylation is Increased in Lung Cancer 
 Data from Chapter 3 indicates that phosphorylation of PTEN at the C-tail compromises its function 
as a tumor suppressor. To validate my findings obtained in cell culture experiments, I stained the lung 
cancer TMA using a phospho-specific PTEN antibody, which recognizes C-tail phosphorylation. Levels of 
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pPTEN (phosphorylated PTEN) were normalized to total PTEN to account for lower PTEN expression in 
tumor samples. I observed that the relative pPTEN levels were elevated in tumor tissue (Figure 5.2A), 
across all histological subtypes (Figure 5.2B) and increased with the grade of the tumor (Figure 5.2C and 
D). These results indicate that PTEN C-tail phosphorylation is a bonafide inactivation mechanism for PTEN 
in human lung cancer and is positively correlated with a higher grade, indicative of its role in driving 
advanced stage lung cancers.  
 
Conclusion  
 A majority of patient lung tumors exhibit aberrant PI3K/AKT/mTOR signaling despite the relative 
low frequency of PTEN mutations (367, 368). Loss of PTEN expression, as shown by me (Figure 5.1) and 
others (22-25, 369), could explain, in part, the hyper-activation of the PI3K/AKT/mTOR pathway as seen 
in lung tumors. Intriguingly, cigarette smoke, which is a risk factor for the development of NSCLC, is 
known to reduce PTEN expression (21). Further, PTEN phosphorylation has increasingly been observed as 
a PTEN inactivating mechanism in several cancers (212, 370-372) and other non-malignant diseases (373-
375). Consistent with these observations, increased PTEN C-tail phosphorylation was observed in my lung 
cancer TMA (Figure 5.2).  
PTEN nuclear localization is controlled by several post-translational modifications, such as 
phosphorylation and ubiquitination (166, 332). PTEN nuclear levels are diminished in several cancer types 
(376-381). Consistent with the emerging nuclear role of PTEN in tumor suppression, low levels of nuclear 
PTEN were observed in my studies with lung cancer samples.  
While it is not clear whether loss of PTEN is a driving factor for development or progression of 
lung cancer, PTEN expression/activity levels frequently influence tumor drug sensitivity (382). Loss of 
PTEN is associated with resistance to tyrosine kinase inhibitor (TKI) therapy, particularly in Epidermal 
Growth Factor Receptor (EGFR) mutant lung tumors (28). PTEN loss also causes resistance to gamma-
secretase inhibitors (GSIs) (383) and T-cell mediated immunotherapy in melanoma (384), two therapeutic 
strategies that are gaining popularity in lung cancer, particularly with the emergence of PD-1/PD-L1 based 
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immunotherapies (385). Further, loss of PTEN renders several different tumor types susceptible to certain 
drugs, allowing the use of synthetic lethal combination therapies. PTEN-deficient cancers are found to be 
particularly susceptible to treatment with PARP inhibitors (386) and PI3K/p110β-specific inhibitors (387-
389).  Nemo-Like Kinase (NLK), Polo-Like Kinase 4 (PLK4) and MonoPolar Spindle 1 (MLK) are other 
synthetic lethal genes in PTEN-deficient tumors (390). Therefore, PTEN status could potentially be 
exploited to tailor therapeutic regimens for lung cancer patients with PTEN-deficient tumors or patients 
whose lung tumors have high levels of phosphorylated PTEN.  
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CHAPTER 6: Discussion 
Despite its discovery over two decades ago, the crystal structure of the entire PTEN protein has yet 
to be determined (285, 286). The intrinsically disordered N- and C-tails of PTEN and its conformational 
changes induced by phosphorylation contribute to the dynamic and heterogeneous PTEN structure making 
it challenging to obtain a single snapshot of the PTEN structure (391). The discovery of PTEN dimers and 
various proteoforms (41) has further increased the level of complexity (200). Several alternate methods 
such as hydrogen deuterium exchange, neutron scattering and protein semi-synthesis based studies have 
been used to understand PTEN membrane binding and phosphorylation mediated confrontational changes 
(192, 297, 392). In my thesis, I have shown that the PTEN C-tail is a bonafide IDR and is a hot spot for 
PTMs and PPIs (101). Interactions of PTEN with other proteins may induce partial order in its C-tail and 
this may represent a strategy to learn more about the structure of the PTEN C-tail in a complex with one of 
its binding partners. This possibility is substantiated by the fact that the PTEN C-tail has two MoRFs that 
may participate in disorder-to-order transitions upon binding to another protein (101). 
PTEN has several translational isoforms that are produced due to non-AUG transcriptional 
initiation resulting in proteoforms with N-terminal extensions (41). The most well characterized PTEN 
proteoform, PTEN-L, has an N-terminal extension comprising of 173 amino acids (N-173 region) that is 
intrinsically disordered (46). The N-173 extension of PTEN-L provides it with unique functionalities such 
as the ability to be secreted and re-enter cells (42, 43). The N-173 region also contains a putative membrane-
binding helix which alters its membrane association dynamics as compared to PTEN (45). Further, studies 
have also indicated that PTEN-L is a constitutively active phosphatase in contrast to PTEN (44). Therefore, 
the intrinsically disordered tails of both PTEN and PTEN-L have a profound effect on its sub-cellular 
localization and function (42, 47).  
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The PTEN C-tail is frequently modified via phosphorylation. The serine/threonine cluster in the 
PTEN C-tail (Ser380, Thr382, Thr383 and Ser385), when phosphorylated, regulates PTEN stability, sub-
cellular localization and activity (193-195). Upon C-tail phosphorylation, the disordered tail intra-
molecularly associates with the rest of the PTEN protein resulting in a closed inactive conformation of 
PTEN wherein its catalytic domain (PD) and membrane binding C2D are occluded by the tail. Upon 
dephosphorylation, the PTEN molecule adopts a more open conformation which is active (193-195). Using 
a phospho-deficient mutant of PTEN, PTEN-4A, I have investigated the effect of PTEN phosphorylation 
on its nuclear function and its ability to bind to the other proteins.  
PTEN-4A is a phospho-deficient constitutively active mutant of PTEN that has more potent tumor 
suppressor properties than PTEN-WT. I observed that PTEN-4A preferentially localized to the nucleus 
compared to PTEN-WT. This is consistent with recently published articles from other groups (166, 312). 
Within the nucleus, PTEN inhibits the cell cycle specifically at the G1/S and G2/M transitions (18, 92, 93, 
100, 316). The role of PTEN phosphorylation on cell cycle progression through the M phase of the cell 
cycle was recently established (100). In my thesis, I focused my attention on elucidating the role of PTEN 
phosphorylation in regulating the G1/S phase of the cell cycle. Consequently, I observed that PTEN-4A 
preferentially inhibits the transcription of E2F1-regulated cell cycle genes. PTEN-4A was also found to be 
physically associated with the E2F1 protein and at E2F1 DNA binding sites on the cyclin D1 and E1 
promoters. The exact mechanism by which PTEN inhibits E2F1 transcription is not known. It is possible 
that the PTEN mediated E2F1 transcriptional suppression is a global effect of the role that PTEN plays in 
regulating chromatin condensation via its interaction with histone H1. Although it is relevant to note that 
ideal chromatin architecture may not be achieved in my transient transcriptional studies with episomal 
templates, nucleosome assembly is observed to occur with appropriate histone octamer stoichiometry along 
with some histone H1 deposition (393). Alternatively, PTEN may recruit a transcriptional suppressor or 
block the binding of an important transcriptional activator near the E2F1 DNA binding sites. For example, 
prohibitin through heterochromatin protein 1 inhibits E2F1 transcription (321, 394-396). Gong et al have 
recently shown that PTEN binds to HP1 to regulate heterochromatin structure (255) and I have identified 
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prohibitin as a PTEN interacting protein in my proteomics study. Further, the effect of PTEN on the cell 
cycle, at least in part, maybe through maintaining hypo-phosphorylated RB through its protein phosphatase 
activity. Further, whether PTEN can directly bind to DNA remains to be determined; although its binding 
to chromatin may suffice its role as a transcriptional modulator. 
Mechanistic studies revealed that the effect of PTEN on E2F-mediated transcription occurs through 
both phosphatase dependent and independent effects. Deletion analysis of PTEN revealed that the C2D 
region is critical for its transcriptional function. Indeed, several disease associated C2D mutants lose their 
ability to suppress E2F1-mediated transcription. The exact mechanism of the loss of function is yet to be 
determined. It is possible that the PTEN mutants have altered nuclear localization patterns or have impaired 
E2F1 binding capabilities.  
Nyugen et al have suggested that PTEN-4A preferentially localizes to the nucleus due to 
accessibility and increased ubiquitination at the Lys13 site (166). Whether this is true in my system and the 
role of Lys13 on the transcriptional role of PTEN remains to be determined. Interestingly, my proteomics 
based experiments revealed that PTEN-4A preferentially binds to Ran, a known nuclear transporter for 
PTEN (154), which could explain the observed increased nuclear localization of PTEN-4A. In contrast to 
PTEN-4A which is a constitutively active form of PTEN, PTEN-4E represents a phospho-mimetic mutant 
of PTEN. PTEN-4E has reduced catalytic activity (297). In my transcriptional assays, however, I observe 
that even PTEN-4E can suppress E2F-transcription (data not shown). This may be explained by the fact 
that PTEN-4E can be monoubiquitinated and transported to the nucleus (161). Further, these observations 
reinforce that PTEN suppresses the transcription of cell cycle genes at least in part by a phosphatase 
independent mechanism. In summary, the transcriptional studies indicate that both PTEN-WT and PTEN-
4A can inhibit the transcription of E2F1 regulated genes and the effect of PTEN-4A is more pronounced 
due to its enhanced phosphatase activity, increased nuclear localization and accessibility of the C2D.  
Further, to investigate the effect of phosphorylation on the PPIs of PTEN, I performed a SILAC 
based proteomics experiment. For this experiment, nuclear and cytoplasmic proteins were isolated using 
dounce homogenization. No detergents were used during the extraction. This method, however, does not 
 81 
  
allow for the detection of chromatin bound PTEN complexes but rather only the soluble nuclear PTEN 
complexes. Several alternate nuclear isolation protocols have resulted in the identification of different 
proteins by proteomics (397). It would be interesting to identify chromatin bound PTEN complexes given 
its increasingly evident roles in regulating transcription and chromatin structure.  
I identified several known PTEN binding proteins validating the method and the strength of my 
analysis. Few proteins exclusively bound to either the WT or the 4A forms of the PTEN protein. Most other 
proteins showed a preferential interaction pattern with one of the PTEN variants. Galectin-1 was identified 
as a candidate for validation given its relevance in oncogenic signaling. Galectin-1 preferentially interacted 
with PTEN-WT. In proliferation and migration assays, PTEN-4A was more effective than PTEN-WT at 
countering the oncogenic effects of Galectin-1, thereby indicating that Galectin-1 suppresses the full 
potential of PTEN-WT function. Whether PTEN can in turn inhibit Galectin-1 function remains yet to be 
determined. Further, the exact mechanism of the preferential binding of PTEN-WT to Galectin-1 is not 
known. It is possible that the closed conformation of PTEN-WT has certain interaction interfaces that are 
lost upon transition to the open conformation of PTEN-4A. Alternatively, it is plausible that a kinase such 
as CK1 or CK2 mediates the interaction between PTEN and Galectin and therefore PTEN-WT which is 
susceptible to phosphorylation preferentially binds to Galectin. Experiments using recombinant Galectin-1 
and Galectin-1 inhibitors can be used to determine whether Galectin-1 affects PTEN phosphorylation 
levels. 
In order to determine the clinical relevance of PTEN phosphorylation in lung cancer, 
immunohistochemical staining of a lung cancer tissue microarray was performed using PTEN and phospho-
PTEN antibodies.  The analysis revealed that PTEN levels were reduced in lung tumors and have an inverse 
correlation with tumor grade. The nuclear levels of PTEN were also reduced in the tumors indicating a 
functional role for PTEN in the nucleus as a tumor suppressor. Further, the relative levels of phospho-PTEN 
(normalized to total PTEN levels) were significantly higher in tumor tissue and had a direct correlation with 
the tumor grade. These observations establish that non-genomic mechanisms such as phosphorylation play 
a key role in downregulation of PTEN expression/activity and alter PTEN subcellular localization. 
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However, I did not, observe a correlation between nuclear levels of phospho-PTEN in tumor and normal 
tissue. This may be explained by additional PTMs such as monoubiquitination or sumoylation which may 
have a more profound effect on PTEN nuclear transport compared to PTEN phosphorylation (163, 332). 
Further, since non-phosphorylated PTEN preferentially localizes to the nucleus it may be more pertinent to 
stain the TMA using a non-phospho specific PTEN antibody. 
In summary, I have identified PTEN C-tail as an intrinsically disordered protein which controls 
PTEN function via various PTMs and PPIs. Phosphorylation at the PTEN C-tail inhibits its nuclear function, 
particularly E2F1-mediated transcription and regulation of cell cycle genes.  Phosphorylation at the PTEN 
C-tail also alters its protein binding profile. Analysis of human patient lung tumor samples reveal that PTEN 
C-tail phosphorylation is elevated in tumors, establishing PTEN-phosphorylation as a bonafide mechanism 
of PTEN inactivation in lung cancer. This phenomenon of PTEN inactivation, via phosphorylation, in 
cancer may play critical roles in driving oncogenesis, EMT and metastasis, opening up avenues that are yet 
to be explored. Small molecule compounds that inhibit PTEN phosphorylation may therefore be used as 
adjunctive cancer therapies in the clinical setting. 
 
 
 
 
 
 
 
 
 
 
 
 
 83 
  
 
 
 
References 
1. Cancer Facts & Figures 2016. Atlanta: American Cancer Society. 
2. Proctor, R.N. 2012. The history of the discovery of the cigarette-lung cancer link: evidentiary 
traditions, corporate denial, global toll. Tob Control 21:87-91. 
3. Field, R.W., and Withers, B.L. 2012. Occupational and Environmental Causes of Lung Cancer. 
Clinics in Chest Medicine 33:681-+. 
4. Kramer, B.S., Berg, C.D., Aberle, D.R., and Prorok, P.C. 2011. Lung cancer screening with low-
dose helical CT: results from the National Lung Screening Trial (NLST). Journal of Medical 
Screening 18:109-111. 
5. Mariotto, A.B., Yabroff, K.R., Shao, Y., Feuer, E.J., and Brown, M.L. 2011. Projections of the cost 
of cancer care in the United States: 2010-2020. J Natl Cancer Inst 103:117-128. 
6. Kumar V., A.A.K., Aster J.C. 2013. Robbins Basic Pathology. Philadelphia, PA: Elsevier Saunders. 
459-515. 
7. Hirsch, F.R., Scagliotti, G.V., Mulshine, J.L., Kwon, R., Curran, W.J., Jr., Wu, Y.L., and Paz-Ares, 
L. 2016. Lung cancer: current therapies and new targeted treatments. Lancet. 
8. Karim, S.M., and Zekri, J. 2012. Chemotherapy for small cell lung cancer: a comprehensive review. 
Oncol Rev 6:e4. 
9. Abidin, A.Z., Garassino, M.C., Califano, R., Harle, A., and Blackhall, F. 2010. Targeted therapies 
in small cell lung cancer: a review. Ther Adv Med Oncol 2:25-37. 
10. Horn, L., Reck, M., and Spigel, D.R. 2016. The Future of Immunotherapy in the Treatment of Small 
Cell Lung Cancer. Oncologist 21:910-921. 
11. Peifer, M., Fernandez-Cuesta, L., Sos, M.L., George, J., Seidel, D., Kasper, L.H., Plenker, D., 
Leenders, F., Sun, R., Zander, T., et al. 2012. Integrative genome analyses identify key somatic 
driver mutations of small-cell lung cancer. Nat Genet 44:1104-1110. 
12. Semenova, E.A., Nagel, R., and Berns, A. 2015. Origins, genetic landscape, and emerging therapies 
of small cell lung cancer. Genes Dev 29:1447-1462. 
13. Rudin, C.M., Durinck, S., Stawiski, E.W., Poirier, J.T., Modrusan, Z., Shames, D.S., Bergbower, 
E.A., Guan, Y.H., Shin, J., Guillory, J., et al. 2012. Comprehensive genomic analysis identifies 
SOX2 as a frequently amplified gene in small-cell lung cancer. Nature Genetics 44:1111-+. 
14. Wistuba, II, Gazdar, A.F., and Minna, J.D. 2001. Molecular genetics of small cell lung carcinoma. 
Semin Oncol 28:3-13. 
15. Mori, N., Yokota, J., Akiyama, T., Sameshima, Y., Okamoto, A., Mizoguchi, H., Toyoshima, K., 
Sugimura, T., and Terada, M. 1990. Variable mutations of the RB gene in small-cell lung 
carcinoma. Oncogene 5:1713-1717. 
16. Arriola, E., Canadas, I., Arumi, M., Rojo, F., Rovira, A., and Albanell, J. 2008. Genetic changes in 
small cell lung carcinoma. Clin Transl Oncol 10:189-197. 
17. Yokomizo A, T.D., Drabkin H, Gemmill R, Franklin W, Yang P, Sugio K, Smith DI, Liu W. 1998. 
PTEN/MMAC1 mutations identified in small cell, but not in non-small cell lung cancers. Oncogene 
17:475-479. 
18. Sun, H., Lesche, R., Li, D.M., Liliental, J., Zhang, H., Gao, J., Gavrilova, N., Mueller, B., Liu, X., 
and Wu, H. 1999. PTEN modulates cell cycle progression and cell survival by regulating 
phosphatidylinositol 3,4,5,-trisphosphate and Akt/protein kinase B signaling pathway. Proc Natl 
Acad Sci U S A 96:6199-6204. 
 84 
  
19. Yanagi, S., Kishimoto, H., Kawahara, K., Sasaki, T., Sasaki, M., Nishio, M., Yajima, N., Hamada, 
K., Horie, Y., Kubo, H., et al. 2007. Pten controls lung morphogenesis, bronchioalveolar stem cells, 
and onset of lung adenocarcinomas in mice. J Clin Invest 117:2929-2940. 
20. Dave, V., Wert, S.E., Tanner, T., Thitoff, A.R., Loudy, D.E., and Whitsett, J.A. 2008. Conditional 
deletion of Pten causes bronchiolar hyperplasia. Am J Respir Cell Mol Biol 38:337-345. 
21. Yamada, K., Asai, K., Ohara, Y., Sugiyama, Y., Shirai, A., Sato, K., Yamamoto, N., Tamagaki, G., 
Watanabe, T., Konishi, K., et al. 2014. The effect of smoking on phosphoinositide 3-kinase (PI3K) 
and phosphatase and tensin homolog deleted from chromosome 10 (PTEN) mRNA expression in 
human airway epithelial cells. European Respiratory Journal 44. 
22. Marsit, C.J., Zheng, S., Aldape, K., Hinds, P.W., Nelson, H.H., Wiencke, J.K., and Kelsey, K.T. 
2005. PTEN expression in non-small-cell lung cancer: evaluating its relation to tumor 
characteristics, allelic loss, and epigenetic alteration. Hum Pathol 36:768-776. 
23. Tang, J.M., He, Q.Y., Guo, R.X., and Chang, X.J. 2006. Phosphorylated Akt overexpression and 
loss of PTEN expression in non-small cell lung cancer confers poor prognosis. Lung Cancer 
51:181-191. 
24. Cetin, Z., Ozbilim, G., Erdogan, A., Luleci, G., and Karauzum, S.B. 2010. Evaluation of PTEN and 
Mcl-1 expressions in NSCLC expressing wild-type or mutated EGFR. Med Oncol 27:853-860. 
25. Yanagawa, N., Leduc, C., Kohler, D., Saieg, M.A., John, T., Sykes, J., Yoshimoto, M., Pintilie, M., 
Squire, J., Shepherd, F.A., et al. 2012. Loss of Phosphatase and Tensin Homolog Protein 
Expression Is an Independent Poor Prognostic Marker in Lung Adenocarcinoma. Journal of 
Thoracic Oncology 7:1513-1521. 
26. Xiao, J., Hu, C.-P., He, B.-X., Chen, X., Lu, X.-X., Xie, M.-X., Li, W., He, S.-Y., You, S.-J., and 
Chen, Q. 2016. PTEN expression is a prognostic marker for patients with non-small cell lung 
cancer: a systematic review and meta-analysis of the literature. 
27. Li, X.B., Yang, Y., Zhang, H.Q., Yue, W.T., Zhang, T.M., Lu, B.H., Li, J., Liu, Z., Wang, Q.H., 
Gao, Y., et al. 2015. High levels of Phosphatase and Tensin Homolog Expression Predict Favorable 
Prognosis in Patients with Non-small Cell Lung Cancer. Cell Biochemistry and Biophysics 73:631-
637. 
28. Sos, M.L., Koker, M., Weir, B.A., Heynck, S., Rabinovsky, R., Zander, T., Seeger, J.M., Weiss, J., 
Fischer, F., Frommolt, P., et al. 2009. PTEN Loss Contributes to Erlotinib Resistance in EGFR-
Mutant Lung Cancer by Activation of Akt and EGFR. Cancer Research 69:3256-3261. 
29. Zeng, T.L., Wang, Q., Fu, J.Y., Lin, Q., Bi, J., Ding, W.C., Qiao, Y.K., Zhang, S., Zhao, W.X., 
Lin, H.Y., et al. 2014. Impeded Nedd4-1-Mediated Ras Degradation Underlies Ras-Driven 
Tumorigenesis. Cell Reports 7:871-882. 
30. Ramaswamy, S., Nakamura, N., Vazquez, F., Batt, D.B., Perera, S., Roberts, T.M., and Sellers, 
W.R. 1999. Regulation of G(1) progression by the PTEN tumor suppressor protein is linked to 
inhibition of the phosphatidylinositol 3-kinase/Akt pathway. Proceedings of the National Academy 
of Sciences of the United States of America 96:2110-2115. 
31. Gu, T.T., Zhang, Z., Wang, J.L., Guo, J.Y., Shen, W.H., and Yin, Y.X. 2011. CREB Is a Novel 
Nuclear Target of PTEN Phosphatase. Cancer Research 71:2821-2825. 
32. Shi, Y.J., Wang, J.R., Chandarlapaty, S., Cross, J., Thompson, C., Rosen, N., and Jiang, X.J. 2014. 
PTEN is a protein tyrosine phosphatase for IRS1. Nature Structural & Molecular Biology 21:522-
527. 
33. Tamura, M., Gu, J.G., Danen, E.H.J., Takino, T., Miyamoto, S., and Yamada, K.M. 1999. PTEN 
interactions with focal adhesion kinase and suppression of the extracellular matrix-dependent 
phosphatidylinositol 3-kinase/Akt cell survival pathway. Journal of Biological Chemistry 
274:20693-20703. 
34. Shinde, S.R., and Maddika, S. 2016. PTEN modulates EGFR late endocytic trafficking and 
degradation by dephosphorylating Rab7. Nature Communications 7. 
35. Song, M.S., Salmena, L., and Pandolfi, P.P. 2012. The functions and regulation of the PTEN 
tumour suppressor. Nat Rev Mol Cell Biol 13:283-296. 
 85 
  
36. McBride, K.L., Varga, E.A., Pastore, M.T., Prior, T.W., Manickam, K., Atkin, J.F., and Herman, 
G.E. 2010. Confirmation Study of PTEN Mutations Among Individuals with Autism or 
Developmental Delays/Mental Retardation and Macrocephaly. Autism Research 3:137-141. 
37. Tan, M.H., Mester, J.L., Ngeow, J., Rybicki, L.A., Orloff, M.S., and Eng, C. 2012. Lifetime cancer 
risks in individuals with germline PTEN mutations. Clin Cancer Res 18:400-407. 
38. Worby, C.A., and Dixon, J.E. 2014. Pten. Annual Review of Biochemistry, Vol 83 83:641-669. 
39. Berger, A.H., Knudson, A.G., and Pandolfi, P.P. 2011. A continuum model for tumour suppression. 
Nature 476:163-169. 
40. Carracedo, A., Alimonti, A., and Pandolfi, P.P. 2011. PTEN Level in Tumor Suppression: How 
Much Is Too Little? Cancer Research 71:629-633. 
41. Tzani, I., Ivanov, I.P., Andreev, D.E., Dmitriev, R.I., Dean, K.A., Baranov, P.V., Atkins, J.F., and 
Loughran, G. 2016. Systematic analysis of the PTEN 5' leader identifies a major AUU initiated 
proteoform. Open Biol 6. 
42. Hopkins, B.D., Fine, B., Steinbach, N., Dendy, M., Rapp, Z., Shaw, J., Pappas, K., Yu, J.S., 
Hodakoski, C., Mense, S., et al. 2013. A Secreted PTEN Phosphatase That Enters Cells to Alter 
Signaling and Survival. Science 341:399-402. 
43. Wang, H., Zhang, P., Lin, C.H., Yu, Q.X., Wu, J.T., Wang, L., Cui, Y.P., Wang, K., Gao, Z.L., and 
Li, H. 2015. Relevance and Therapeutic Possibility of PTEN-Long in Renal Cell Carcinoma. Plos 
One 10. 
44. Johnston, S.B., and Raines, R.T. 2015. Catalysis by the Tumor-Suppressor Enzymes PTEN and 
PTEN-L. Plos One 10. 
45. Masson, G.R., Perisic, O., Burke, J.E., and Williams, R.L. 2016. The intrinsically disordered tails 
of PTEN and PTEN-L have distinct roles in regulating substrate specificity and membrane activity. 
Biochemical Journal 473:135-144. 
46. Malaney, P., Uversky, V.N., and Dave, V. 2013. The PTEN Long N-tail is intrinsically disordered: 
increased viability for PTEN therapy. Molecular Biosystems 9:2877-2888. 
47. Liang, H., He, S.M., Yang, J.Y., Jia, X.Y., Wang, P., Chen, X., Zhang, Z., Zou, X.J., McNutt, M.A., 
Shen, W.H., et al. 2014. PTEN alpha, a PTEN Isoform Translated through Alternative Initiation, 
Regulates Mitochondrial Function and Energy Metabolism. Cell Metabolism 19:836-848. 
48. Shen, S.M., Guo, M., Xiong, Z., Yu, Y., Zhao, X.Y., Zhang, F.F., and Chen, G.Q. 2015. AIF 
inhibits tumor metastasis by protecting PTEN from oxidation. Embo Reports 16:1563-1580. 
49. Zu, L.Y., Zheng, X.X., Wang, B., Parajuli, N., Steenbergen, C., Becker, L.C., and Cai, Z.P. 2011. 
Ischemic preconditioning attenuates mitochondrial localization of PTEN induced by ischemia-
reperfusion. American Journal of Physiology-Heart and Circulatory Physiology 300:H2177-
H2186. 
50. Bononi, A., Bonora, M., Marchi, S., Missiroli, S., Poletti, F., Giorgi, C., Pandolfi, P.P., and Pinton, 
P. 2013. Identification of PTEN at the ER and MAMs and its regulation of Ca2+ signaling and 
apoptosis in a protein phosphatase-dependent manner. Cell Death and Differentiation 20:1631-
1643. 
51. Zhu, Y., Hoell, P., Ahlemeyer, B., and Krieglstein, J. 2006. PTEN: A crucial mediator of 
mitochondria-dependent apoptosis. Apoptosis 11:197-207. 
52. Naguib, A., Bencze, G., Cho, H., Zheng, W., Tocilj, A., Elkayam, E., Faehnle, C.R., Jaber, N., 
Pratt, C.P., Chen, M.H., et al. 2015. PTEN Functions by Recruitment to Cytoplasmic Vesicles. 
Molecular Cell 58:255-268. 
53. Putz, U., Howitt, J., Doan, A., Goh, C.P., Low, L.H., Silke, J., and Tan, S.S. 2012. The Tumor 
Suppressor PTEN Is Exported in Exosomes and Has Phosphatase Activity in Recipient Cells. 
Science Signaling 5. 
54. Gabriel, K., Ingram, A., Austin, R., Kapoor, A., Tang, D., Majeed, F., Qureshi, T., and Al-Nedawi, 
K. 2013. Regulation of the Tumor Suppressor PTEN through Exosomes: A Diagnostic Potential 
for Prostate Cancer. Plos One 8. 
 86 
  
55. Garcia-Cao, I., Song, M.S., Hobbs, R.M., Laurent, G., Giorgi, C., de Boer, V.C.J., Anastasiou, D., 
Ito, K., Sasaki, A.T., Rameh, L., et al. 2012. Systemic Elevation of PTEN Induces a Tumor-
Suppressive Metabolic State. Cell 149:49-62. 
56. Ortega-Molina, A., Efeyan, A., Lopez-Guadamillas, E., Munoz-Martin, M., Gomez-Lopez, G., 
Canamero, M., Mulero, F., Pastor, J., Martinez, S., Romanos, E., et al. 2012. Pten Positively 
Regulates Brown Adipose Function, Energy Expenditure, and Longevity. Cell Metabolism 15:382-
394. 
57. Palian, B.M., Rohira, A.D., Johnson, S.A.S., He, L., Zheng, N., Dubeau, L., Stiles, B.L., and 
Johnson, D.L. 2014. Maf1 Is a Novel Target of PTEN and PI3K Signaling That Negatively 
Regulates Oncogenesis and Lipid Metabolism. Plos Genetics 10. 
58. Gassama-Diagne, A., Yu, W., ter Beest, M., Martin-Belmonte, F., Kierbel, A., Engel, J., and 
Mostov, K. 2006. Phosphatidylinositol-3,4,5-trisphosphate regulates the formation of the 
basolateral plasma membrane in epithelial cells. Nat Cell Biol 8:963-970. 
59. Martin-Belmonte, F., Gassama, A., Datta, A., Yu, W., Rescher, U., Gerke, V., and Mostov, K. 
2007. PTEN-mediated apical segregation of phosphoinositides controls epithelial morphogenesis 
through Cdc42. Cell 128:383-397. 
60. von Stein, W., Ramrath, A., Grimm, A., Muller-Borg, M., and Wodarz, A. 2005. Direct association 
of Bazooka/PAR-3 with the lipid phosphatase PTEN reveals a link between the PAR/aPKC 
complex and phosphoinositide signaling. Development 132:1675-1686. 
61. Kotelevets, L., van Hengel, J., Bruyneel, E., Mareel, M., van Roy, F., and Chastre, E. 2005. 
Implication of the MAGI-1b/PTEN signalosome in stabilization of adherens junctions and 
suppression of invasiveness. FASEB J 19:115-117. 
62. Yan, M., Or, P., and Chan, A. 2015. Abstract 308: The role of PTEN PDZ-binding domain in 
mammary gland tumorigenesis. Cancer Research 75:308-308. 
63. Shnitsar, I., Bashkurov, M., Masson, G.R., Ogunjimi, A.A., Mosessian, S., Cabeza, E.A., Hirsch, 
C.L., Trcka, D., Gish, G., Jiao, J., et al. 2015. PTEN regulates cilia through Dishevelled. Nature 
Communications 6. 
64. Ohtoshi, A. 2008. Hydrocephalus caused by conditional ablation of the Pten or beta-catenin gene. 
Cerebrospinal Fluid Res 5:16. 
65. Louvi, A., and Grove, E.A. 2011. Cilia in the CNS: the quiet organelle claims center stage. Neuron 
69:1046-1060. 
66. Tiozzo, C., De Langhe, S., Yu, M.K., Londhe, V.A., Carraro, G., Li, M., Li, C.G., Xing, Y.M., 
Anderson, S., Borok, Z., et al. 2009. Deletion of Pten Expands Lung Epithelial Progenitor Pools 
and Confers Resistance to Airway Injury. American Journal of Respiratory and Critical Care 
Medicine 180:701-712. 
67. Zacharek, S.J., Fillmore, C.M., Lau, A.N., Gludish, D.W., Chou, A., Ho, J.W.K., Zamponi, R., 
Gazit, R., Bock, C., Jager, N., et al. 2011. Lung Stem Cell Self-Renewal Relies on BMI1-
Dependent Control of Expression at Imprinted Loci. Cell Stem Cell 9:272-280. 
68. Song, L.B., Li, J., Liao, W.T., Feng, Y., Yu, C.P., Hu, L.J., Kong, Q.L., Xu, L.H., Zhang, X., Liu, 
W.L., et al. 2009. The polycomb group protein Bmi-1 represses the tumor suppressor PTEN and 
induces epithelial-mesenchymal transition in human nasopharyngeal epithelial cells. Journal of 
Clinical Investigation 119:3626-3636. 
69. Yilmaz, O.H., Valdez, R., Theisen, B.K., Guo, W., Ferguson, D.O., Wu, H., and Morrison, S.J. 
2006. Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. 
Nature 441:475-482. 
70. Zhang, J., Grindley, J.C., Yin, T., Jayasinghe, S., He, X.C., Ross, J.T., Haug, J.S., Rupp, D., Porter-
Westpfahl, K.S., Wiedemann, L.M., et al. 2006. PTEN maintains haematopoietic stem cells and 
acts in lineage choice and leukaemia prevention. Nature 441:518-522. 
71. Duan, S.L., Yuan, G.H., Liu, X.M., Ren, R.T., Li, J.Y., Zhang, W.Z., Wu, J., Xu, X.L., Fu, L.N., 
Li, Y., et al. 2015. PTEN deficiency reprogrammes human neural stem cells towards a glioblastoma 
stem cell-like phenotype. Nature Communications 6. 
 87 
  
72. Richmond, C.A., Shah, M.S., Deary, L.T., Trotier, D.C., Thomas, H., Ambruzs, D.M., Jiang, L., 
Whiles, B.B., Rickner, H.D., Montgomery, R.K., et al. 2015. Dormant Intestinal Stem Cells Are 
Regulated by PTEN and Nutritional Status. Cell Rep 13:2403-2411. 
73. White, A.C., Khuu, J.K., Dang, C.Y., Hu, J., Tran, K.V., Liu, A., Gomez, S., Zhang, Z., Yi, R., 
Scumpia, P., et al. 2014. Stem cell quiescence acts as a tumour suppressor in squamous tumours. 
Nature Cell Biology 16:99-+. 
74. Shen, W.H., Balajee, A.S., Wang, J., Wu, H., Eng, C., Pandolfi, P.P., and Yin, Y. 2007. Essential 
role for nuclear PTEN in maintaining chromosomal integrity. Cell 128:157-170. 
75. Sun, Z., Huang, C., He, J., Lamb, K.L., Kang, X., Gu, T., Shen, W.H., and Yin, Y. 2014. PTEN C-
terminal deletion causes genomic instability and tumor development. Cell Rep 6:844-854. 
76. Choi, B.H., Chen, Y., and Dai, W. 2013. Chromatin PTEN is involved in DNA damage response 
partly through regulating Rad52 sumoylation. Cell Cycle 12:3442-3447. 
77. Chen, J.H., Zhang, P., Chen, W.D., Li, D.D., Wu, X.Q., Deng, R., Jiao, L., Li, X., Ji, J., Feng, G.K., 
et al. 2015. ATM-mediated PTEN phosphorylation promotes PTEN nuclear translocation and 
autophagy in response to DNA-damaging agents in cancer cells. Autophagy 11:239-252. 
78. Ming, M., Feng, L., Shea, C.R., Soltani, K., Zhao, B.Z., Han, W.N., Smart, R.C., Trempus, C.S., 
and He, Y.Y. 2011. PTEN Positively Regulates UVB-Induced DNA Damage Repair. Cancer 
Research 71:5287-5295. 
79. Kang, X., Song, C., Du, X., Zhang, C., Liu, Y., Liang, L., He, J.X., Lamb, K., Shen, W.H., and 
Yin, Y.X. 2015. PTEN stabilizes TOP2A and regulates the DNA decatenation. Scientific Reports 
5. 
80. Feng, J.W., Liang, J., Li, J.J., Li, Y.Q., Liang, H., Zhao, X.Y., McNutt, M.A., and Yin, Y.X. 2015. 
PTEN Controls the DNA Replication Process through MCM2 in Response to Replicative Stress. 
Cell Reports 13:1295-1303. 
81. Chen, Z.H., Zhu, M., Yang, J., Liang, H., He, J., He, S., Wang, P., Kang, X., McNutt, M.A., Yin, 
Y., et al. 2014. PTEN interacts with histone H1 and controls chromatin condensation. Cell Rep 
8:2003-2014. 
82. Fan, C., He, L., Kapoor, A., Rybak, A.P., De Melo, J., Cutz, J.C., and Tang, D. 2009. PTEN inhibits 
BMI1 function independently of its phosphatase activity. Mol Cancer 8:98. 
83. Horita, H., Wysoczynski, C.L., Walker, L.A., Moulton, K.S., Li, M., Ostriker, A., Tucker, R., 
McKinsey, T.A., Churchill, M.E.A., Nemenoff, R.A., et al. 2016. Nuclear PTEN functions as an 
essential regulator of SRF-dependent transcription to control smooth muscle differentiation. Nature 
Communications 7. 
84. Conde-Perez, A., Gros, G., Longvert, C., Pedersen, M., Petit, V., Aktary, Z., Viros, A., Gesbert, F., 
Delmas, V., Rambow, F., et al. 2015. A caveolin-dependent and PI3K/AKT-independent role of 
PTEN in beta-catenin transcriptional activity. Nat Commun 6:8093. 
85. Zhang, L.L., Mu, G.G., Ding, Q.S., Li, Y.X., Shi, Y.B., Dai, J.F., and Yu, H.G. 2015. Phosphatase 
and Tensin Homolog (PTEN) Represses Colon Cancer Progression through Inhibiting Paxillin 
Transcription via PI3K/AKT/NF-kappa B Pathway. Journal of Biological Chemistry 290:15018-
15029. 
86. Li, A.G., Piluso, L.G., Cai, X., Wei, G., Sellers, W.R., and Liu, X. 2006. Mechanistic insights into 
maintenance of high p53 acetylation by PTEN. Molecular Cell 23:575-587. 
87. Lin, M.C., Liu, Y.C., Tam, M.F., Lu, Y.J., Hsieh, Y.T., and Lin, L.Y. 2012. PTEN interacts with 
metal-responsive transcription factor 1 and stimulates its transcriptional activity. Biochemical 
Journal 441:367-377. 
88. Woiwode, A., Johnson, S.A.S., Zhong, S.P., Zhang, C., Roeder, R.G., Teichmann, M., and Johnson, 
D.L. 2008. PTEN represses RNA polymerase III-dependent transcription by targeting the TFIIIB 
complex. Molecular and Cellular Biology 28:4204-4214. 
89. Liu, J.L., Sheng, X.Y., Hortobagyi, Z.K., Mao, Z.Y., Gallick, G.E., and Yung, W.K.A. 2005. 
Nuclear PTEN-mediated growth suppression is independent of Akt down-regulation. Molecular 
and Cellular Biology 25:6211-6224. 
 88 
  
90. Song, M.S., Carracedo, A., Salmena, L., Song, S.J., Egia, A., Malumbres, M., and Pandolfi, P.P. 
2011. Nuclear PTEN regulates the APC-CDH1 tumor-suppressive complex in a phosphatase-
independent manner. Cell 144:187-199. 
91. Paramio, J.M., Navarro, M., Segrelles, C., Gomez-Casero, E., and Jorcano, J.L. 1999. PTEN 
tumour suppressor is linked to the cell cycle control through the retinoblastoma protein. Oncogene 
18:7462-7468. 
92. Radu, A., Neubauer, V., Akagi, T., Hanafusa, H., and Georgescu, M.M. 2003. PTEN induces cell 
cycle arrest by decreasing the level and nuclear localization of cyclin D1. Molecular and Cellular 
Biology 23:6139-6149. 
93. Weng, L.P., Brown, J.L., and Eng, C. 2001. PTEN induces apoptosis and cell cycle arrest through 
phosphoinositol-3-kinase/Akt-dependent and -independent pathways. Human Molecular Genetics 
10:237-242. 
94. Hlobilkova, A., Knillova, J., Svachova, M., Skypalova, P., Krystof, V., and Kolar, Z. 2006. Tumour 
suppressor PTEN regulates cell cycle and protein kinase B/Akt pathway in breast cancer cells. 
Anticancer Res 26:1015-1022. 
95. Chung, J.H., Ostrowski, M.C., Romigh, T., Minaguchi, T., Waite, K.A., and Eng, C. 2006. The 
ERK1/2 pathway modulates nuclear PTEN-mediated cell cycle arrest by cyclin D1 transcriptional 
regulation. Hum Mol Genet 15:2553-2559. 
96. Zeng, N., Yang, K.-T., Bayan, J.-A., He, L., Aggarwal, R., Stiles, J.W., Hou, X., Medina, V., Abad, 
D., Palian, B.M., et al. 2013. PTEN controls β-cell regeneration in aged mice by regulating cell 
cycle inhibitor p16ink4a. Aging Cell 12:1000-1011. 
97. Zhu, X.Y., Kwon, C.H., Schlosshauer, P.W., Ellenson, L.H., and Baker, S.J. 2001. PTEN induces 
G(1) cell cycle arrest and decreases cyclin D3 levels in endometrial carcinoma cells. Cancer 
Research 61:4569-4575. 
98. Moon, S.K., Kim, H.M., and Kim, C.H. 2004. PTEN induces G1 cell cycle arrest and inhibits 
MMP-9 expression via the regulation of NF-kappaB and AP-1 in vascular smooth muscle cells. 
Arch Biochem Biophys 421:267-276. 
99. Kim, S.J., Lee, H.W., Baek, J.H., Cho, Y.H., Kang, H.G., Jeong, J.S., Song, J., Park, H.S., and 
Chun, K.H. 2016. Activation of nuclear PTEN by inhibition of Notch signaling induces G2/M cell 
cycle arrest in gastric cancer. Oncogene 35:251-260. 
100. Choi, B.H., Pagano, M., and Dai, W. 2014. Plk1 Protein Phosphorylates Phosphatase and Tensin 
Homolog ( PTEN) and Regulates Its Mitotic Activity during the Cell Cycle. Journal of Biological 
Chemistry 289:14066-14074. 
101. Malaney, P., Pathak, R.R., Xue, B., Uversky, V.N., and Dave, V. 2013. Intrinsic disorder in PTEN 
and its interactome confers structural plasticity and functional versatility. Sci Rep 3:2035. 
102. Hollander, M.C., Blumenthal, G.M., and Dennis, P.A. 2011. PTEN loss in the continuum of 
common cancers, rare syndromes and mouse models. Nat Rev Cancer 11:289-301. 
103. Soria, J.C., Lee, H.Y., Lee, J.I., Wang, L., Issa, J.P., Kemp, B.L., Liu, D.D., Kurie, J.M., Mao, L., 
and Khuri, F.R. 2002. Lack of PTEN expression in non-small cell lung cancer could be related to 
promoter methylation. Clinical Cancer Research 8:1178-1184. 
104. Tamguney, T., and Stokoe, D. 2007. New insights into PTEN. Journal of Cell Science 120:4071-
4079. 
105. Noguera, N.I., Piredda, M.L., Taulli, R., Catalano, G., Angelini, G., Gaur, G., Nervi, C., Voso, 
M.T., Lunardi, A., Pandolfi, P.P., et al. 2016. PML/RARa inhibits PTEN expression in 
hematopoietic cells by competing with PU.1 transcriptional activity. Oncotarget. 
106. Chou, H.T., Vazquez, R.G., Wang, K., Campbell, R., Milledge, G.Z., Walthall, W.W., and Johnson, 
C.M. 2015. HES-Mediated Repression of Pten in Caenorhabditis elegans. G3 (Bethesda) 5:2619-
2628. 
107. Uygur, B., Abramo, K., Leikina, E., Vary, C., Liaw, L., and Wu, W.S. 2015. SLUG is a Direct 
Transcriptional Repressor of PTEN Tumor Suppressor. Prostate 75:907-916. 
 89 
  
108. Wang, S., Tie, J., Wang, R., Hu, F., Gao, L., Wang, W., Wang, L., Li, Z., Hu, S., Tang, S., et al. 
2015. SOX2, a predictor of survival in gastric cancer, inhibits cell proliferation and metastasis by 
regulating PTEN. Cancer Lett 358:210-219. 
109. Lin, Y., Kang, T., and Zhou, B.P. 2014. Doxorubicin enhances Snail/LSD1-mediated PTEN 
suppression in a PARP1-dependent manner. Cell Cycle 13:1708-1716. 
110. Escriva, M., Peiro, S., Herranz, N., Villagrasa, P., Dave, N., Montserrat-Sentis, B., Murray, S.A., 
Franci, C., Gridley, T., Virtanen, I., et al. 2008. Repression of PTEN phosphatase by Snail1 
transcriptional factor during gamma radiation-induced apoptosis. Mol Cell Biol 28:1528-1540. 
111. Yoshimi, A., Goyama, S., Watanabe-Okochi, N., Yoshiki, Y., Nannya, Y., Nitta, E., Arai, S., Sato, 
T., Shimabe, M., Nakagawa, M., et al. 2011. Evi1 represses PTEN expression and activates 
PI3K/AKT/mTOR via interactions with polycomb proteins. Blood 117:3617-3628. 
112. Lu, J.Y., Jeong, H., Kong, N., Yang, Y.Y., Carroll, J., Luo, H.B.R., Silberstein, L.E., Ma, Y.P., and 
Chai, L. 2009. Stem Cell Factor SALL4 Represses the Transcriptions of PTEN and SALL1 through 
an Epigenetic Repressor Complex. Plos One 4. 
113. Lee, J.Y., Kang, M.B., Jang, S.H., Qian, T., Kim, H.J., Kim, C.H., Kim, Y., and Kong, G. 2009. 
Id-1 activates Akt-mediated Wnt signaling and p27(Kip1) phosphorylation through PTEN 
inhibition. Oncogene 28:824-831. 
114. Zhang, P., Chen, J.H., and Guo, X.L. 2012. New insights into PTEN regulation mechanisms and 
its potential function in targeted therapies. Biomedicine & Pharmacotherapy 66:485-490. 
115. Xia, D., Srinivas, H., Ahn, Y.-h., Sethi, G., Sheng, X., Yung, W.K.A., Xia, Q., Chiao, P.J., Kim, 
H., Brown, P.H., et al. 2007. Mitogen-activated Protein Kinase Kinase-4 Promotes Cell Survival 
by Decreasing PTEN Expression through an NFκB-dependent Pathway. Journal of Biological 
Chemistry 282:3507-3519. 
116. Zhang, H., Zhao, X., Liu, S., Li, J., Wen, Z., and Li, M. 2010. 17betaE2 promotes cell proliferation 
in endometriosis by decreasing PTEN via NFkappaB-dependent pathway. Mol Cell Endocrinol 
317:31-43. 
117. Chow, J.Y., Quach, K.T., Cabrera, B.L., Cabral, J.A., Beck, S.E., and Carethers, J.M. 2007. 
RAS/ERK modulates TGFbeta-regulated PTEN expression in human pancreatic adenocarcinoma 
cells. Carcinogenesis 28:2321-2327. 
118. Tang, Y.A., Chen, C.H., Sun, H.S., Cheng, C.P., Tseng, V.S., Hsu, H.S., Su, W.C., Lai, W.W., and 
Wang, Y.C. 2015. Global Oct4 target gene analysis reveals novel downstream PTEN and TNC 
genes required for drug-resistance and metastasis in lung cancer. Nucleic Acids Res 43:1593-1608. 
119. Tang, B., Qi, G., Tang, F., Yuan, S., Wang, Z., Liang, X., Li, B., Yu, S., Liu, J., Huang, Q., et al. 
2015. JARID1B promotes metastasis and epithelial-mesenchymal transition via PTEN/AKT 
signaling in hepatocellular carcinoma cells. Oncotarget 6:12723-12739. 
120. Sacco, J.J., Yau, T.Y., Darling, S., Patel, V., Liu, H., Urbe, S., Clague, M.J., and Coulson, J.M. 
2013. The deubiquitylase Ataxin-3 restricts PTEN transcription in lung cancer cells. Oncogene. 
121. Whelan, J.T., Forbes, S.L., and Bertrand, F.E. 2007. CBF-1 (RBP-J kappa) binds to the PTEN 
promoter and regulates PTEN gene expression. Cell Cycle 6:80-84. 
122. Li, Y., Tsang, C.K., Wang, S.H., Li, X.X., Yang, Y., Fu, L.W., Huang, W.L., Li, M., Wang, H.Y., 
and Zheng, X.F.S. 2016. MAF1 Suppresses AKT-mTOR Signaling and Liver Cancer Through 
Activation of PTEN Transcription. Hepatology 63:1928-1942. 
123. Pei, Y.F., Tao, R., Li, J.F., Su, L.P., Yu, B.Q., Wu, X.Y., Yan, M., Gu, Q.L., Zhu, Z.G., and Liu, 
B.Y. 2016. TET1 inhibits gastric cancer growth and metastasis by PTEN demethylation and re-
expression. Oncotarget 7:31322-31335. 
124. Stambolic, V., MacPherson, D., Sas, D., Lin, Y., Snow, B., Jang, Y., Benchimol, S., and Mak, T.W. 
2001. Regulation of PTEN transcription by p53. Molecular Cell 8:317-325. 
125. Hettinger, K., Vikhanskaya, F., Poh, M.K., Lee, M.K., de Belle, I., Zhang, J.T., Reddy, S.A.G., and 
Sabapathy, K. 2007. c-Jun promotes cellular survival by suppression of PTEN. Cell Death and 
Differentiation 14:218-229. 
 90 
  
126. Patel, L., Pass, I., Coxon, P., Downes, C.P., Smith, S.A., and Macphee, C.H. 2001. Tumor 
suppressor and anti-inflammatory actions of PPARgamma agonists are mediated via upregulation 
of PTEN. Curr Biol 11:764-768. 
127. Virolle, T., Adamson, E.D., Baron, V., Birle, D., Mercola, D., Mustelin, T., and de Belle, I. 2001. 
The Egr-1 transcription factor directly activates PTEN during irradiation-induced signalling. Nat 
Cell Biol 3:1124-1128. 
128. Shen, Y.H., Zhang, L., Gan, Y.H., Wang, X.W., Wang, J., LeMaire, S.A., Coselli, J.S., and Wang, 
X.L. 2006. Up-regulation of PTEN (phosphatase and tensin homolog deleted on chromosome ten) 
mediates p38 MAPK stress signal-induced inhibition of insulin signaling - A cross-talk between 
stress signaling and insulin signaling in resistin-treated human endothelial cells. Journal of 
Biological Chemistry 281:7727-7736. 
129. Moorehead, R.A., Hojilla, C.V., De Belle, I., Wood, G.A., Fata, J.E., Adamson, E.D., Watson, 
K.L.M., Edwards, D.R., and Khokha, R. 2003. Insulin-like growth factor-II regulates PTEN 
expression in the mammary gland. Journal of Biological Chemistry 278:50422-50427. 
130. Waite, K.A., Sinden, M.R., and Eng, C. 2005. Phytoestrogen exposure elevates PTEN levels. 
Human Molecular Genetics 14:1457-1463. 
131. Dave, B., Eason, R.R., Till, S.R., Geng, Y., Velarde, M.C., Badger, T.M., and Simmen, R.C.M. 
2005. The soy isoflavone genistein promotes apoptosis in mammary epithelial cells by inducing 
the tumor suppressor PTEN. Carcinogenesis 26:1793-1803. 
132. Qi, M., Anderson, A.E., Chen, D.Z., Sun, S., and Auborn, K.J. 2005. Indole-3-carbinol prevents 
PTEN loss in cervical cancer in vivo. Molecular Medicine 11:59-63. 
133. Tian, L., Fang, Y.X., Xue, J.L., and Chen, J.Z. 2013. Four MicroRNAs Promote Prostate Cell 
Proliferation with Regulation of PTEN and Its Downstream Signals. PLoS One 8:e75885. 
134. Xiao, C.C., Srinivasan, L., Calado, D.P., Patterson, H.C., Zhang, B.C., Wang, J., Henderson, J.M., 
Kutok, J.L., and Rajewsky, K. 2008. Lymphoproliferative disease and autoimmunity in mice with 
increased miR-17-92 expression in lymphocytes. Nature Immunology 9:405-414. 
135. Mavrakis, K.J., Wolfe, A.L., Oricchio, E., Palomero, T., de Keersmaecker, K., McJunkin, K., 
Zuber, J., James, T., Chang, K., Khan, A.A., et al. 2010. Genome-wide RNA-mediated interference 
screen identifies miR-19 targets in Notch-induced T-cell acute lymphoblastic leukaemia. Nature 
Cell Biology 12:372-U159. 
136. Meng, F.Y., Henson, R., Wehbe-Janek, H., Ghoshal, K., Jacob, S.T., and Patel, T. 2007. 
MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular 
cancer. Gastroenterology 133:647-658. 
137. Ma, X.D., Kumar, M., Choudhury, S.N., Buscaglia, L.E.B., Barker, J.R., Kanakamedala, K., Liu, 
M.F., and Li, Y. 2011. Loss of the miR-21 allele elevates the expression of its target genes and 
reduces tumorigenesis. Proceedings of the National Academy of Sciences of the United States of 
America 108:10144-10149. 
138. Poliseno, L., Salmena, L., Riccardi, L., Fornari, A., Song, M.S., Hobbs, R.M., Sportoletti, P., 
Varmeh, S., Egia, A., Fedele, G., et al. 2010. Identification of the miR-106b similar to 25 
MicroRNA Cluster as a Proto-Oncogenic PTEN-Targeting Intron That Cooperates with Its Host 
Gene MCM7 in Transformation (vol 3, artn ra29, 2010). Science Signaling 3. 
139. Huse, J.T., Brennan, C., Hambardzumyan, D., Wee, B., Pena, J., Rouhanifard, S.H., Sohn-Lee, C., 
le Sage, C., Agami, R., Tuschl, T., et al. 2009. The PTEN-regulating microRNA miR-26a is 
amplified in high-grade glioma and facilitates gliomagenesis in vivo. Genes & Development 
23:1327-1337. 
140. Wang, C., Bian, Z., Wei, D., and Zhang, J.G. 2011. miR-29b regulates migration of human breast 
cancer cells. Molecular and Cellular Biochemistry 352:197-207. 
141. Wang, B., Majumder, S., Nuovo, G., Kutay, H., Volinia, S., Patel, T., Schmittgen, T.D., Croce, C., 
Ghoshal, K., and Jacob, S.T. 2009. Role of MicroRNA-155 at Early Stages of 
Hepatocarcinogenesis Induced by Choline-Deficient and Amino Acid-Defined Diet in C57BL/6 
Mice. Hepatology 50:1152-1161. 
 91 
  
142. Yang, H., Kong, W., He, L., Zhao, J.J., O'Donnell, J.D., Wang, J., Wenham, R.M., Coppola, D., 
Kruk, P.A., Nicosia, S.V., et al. 2008. MicroRNA expression profiling in human ovarian cancer: 
miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Research 
68:425-433. 
143. Li, L.M., Hou, D.X., Guo, Y.L., Yang, J.W., Liu, Y.A., Zhang, C.Y., and Zen, K. 2011. Role of 
MicroRNA-214-Targeting Phosphatase and Tensin Homolog in Advanced Glycation End Product-
Induced Apoptosis Delay in Monocytes. Journal of Immunology 186:2552-2560. 
144. Kato, M., Putta, S., Wang, M., Yuan, H., Lanting, L., Nair, I., Gunn, A., Nakagawa, Y., Shimano, 
H., Todorov, I., et al. 2009. TGF-beta activates Akt kinase through a microRNA-dependent 
amplifying circuit targeting PTEN. Nature Cell Biology 11:881-U263. 
145. Zhang, C.Z., Han, L., Zhang, A.L., Fu, Y.C., Yue, X.A., Wang, G.X., Jia, Z.F., Pu, P.Y., Zhang, 
Q.Y., and Kang, C.S. 2010. MicroRNA-221 and microRNA-222 regulate gastric carcinoma cell 
proliferation and radioresistance by targeting PTEN. Bmc Cancer 10. 
146. Shi, W., Gerster, K., Alajez, N.M., Tsang, J., Waldron, L., Pintilie, M., Hui, A.B., Sykes, J., P'ng, 
C., Miller, N., et al. 2011. MicroRNA-301 Mediates Proliferation and Invasion in Human Breast 
Cancer. Cancer Research 71:2926-2937. 
147. Small, E.M., O'Rourke, J.R., Moresi, V., Sutherland, L.B., McAnally, J., Gerard, R.D., Richardson, 
J.A., and Olson, E.N. 2010. Regulation of PI3-kinase/Akt signaling by muscle-enriched 
microRNA-486. Proceedings of the National Academy of Sciences of the United States of America 
107:4218-4223. 
148. Wang, X.H., Zhang, X.W., Ren, X.P., Chen, J., Liu, H.Z., Yang, J.Q., Medvedovic, M., Hu, Z.W., 
and Fan, G.C. 2010. MicroRNA-494 Targeting Both Proapoptotic and Antiapoptotic Proteins 
Protects Against Ischemia/Reperfusion-Induced Cardiac Injury. Circulation 122:1308-U1145. 
149. Poliseno, L., Salmena, L., Zhang, J., Carver, B., Haveman, W.J., and Pandolfi, P.P. 2010. A coding-
independent function of gene and pseudogene mRNAs regulates tumour biology. Nature 465:1033-
1038. 
150. Xia, H., Khalil, W., Kahm, J., Jessurun, J., Kleidon, J., and Henke, C.A. 2010. Pathologic Caveolin-
1 Regulation of PTEN in Idiopathic Pulmonary Fibrosis. American Journal of Pathology 176:2626-
2637. 
151. Zmajkovicova, K., Jesenberger, V., Catalanotti, F., Baumgartner, C., Reyes, G., and Baccarini, M. 
2013. MEK1 Is Required for PTEN Membrane Recruitment, AKT Regulation, and the 
Maintenance of Peripheral Tolerance. Molecular Cell 50:43-55. 
152. Minaguchi, T., Waite, K.A., and Eng, C. 2006. Nuclear localization of PTEN is regulated by Ca2+ 
through a tyrosil phosphorylation-independent conformational modification in major vault protein. 
Cancer Research 66:11677-11682. 
153. Stumpf, M. 2016. Interplay of PTEN subcellular localization and catalytic activities in vivo. 
Netherlands: Utrecht University. 
154. Gil, A., Andres-Pons, A., Fernandez, E., Valiente, M., Torres, J., Cervera, J., and Pulido, R. 2006. 
Nuclear localization of PTEN by a Ran-dependent mechanism enhances apoptosis: Involvement of 
an N-terminal nuclear localization domain and multiple nuclear exclusion motifs. Mol Biol Cell 
17:4002-4013. 
155. Chen, M., Nowak, D. G., Ambrico, A., Watrud, K., Plafker, S. M., Trotman, L. C. 2016. The 
Nuclear Transport Receptor Importin-11 is a Tumor Suppressor that maintains PTEN Protein. In 
The PI3K-mTOR-PTEN Network in Health and Disease. Cold Spring Harbor Laboratory. 
156. Uversky, V.N., Dave, V., Iakoucheva, L.M., Malaney, P., Metallo, S.J., Pathak, R.R., and Joerger, 
A.C. 2014. Pathological Unfoldomics of Uncontrolled Chaos: Intrinsically Disordered Proteins and 
Human Diseases. Chemical Reviews 114:6844-6879. 
157. Fata, J.E., Debnath, S., Jenkins, E.C., Jr., and Fournier, M.V. 2012. Nongenomic Mechanisms of 
PTEN Regulation. Int. J. Cell. Biol. 2012:379685. 
 92 
  
158. Ahmed, S.F., Deb, S., Paul, I., Chatterjee, A., Mandal, T., Chatterjee, U., and Ghosh, M.K. 2012. 
The chaperone-assisted E3 ligase C terminus of Hsc70-interacting protein (CHIP) targets PTEN 
for proteasomal degradation. J Biol Chem 287:15996-16006. 
159. Leonard, M.K., Kommagani, R., Payal, V., Mayo, L.D., Shamma, H.N., and Kadakia, M.P. 2011. 
DeltaNp63alpha regulates keratinocyte proliferation by controlling PTEN expression and 
localization. Cell Death Differ. 18:1924-1933. 
160. Zhang, S., Taghibiglou, C., Girling, K., Dong, Z., Lin, S.Z., Lee, W., Shyu, W.C., and Wang, Y.T. 
2013. Critical role of increased PTEN nuclear translocation in excitotoxic and ischemic neuronal 
injuries. J Neurosci 33:7997-8008. 
161. Howitt, J., Lackovic, J., Low, L.H., Naguib, A., Macintyre, A., Goh, C.P., Callaway, J.K., 
Hammond, V., Thomas, T., Dixon, M., et al. 2012. Ndfip1 regulates nuclear Pten import in vivo to 
promote neuronal survival following cerebral ischemia. J Cell Biol 196:29-36. 
162. Li, Y.J., Low, L.H., Putz, U., Goh, C.P., Tan, S.S., and Howitt, J. 2014. Rab5 and Ndfip1 Are 
Involved in Pten Ubiquitination and Nuclear Trafficking. Traffic 15:749-761. 
163. Bassi, C., Ho, J., Srikumar, T., Dowling, R.J., Gorrini, C., Miller, S.J., Mak, T.W., Neel, B.G., 
Raught, B., and Stambolic, V. 2013. Nuclear PTEN controls DNA repair and sensitivity to 
genotoxic stress. Science 341:395-399. 
164. Kavela, S., Shinde, S.R., Ratheesh, R., Viswakalyan, K., Bashyam, M.D., Gowrishankar, S., 
Vamsy, M., Pattnaik, S., Rao, S., Sastry, R.A., et al. 2013. PNUTS Functions as a Proto-Oncogene 
by Sequestering PTEN. Cancer Research 73:205-214. 
165. Wu, Y., Zhou, H., Wu, K., Lee, S., Li, R.J., and Liu, X. 2014. PTEN Phosphorylation and Nuclear 
Export Mediate Free Fatty Acid-Induced Oxidative Stress. Antioxidants & Redox Signaling 
20:1382-1395. 
166. Nguyen, H.N., Yang, J.M., Miyamoto, T., Itoh, K., Rho, E., Zhang, Q., Inoue, T., Devreotes, P.N., 
Sesaki, H., and Iijima, M. 2015. Opening the conformation is a master switch for the dual 
localization and phosphatase activity of PTEN. Scientific Reports 5. 
167. Beckham, T.H., Cheng, J.C., Lu, P., Marrison, S.T., Norris, J.S., and Liu, X. 2013. Acid 
Ceramidase Promotes Nuclear Export of PTEN through Sphingosine 1-Phosphate Mediated Akt 
Signaling. Plos One 8. 
168. Lobo, G.P., Waite, K.A., Planchon, S.M., Romigh, T., Houghton, J.A., and Eng, C. 2008. ATP 
modulates PTEN subcellular localization in multiple cancer cell lines. Human Molecular Genetics 
17:2877-2885. 
169. Jung, S., Li, C., Jeong, D., Lee, S., Ohk, J., Park, M., Han, S., Duan, J., Kim, C., Yang, Y., Kim, 
K., Lim, J., Kang, Y., & Lee, M. 2013. Oncogenic function of p34SEI-1 via NEDD4‑1‑mediated 
PTEN ubiquitination/degradation and activation of the PI3K/AKT pathway. Int. J. Oncol. 43:1587-
1595. 
170. Gupta, A., and Leslie, N.R. 2016. Controlling PTEN (Phosphatase and Tensin Homolog) Stability: 
A DOMINANT ROLE FOR LYSINE 66. J Biol Chem 291:18465-18473. 
171. Mund, T., and Pelham, H.R.B. 2010. Regulation of PTEN/Akt and MAP kinase signaling pathways 
by the ubiquitin ligase activators Ndfip1 and Ndfip2. Proceedings of the National Academy of 
Sciences of the United States of America 107:11429-11434. 
172. Li, N., Zhang, Y.J., Han, X., Liang, K., Wang, J.D., Feng, L., Wang, W.Q., Zhou, S.Y., Lin, C.R., 
Yang, L.Q., et al. 2015. Poly-ADP ribosylation of PTEN by tankyrases promotes PTEN 
degradation and tumor growth. Genes & Development 29:157-170. 
173. Tang, Y.F., and Eng, C. 2006. p53 Down-regulates phosphatase and tensin homologue deleted on 
chromosome 10 protein stability partially through caspase-mediated degradation in cells with 
proteasome dysfunction. Cancer Research 66:6139-6148. 
174. Singh, G., and Chan, A.M. 2011. Post-Translational Modifications of PTEN and their Potential 
Therapeutic Implications. Curr. Cancer Drug Tar. 11:536-547. 
 93 
  
175. Torres, J., and Pulido, R. 2001. The tumor suppressor PTEN is phosphorylated by the protein kinase 
CK2 at its C terminus - Implications for PTEN stability to proteasome-mediated degradation. 
Journal of Biological Chemistry 276:993-998. 
176. Wu, Y., Zhou, H., Wu, K., Lee, S., Li, R., and Liu, X. 2013. PTEN phosphorylation and nuclear 
export mediate free fatty acid-induced oxidative stress. Antioxid. Redox Signal. 
177. Maccario, H., Pereira, N.M., Davidson, L., Downes, C.P., and Leslie, N.R. 2007. PTEN is 
destabilized by phosphorylation on Thr(366). Biochemical Journal 405:439-444. 
178. Al-Khouri, A.M., Ma, Y., Togo, S.H., Williams, S., and Mustelin, T. 2005. Cooperative 
phosphorylation of the tumor suppressor phosphatase and tensin homologue (PTEN) by casein 
kinases and glycogen synthase kinase 3beta. J Biol Chem 280:35195-35202. 
179. Xu, D., Yao, Y., Jiang, X., Lu, L., and Dai, W. 2010. Regulation of PTEN stability and activity by 
Plk3. J. Biol. Chem. 285:39935-39942. 
180. Li, Z.G., Li, J., Bi, P.P., Lu, Y., Burcham, G., Elzey, B.D., Ratliff, T., Konieczny, S.F., Ahmad, N., 
Kuang, S.H., et al. 2014. Plk1 Phosphorylation of PTEN Causes a Tumor-Promoting Metabolic 
State. Molecular and Cellular Biology 34:3642-3661. 
181. Okahara, F., Ikawa, H., Kanaho, Y., and Maehama, T. 2004. Regulation of PTEN phosphorylation 
and stability by a tumor suppressor candidate protein. Journal of Biological Chemistry 279:45300-
45303. 
182. Li, Z., Dong, X., Wang, Z., Liu, W., Deng, N., Ding, Y., Tang, L., Hla, T., Zeng, R., Li, L., et al. 
2005. Regulation of PTEN by Rho small GTPases. Nat Cell Biol 7:399-404. 
183. Yim, E.K., Peng, G., Dai, H., Hu, R.Z., Li, K.Y., Lu, W., Mills, G.B., Meric-Bernstam, F., 
Hennessy, B.T., Craven, R.J., et al. 2009. Rak Functions as a Tumor Suppressor by Regulating 
PTEN Protein Stability and Function. Cancer Cell 15:304-314. 
184. Lu, Y.L., Yu, Q.H., Liu, J.H., Zhang, J.Y., Wang, H.W., Koul, D., McMurray, J.S., Fang, X.J., 
Yung, W.K.A., Siminovitch, K.A., et al. 2003. Src family protein-tyrosine kinases alter the function 
of PTEN to regulate phosphatidylinositol 3-kinase/AKT cascades. Journal of Biological Chemistry 
278:40057-40066. 
185. Liu, J., Visser-Grieve, S., Boudreau, J., Yeung, B., Lo, S., Chamberlain, G., Yu, F., Sun, T., 
Papanicolaou, T., Lam, A., et al. 2014. Insulin activates the insulin receptor to downregulate the 
PTEN tumour suppressor. Oncogene 33:3878-3885. 
186. Ning, K., Miller, L.C., Laidlaw, H.A., Watterson, K.R., Gallagher, J., Sutherland, C., and Ashford, 
M.L.J. 2009. Leptin-dependent Phosphorylation of PTEN Mediates Actin Restructuring and 
Activation of ATP-sensitive K+ Channels. Journal of Biological Chemistry 284:9331-9340. 
187. Aoyama, D., Hashimoto, N., Sakamoto, K., Kohnoh, T., Kusunose, M., Kimura, M., Ogata, R., 
Imaizumi, K., Kawabe, T., and Hasegawa, Y. 2013. Involvement of TGFbeta-induced 
phosphorylation of the PTEN C-terminus on TGFbeta-induced acquisition of malignant phenotypes 
in lung cancer cells. PLoS One 8:e81133. 
188. Young, M.R. 2004. Tumor-derived prostaglandin E2 and transforming growth factor-beta stimulate 
endothelial cell motility through inhibition of protein phosphatase-2A and involvement of PTEN 
and phosphatidylinositide 3-kinase. Angiogenesis 7:123-131. 
189. Scully, M.M., Palacios-Helgeson, L.K., Wah, L.S., and Jackson, T.A. 2014. Rapid Estrogen 
Signaling Negatively Regulates PTEN Activity Through Phosphorylation in Endometrial Cancer 
Cells. Hormones & Cancer 5:218-231. 
190. Omori, N., Jin, G., Li, F., Zhang, W.R., Wang, S.J., Hamakawa, Y., Nagano, I., Manabe, Y., Shoji, 
M., and Abe, K. 2002. Enhanced phosphorylation of PTEN in rat brain after transient middle 
cerebral artery occlusion. Brain Res 954:317-322. 
191. Yang, Z., Xie, C., Xu, W.T., Liu, G.M.Z., Cao, X.M., Li, W., Chen, J., Zhu, Y., Luo, S.W., Luo, 
Z.J., et al. 2015. Phosphorylation and inactivation of PTEN at residues Ser380/Thr382/383 induced 
by Helicobacter pylori promotes gastric epithelial cell survival through PI3K/Akt pathway. 
Oncotarget 6:31916-31926. 
 94 
  
192. Bolduc, D., Rahdar, M., Tu-Sekine, B., Sivakumaren, S.C., Raben, D., Amzel, L.M., Devreotes, 
P., Gabelli, S.B., and Cole, P. 2013. Phosphorylation-mediated PTEN conformational closure and 
deactivation revealed with protein semisynthesis. Elife 2. 
193. Odriozola, L., Singh, G., Hoang, T., and Chan, A.M. 2007. Regulation of PTEN activity by its 
carboxyl-terminal autoinhibitory domain. Journal of Biological Chemistry 282:23306-23315. 
194. Rahdar, M., Inoue, T., Meyer, T., Zhang, J., Vazquez, F., and Devreotes, P.N. 2009. A 
phosphorylation-dependent intramolecular interaction regulates the membrane association and 
activity of the tumor suppressor PTEN. Proceedings of the National Academy of Sciences of the 
United States of America 106:480-485. 
195. Vazquez, F., Ramaswamy, S., Nakamura, N., and Sellers, W.R. 2000. Phosphorylation of the PTEN 
tail regulates protein stability and function. Molecular and Cellular Biology 20:5010-5018. 
196. Okumura, K., Mendoza, M., Bachoo, R.M., DePinho, R.A., Cavenee, W.K., and Furnari, F.B. 2006. 
PCAF modulates PTEN activity. Journal of Biological Chemistry 281:26562-26568. 
197. Ikenoue, T., Inoki, K., Zhao, B., and Guan, K.L. 2008. PTEN acetylation modulates its interaction 
with PDZ domain. Cancer Res 68:6908-6912. 
198. Meng, Z., Jia, L.F., and Gan, Y.H. 2016. PTEN activation through K163 acetylation by inhibiting 
HDAC6 contributes to tumour inhibition. Oncogene 35:2333-2344. 
199. Lee, J.T., Shan, J., Zhong, J., Li, M., Zhou, B., Zhou, A., Parsons, R., and Gu, W. 2013. RFP-
mediated ubiquitination of PTEN modulates its effect on AKT activation. Cell Res. 23:552-564. 
200. Papa, A., Wan, L., Bonora, M., Salmena, L., Song, M.S., Hobbs, R.M., Lunardi, A., Webster, K., 
Ng, C., Newton, R.H., et al. 2014. Cancer-associated PTEN mutants act in a dominant-negative 
manner to suppress PTEN protein function. Cell 157:595-610. 
201. Pandolfi, P.P. 2016. Tumor Suppressor Phosphatases in Tumorigenesis. In The PI3K-mTOR-PTEN 
Network in Health and Disease. Cold Spring Harbor Laboratory. 
202. Lee, S.R., Yang, K.S., Kwon, J., Lee, C., Jeong, W., and Rhee, S.G. 2002. Reversible inactivation 
of the tumor suppressor PTEN by H2O2. J Biol Chem 277:20336-20342. 
203. Cao, J., Schulte, J., Knight, A., Leslie, N.R., Zagozdzon, A., Bronson, R., Manevich, Y., Beeson, 
C., and Neumann, C.A. 2009. Prdx1 inhibits tumorigenesis via regulating PTEN/AKT activity. 
EMBO J 28:1505-1517. 
204. Hui, S.T., Andres, A.M., Miller, A.K., Spann, N.J., Potter, D.W., Post, N.M., Chen, A.Z., 
Sachithanantham, S., Jung, D.Y., Kim, J.K., et al. 2008. Txnip balances metabolic and growth 
signaling via PTEN disulfide reduction. Proc Natl Acad Sci U S A 105:3921-3926. 
205. Kwak, Y.D., Ma, T., Diao, S.Y., Zhang, X., Chen, Y.M., Hsu, J., Lipton, S.A., Masliah, E., Xu, 
H.X., and Liao, F.F. 2010. NO signaling and S-nitrosylation regulate PTEN inhibition in 
neurodegeneration. Molecular Neurodegeneration 5. 
206. Nakakido, M., Deng, Z.Z., Suzuki, T., Dohmae, N., Nakamura, Y., and Hamamoto, R. 2015. 
Dysregulation of AKT Pathway by SMYD2-Mediated Lysine Methylation on PTEN. Neoplasia 
17:367-373. 
207. Zhang, J., Lee, Y. R., Gan, W., Asara, J. M., Pandolfi, P. P., Wei W. 2016. Methylation of PTEN 
dictates Cellular Sensitivity to DNA Damage. In The PI3K-mTOR-PTEN Network in Health and 
Disease. Cold Spring Harbor Laboratory. 
208. Sumitomo, M., Iwase, A., Zheng, R., Navarro, D., Kaminetzky, D., Shen, R., Georgescu, M.M., 
and Nanus, D.M. 2004. Synergy in tumor suppression by direct interaction of neutral endopeptidase 
with PTEN. Cancer Cell 5:67-78. 
209. Sanchez, T., Thangada, S., Wu, M.T., Kontos, C.D., Wu, D.Q., Wu, H., and Hla, T. 2005. PTEN 
as an effector in the signaling of antimigratory G protein-coupled receptor. Proceedings of the 
National Academy of Sciences of the United States of America 102:4312-4317. 
210. Yin, H.H., Tan, Y., Wu, X.F., Yan, H., Liu, F., Yao, Y.Z., Jiang, J.X., Wan, Q., and Li, L. 2016. 
Association between TLR4 and PTEN Involved in LPS-TLR4 Signaling Response. Biomed 
Research International. 
 95 
  
211. Lima-Fernandes, E., Enslen, H., Camand, E., Kotelevets, L., Boularan, C., Achour, L., Benmerah, 
A., Gibson, L.C., Baillie, G.S., Pitcher, J.A., et al. 2011. Distinct functional outputs of PTEN 
signalling are controlled by dynamic association with beta-arrestins. EMBO J 30:2557-2568. 
212. Nakahata, S., Ichikawa, T., Maneesaay, P., Saito, Y., Nagai, K., Tamura, T., Manachai, N., 
Yamakawa, N., Hamasaki, M., Kitabayashi, I., et al. 2014. Loss of NDRG2 expression activates 
PI3K-AKT signalling via PTEN phosphorylation in ATLL and other cancers. Nature 
Communications 5. 
213. Chagpar, R.B., Links, P.H., Pastor, M.C., Furber, L.A., Hawrysh, A.D., Chamberlain, M.D., and 
Anderson, D.H. 2010. Direct positive regulation of PTEN by the p85 subunit of 
phosphatidylinositol 3-kinase. Proc Natl Acad Sci U S A 107:5471-5476. 
214. Rabinovsky, R., Pochanard, P., McNear, C., Brachmann, S.M., Duke-Cohan, J.S., Garraway, L.A., 
and Sellers, W.R. 2009. p85 Associates with Unphosphorylated PTEN and the PTEN-Associated 
Complex. Molecular and Cellular Biology 29:5377-5388. 
215. Cheung, L.W.T., Walkiewicz, K.W., Besong, T.M.D., Guo, H.F., Hawke, D.H., Arold, S.T., and 
Mills, G.B. 2015. Regulation of the PI3K pathway through a p85 alpha monomer-homodimer 
equilibrium. Elife 4. 
216. Cao, J.X., Schulte, J., Knight, A., Leslie, N.R., Zagozdzon, A., Bronson, R., Manevich, Y., Beeson, 
C., and Neumann, C.A. 2009. Prdx1 inhibits tumorigenesis via regulating PTEN/AKT activity. 
Embo Journal 28:1505-1517. 
217. Schwertassek, U., Haque, A., Krishnan, N., Greiner, R., Weingarten, L., Dick, T.P., and Tonks, 
N.K. 2014. Reactivation of oxidized PTP1B and PTEN by thioredoxin 1. Febs Journal 281:3545-
3558. 
218. Perez-Garcia, V., Redondo-Munoz, J., Kumar, A., and Carrera, A.C. 2014. Cell activation-induced 
phosphoinositide 3-kinase alpha/beta dimerization regulates PTEN activity. Mol Cell Biol 34:3359-
3373. 
219. Jiao, Y., Sun, K.K., Zhao, L., Xu, J.Y., Wang, L.L., and Fan, S.J. 2012. Suppression of human lung 
cancer cell proliferation and metastasis in vitro by the transducer of ErbB-2.1 (T0B1). Acta 
Pharmacologica Sinica 33:250-260. 
220. Kim, Y.C., Kitaura, H., Taira, T., Iguchi-Ariga, S.M., and Ariga, H. 2009. Oxidation of DJ-1-
dependent cell transformation through direct binding of DJ-1 to PTEN. Int J Oncol 35:1331-1341. 
221. He, L., Fan, C., Kapoor, A., Ingram, A.J., Rybak, A.P., Austin, R.C., Dickhout, J., Cutz, J.C., 
Scholey, J., and Tang, D. 2011. alpha-Mannosidase 2C1 attenuates PTEN function in prostate 
cancer cells. Nat Commun 2:307. 
222. Li, Z., Li, J., Bi, P., Lu, Y., Burcham, G., Elzey, B.D., Ratliff, T., Konieczny, S.F., Ahmad, N., 
Kuang, S., et al. 2014. Plk1 phosphorylation of PTEN causes a tumor-promoting metabolic state. 
Mol Cell Biol 34:3642-3661. 
223. Obeidat, M., Li, L.J., and Ballermann, B.J. 2014. TIMAP promotes angiogenesis by suppressing 
PTEN-mediated Akt inhibition in human glomerular endothelial cells. American Journal of 
Physiology-Renal Physiology 307:F623-F633. 
224. Hodakoski, C., Hopkins, B.D., Barrows, D., Mense, S.M., Keniry, M., Anderson, K.E., Kern, P.A., 
Hawkins, P.T., Stephens, L.R., and Parsons, R. 2014. Regulation of PTEN inhibition by the 
pleckstrin homology domain of P-REX2 during insulin signaling and glucose homeostasis. 
Proceedings of the National Academy of Sciences of the United States of America 111:155-160. 
225. He, L.Z., Ingram, A., Rybak, A.P., and Tang, D.M. 2010. Shank-interacting protein-like 1 promotes 
tumorigenesis via PTEN inhibition in human tumor cells. Journal of Clinical Investigation 
120:2094-2108. 
226. Meuillet, E.J., Mahadevan, D., Berggren, M., Coon, A., and Powis, G. 2004. Thioredoxin-1 binds 
to the C2 domain of PTEN inhibiting PTEN's lipid phosphatase activity and membrane binding: a 
mechanism for the functional loss of PTEN's tumor suppressor activity. Archives of Biochemistry 
and Biophysics 429:123-133. 
 96 
  
227. Maddika, S., Kavela, S., Rani, N., Palicharla, V.R., Pokorny, J.L., Sarkaria, J.N., and Chen, J.J. 
2011. WWP2 is an E3 ubiquitin ligase for PTEN. Nature Cell Biology 13:728-U224. 
228. Wang, X.J., Shi, Y.J., Wang, J.R., Huang, G.C., and Jiang, X.J. 2008. Crucial role of the C-terminus 
of PTEN in antagonizing NEDD4-1-mediated PTEN ubiquitination and degradation. Biochemical 
Journal 414:221-229. 
229. Lee, M.S., Jeong, M.H., Lee, H.W., Han, H.J., Ko, A., Hewitt, S.M., Kim, J.H., Chun, K.H., Chung, 
J.Y., Lee, C., et al. 2015. PI3K/AKT activation induces PTEN ubiquitination and destabilization 
accelerating tumourigenesis. Nat Commun 6:7769. 
230. Van Themsche, C., Leblanc, V., Parent, S., and Asselin, E. 2009. X-linked Inhibitor of Apoptosis 
Protein (XIAP) Regulates PTEN Ubiquitination, Content, and Compartmentalization. Journal of 
Biological Chemistry 284:20462-20466. 
231. Li, X., Li, Z.X., Li, N., Qi, J.J., Fan, K., Yin, P., Zhao, C., Liu, Y.L., Yao, W.T., Cai, X.M., et al. 
2013. MAGI2 enhances the sensitivity of BEL-7404 human hepatocellular carcinoma cells to 
staurosporine-induced apoptosis by increasing PTEN stability. International Journal of Molecular 
Medicine 32:439-447. 
232. Valiente, M., Andres-Pons, A., Gomar, B., Torres, J., Gil, A., Tapparel, C., Antonarakis, S.E., and 
Pulido, R. 2005. Binding of PTEN to specific PDZ domains contributes to PTEN protein stability 
and phosphorylation by microtubule-associated serine/threonine kinases. Journal of Biological 
Chemistry 280:28936-28943. 
233. Cao, J.X., Wan, L.X., Hacker, E., Dai, X.P., Lenna, S., Jimenez-Cervantes, C., Wang, Y.J., Leslie, 
N.R., Xu, G.X., Widlund, H.R., et al. 2013. MC1R Is a Potent Regulator of PTEN after UV 
Exposure in Melanocytes. Molecular Cell 51:409-422. 
234. Yang, L.Y., Wang, Y., Chen, P., Hu, J., Xiong, Y., Feng, D.P., Liu, H., Zhang, H., Yang, H., and 
He, J.Q. 2011. Na(+)/H(+) Exchanger Regulatory Factor 1 (NHERF1) Is Required for the 
Estradiol-Dependent Increase of Phosphatase and Tensin Homolog (PTEN) Protein Expression. 
Endocrinology 152:4537-4549. 
235. Zhang, J., Zhang, P., Wei, Y., Piao, H.L., Wang, W., Maddika, S., Wang, M., Chen, D., Sun, Y., 
Hung, M.C., et al. 2013. Deubiquitylation and stabilization of PTEN by USP13. Nat Cell Biol 
15:1486-1494. 
236. Zaidi, A.H., and Manna, S.K. 2016. Profilin-PTEN interaction suppresses NF-kappaB activation 
via inhibition of IKK phosphorylation. Biochem J 473:859-872. 
237. Waite, K.A., and Eng, C. 2003. BMP2 exposure results in decreased PTEN protein degradation and 
increased PTEN levels. Human Molecular Genetics 12:679-684. 
238. Caselli, A., Mazzinghi, B., Camici, G., Manao, G., and Ramponi, G. 2002. Some protein tyrosine 
phosphatases target in part to lipid rafts and interact with caveolin-1. Biochemical and Biophysical 
Research Communications 296:692-697. 
239. Tolkacheva, T., Boddapati, M., Sanfiz, A., Tsuchida, K., Kimmelman, A.C., and Chan, A.M. 2001. 
Regulation of PTEN binding to MAGI-2 by two putative phosphorylation sites at threonine 382 
and 383. Cancer Res 61:4985-4989. 
240. Wu, Y., Dowbenko, D., Spencer, S., Laura, R., Lee, J., Gu, Q.M., and Lasky, L.A. 2000. Interaction 
of the tumor suppressor PTEN/MMAC with a PDZ domain of MAGI3, a novel membrane-
associated guanylate kinase. Journal of Biological Chemistry 275:21477-21485. 
241. van Diepen, M.T., Parsons, M., Downes, C.P., Leslie, N.R., Hindges, R., and Eickholt, B.J. 2009. 
MyosinV controls PTEN function and neuronal cell size (vol 11, pg 1191, 2009). Nature Cell 
Biology 11:1387-1387. 
242. Georgescu, M.M., Cote, G., Agarwal, N.K., and White, C.L. 2014. NHERF1/EBP50 Controls 
Morphogenesis of 3D Colonic Glands by Stabilizing PTEN and Ezrin-Radixin-Moesin Proteins at 
the Apical Membrane. Neoplasia 16:365-+. 
243. Huang, J., Yan, J., Zhang, J., Zhu, S., Wang, Y., Shi, T., Zhu, C., Chen, C., Liu, X., Cheng, J., et 
al. 2012. SUMO1 modification of PTEN regulates tumorigenesis by controlling its association with 
the plasma membrane. Nat Commun 3:911. 
 97 
  
244. Gonzalez-Santamaria, J., Campagna, M., Ortega-Molina, A., Marcos-Villar, L., de la Cruz-Herrera, 
C.F., Gonzalez, D., Gallego, P., Lopitz-Otsoa, F., Esteban, M., Rodriguez, M.S., et al. 2012. 
Regulation of the tumor suppressor PTEN by SUMO. Cell Death & Disease 3. 
245. Yu, Z.B., Fotouhi-Ardakani, N., Wu, L.T., Maoui, M., Wang, S.L., Banville, D., and Shen, S.H. 
2002. PTEN associates with the vault particles in HeLa cells. Journal of Biological Chemistry 
277:40247-40252. 
246. Jurado, S., Benoist, M., Lario, A., Knafo, S., Petrok, C.N., and Esteban, J.A. 2010. PTEN is 
recruited to the postsynaptic terminal for NMDA receptor-dependent long-term depression. Embo 
Journal 29:2827-2840. 
247. Kreis, P., Hendricusdottir, R., Kay, L., Papageorgiou, I.E., van Diepen, M., Mack, T., Ryves, J., 
Harwood, A., Leslie, N.R., Kann, O., et al. 2013. Phosphorylation of the Actin Binding Protein 
Drebrin at S647 Is Regulated by Neuronal Activity and PTEN. Plos One 8. 
248. Lin, H.K., Hu, Y.C., Lee, D.K., and Chang, C.S. 2004. Regulation of androgen receptor signaling 
by PTEN (phosphatase and tensin homolog deleted on chromosome 10) tumor suppressor through 
distinct mechanisms in prostate cancer cells. Molecular Endocrinology 18:2409-2423. 
249. Sotelo, N.S., Valiente, M., Gil, A., and Pulido, R. 2012. A functional network of the tumor 
suppressors APC, hDlg, and PTEN, that relies on recognition of specific PDZ-domains. Journal of 
Cellular Biochemistry 113:2661-2670. 
250. Adey, N.B., Huang, L., Ormonde, P.A., Baumgard, M.L., Pero, R., Byreddy, D.V., Tavtigian, S.V., 
and Bartel, P.L. 2000. Threonine Phosphorylation of the MMAC1/PTEN PDZ Binding Domain 
Both Inhibits and Stimulates PDZ Binding. Cancer Research 60:35-37. 
251. van Ree, J.H., Nam, H.J., Jeganathan, K.B., Kanakkanthara, A., and van Deursen, J.M. 2016. Pten 
regulates spindle pole movement through Dlg1-mediated recruitment of Eg5 to centrosomes. 
Nature Cell Biology 18:814-+. 
252. Freeman, D.J., Li, A.G., Wei, G., Li, H.H., Kertesz, N., Lesche, R., Whale, A.D., Martinez-Diaz, 
H., Rozengurt, N., Cardiff, R.D., et al. 2003. PTEN tumor suppressor regulates p53 protein levels 
and activity through phosphatase-dependent and -independent mechanisms. Cancer Cell 3:117-
130. 
253. He, M., Zheng, B., Zhang, Y., Zhang, X.H., Wang, C., Yang, Z., Sun, Y., Wu, X.L., and Wen, J.K. 
2015. KLF4 mediates the link between TGF-beta1-induced gene transcription and H3 acetylation 
in vascular smooth muscle cells. FASEB J 29:4059-4070. 
254. Mosessian, S., Avliyakulov, N.K., Mulholland, D.J., Boontheung, P., Loo, J.A., and Wu, H. 2009. 
Analysis of PTEN Complex Assembly and Identification of Heterogeneous Nuclear 
Ribonucleoprotein C as a Component of the PTEN-associated Complex. Journal of Biological 
Chemistry 284:30159-30166. 
255. Gong, L.L., Govan, J.M., Evans, E.B., Dai, H., Wang, E., Lee, S.W., Lin, H.K., Lazar, A.J., Mills, 
G.B., and Lin, S.Y. 2015. Nuclear PTEN tumor-suppressor functions through maintaining 
heterochromatin structure. Cell Cycle 14:2323-2332. 
256. Lehman, J.A., Waning, D.L., Batuello, C.N., Cipriano, R., Kadakia, M.P., and Mayo, L.D. 2011. 
Induction of Apoptotic Genes by a p73-Phosphatase and Tensin Homolog (p73-PTEN) Protein 
Complex in Response to Genotoxic Stress. Journal of Biological Chemistry 286:36631-36640. 
257. Mistafa, O., Ghalali, A., Kadekar, S., Hogberg, J., and Stenius, U. 2010. Purinergic Receptor-
mediated Rapid Depletion of Nuclear Phosphorylated Akt Depends on Pleckstrin Homology 
Domain Leucine-rich Repeat Phosphatase, Calcineurin, Protein Phosphatase 2A, and PTEN 
Phosphatases. Journal of Biological Chemistry 285:27900-27910. 
258. De Melo, J., Lin, X.Z., He, L.Z., Wei, F.X., Major, P., and Tang, D.M. 2014. SIPL1-facilitated 
PTEN ubiquitination contributes to its association with PTEN. Cellular Signalling 26:2749-2756. 
259. Mehenni, H., Lin-Marq, N., Buchet-Poyau, K., Reymond, A., Collart, M.A., Picard, D., and 
Antonarakis, S.E. 2005. LKB1 interacts with and phosphorylates PTEN: a functional link between 
two proteins involved in cancer predisposing syndromes. Human Molecular Genetics 14:2209-
2219. 
 98 
  
260. Haier, J., and Nicolson, G.L. 2002. PTEN regulates tumor cell adhesion of colon carcinoma cells 
under dynamic conditions of fluid flow. Oncogene 21:1450-1460. 
261. Gonzalez-Sanchez, A., Jaraiz-Rodriguez, M., Dominguez-Prieto, M., Herrero-Gonzalez, S., 
Medina, J.M., and Tabernero, A. 2016. Connexin43 recruits PTEN and Csk to inhibit c-Src activity 
in glioma cells and astrocytes. Oncotarget. 
262. You, D.W., Xin, J.P., Volk, A., Wei, W., Schmidt, R., Scurti, G., Nand, S., Breuer, E.K., Kuo, P.C., 
Breslin, P., et al. 2015. FAK Mediates a Compensatory Survival Signal Parallel to PI3K-AKT in 
PTEN-Null T-ALL Cells. Cell Reports 10:2055-2068. 
263. Rodriguez, S., and Huynh-Do, U. 2013. Phosphatase and tensin homolog regulates stability and 
activity of EphB1 receptor. Faseb Journal 27:632-644. 
264. Okumura, K., Zhao, M.J., DePinho, R.A., Furnari, F.B., and Cavenee, W.K. 2005. Cellular 
transformation by the MSP58 oncogene is inhibited by its physical interaction with the PTEN tumor 
suppressor. Proceedings of the National Academy of Sciences of the United States of America 
102:2703-2706. 
265. Yang, C.H., Li, S.J., Wang, M., Chang, A.K., Liu, Y., Zhao, F., Xiao, L.Y., Han, L., Wang, D., Li, 
S., et al. 2013. PTEN suppresses the oncogenic function of AIB1 through decreasing its protein 
stability via mechanism involving Fbw7 alpha. Molecular Cancer 12. 
266. Takahashi, Y., Morales, F.C., Kreimann, E.L., and Georgescu, M.M. 2006. PTEN tumor suppressor 
associates with NHERF proteins to attenuate PDGF receptor signaling. Embo Journal 25:910-920. 
267. Mense, S.M., Barrows, D., Hodakoski, C., Steinbach, N., Schoenfeld, D., Su, W., Hopkins, B.D., 
Su, T., Fine, B., Hibshoosh, H., et al. 2015. PTEN inhibits PREX2-catalyzed activation of RAC1 
to restrain tumor cell invasion. Science Signaling 8. 
268. Hjelmeland, A.B., Hjelmeland, M.D., Shi, Q., Hart, S.L., Bigner, D.D., Wang, X.F., Kontos, C.D., 
and Rich, J.N. 2005. Loss of phosphatase and tensin homologue increases transforming growth 
factor beta-mediated invasion with enhanced SMAD3 transcriptional activity. Cancer Research 
65:11276-11281. 
269. Zheng, J.F., Dai, Y.P., Yang, Z.Y., Yang, L.Y., Peng, Z.Q., Meng, R., Xiong, Y., and He, J.Q. 
2016. Ezrin-radixin-moesin-binding phosphoprotein-50 regulates EGF-induced AKT activation 
through interaction with EGFR and PTEN. Oncology Reports 35:530-537. 
270. Gunaratne, J., Goh, M.X., Swa, H.L.F., Lee, F.Y., Sanford, E., Wong, L.M., Hogue, K.A., 
Blackstock, W.P., and Okumura, K. 2011. Protein Interactions of Phosphatase and Tensin 
Homologue (PTEN) and Its Cancer-associated G20E Mutant Compared by Using Stable Isotope 
Labeling by Amino Acids in Cell Culture-based Parallel Affinity Purification. Journal of Biological 
Chemistry 286:18093-18103. 
271. Kim, Y.J., Park, S.J., Choi, E.Y., Kim, S., Kwak, H.J., Yoo, B.C., Yoo, H., Lee, S.H., Kim, D., 
Park, J.B., et al. 2011. PTEN Modulates miR-21 Processing via RNA-Regulatory Protein RNH1. 
Plos One 6. 
272. Ji, S.P., Zhang, Y., Van Cleemput, J., Jiang, W., Liao, M.X., Li, L., Wan, Q., Backstrom, J.R., and 
Zhang, X. 2006. Disruption of PTEN coupling with 5-HT2C receptors suppresses behavioral 
responses induced by drugs of abuse. Nature Medicine 12:324-329. 
273. Cotter, L., Ozcelik, M., Jacob, C., Pereira, J.A., Locher, V., Baumann, R., Relvas, J.B., Suter, U., 
and Tricaud, N. 2010. Dlg1-PTEN Interaction Regulates Myelin Thickness to Prevent Damaging 
Peripheral Nerve Overmyelination. Science 328:1415-1418. 
274. Terrien, E., Chaffotte, A., Lafage, M., Khan, Z., Prehaud, C., Cordier, F., Simenel, C., Delepierre, 
M., Buc, H., Lafon, M., et al. 2012. Interference with the PTEN-MAST2 interaction by a viral 
protein leads to cellular relocalization of PTEN. Sci Signal 5:ra58. 
275. Feng, W., Wu, H., Chan, L.N., and Zhang, M.J. 2008. Par-3-mediated junctional localization of the 
lipid phosphatase PTEN is required for cell polarity establishment. Journal of Biological Chemistry 
283:23440-23449. 
 99 
  
276. Gorbenko, O., Panayotou, G., Zhyvoloup, A., Volkova, D., Gout, I., and Filonenko, V. 2010. 
Identification of novel PTEN-binding partners: PTEN interaction with fatty acid binding protein 
FABP4. Mol Cell Biochem 337:299-305. 
277. Herlevsen, M., Oxford, G., Ptak, C., Shabanowitz, J., Hunt, D.F., Conaway, M., and Theodorescu, 
D. 2007. A novel model to identify interaction partners of the PTEN tumor suppressor gene in 
human bladder cancer. Biochemical and Biophysical Research Communications 352:549-555. 
278. Sotelo, N.S., Schepens, J.T.G., Valiente, M., Hendriks, W.J.A.J., and Pulido, R. 2015. PTEN-PDZ 
domain interactions: Binding of PTEN to PDZ domains of PTPN13. Methods 77-78:147-156. 
279. Zhu, M.Y., Lin, B., Zhou, P., and Li, M.S. 2015. Molecular Analysis of AFP and HSA Interactions 
with PTEN Protein. Biomed Research International. 
280. Flores-Delgado, G., Liu, C.W., Sposto, R., and Berndt, N. 2007. A limited screen for protein 
interactions reveals new roles for protein phosphatase 1 in cell cycle control and apoptosis. J 
Proteome Res 6:1165-1175. 
281. Xue, B., Dunbrack, R.L., Williams, R.W., Dunker, A.K., and Uversky, V.N. 2010. PONDR-FIT: a 
meta-predictor of intrinsically disordered amino acids. Biochim Biophys Acta 1804:996-1010. 
282. Vacic, V., Uversky, V.N., Dunker, A.K., and Lonardi, S. 2007. Composition Profiler: a tool for 
discovery and visualization of amino acid composition differences. Bmc Bioinformatics 8. 
283. Disfani, F.M., Hsu, W.L., Mizianty, M.J., Oldfield, C.J., Xue, B., Dunker, A.K., Uversky, V.N., 
and Kurgan, L. 2012. MoRFpred, a computational tool for sequence-based prediction and 
characterization of short disorder-to-order transitioning binding regions in proteins. Bioinformatics 
28:i75-i83. 
284. Dinkel, H., Michael, S., Weatheritt, R.J., Davey, N.E., Van Roey, K., Altenberg, B., Toedt, G., 
Uyar, B., Seiler, M., Budd, A., et al. 2012. ELM-the database of eukaryotic linear motifs. Nucleic 
Acids Research 40:D242-D251. 
285. Lee, J.O., Yang, H., Georgescu, M.M., Di Cristofano, A., Maehama, T., Shi, Y., Dixon, J.E., 
Pandolfi, P., and Pavletich, N.P. 1999. Crystal structure of the PTEN tumor suppressor: 
implications for its phosphoinositide phosphatase activity and membrane association. Cell 99:323-
334. 
286. Lee, C.U., Hahne, G., Hanske, J., Bange, T., Bier, D., Rademacher, C., Hennig, S., and Grossmann, 
T.N. 2015. Redox Modulation of PTEN Phosphatase Activity by Hydrogen Peroxide and 
Bisperoxidovanadium Complexes. Angew Chem Int Ed Engl 54:13796-13800. 
287. Ross, A.H., and Gericke, A. 2009. Phosphorylation keeps PTEN phosphatase closed for business. 
Proc Natl Acad Sci U S A 106:1297-1298. 
288. Romero, P., Obradovic, Z., Li, X., Garner, E.C., Brown, C.J., and Dunker, A.K. 2001. Sequence 
complexity of disordered protein. Proteins 42:38-48. 
289. Dunker, A.K., Lawson, J.D., Brown, C.J., Williams, R.M., Romero, P., Oh, J.S., Oldfield, C.J., 
Campen, A.M., Ratliff, C.M., Hipps, K.W., et al. 2001. Intrinsically disordered protein. J Mol 
Graph Model 19:26-59. 
290. Uversky, V.N., Oldfield, C.J., and Dunker, A.K. 2008. Intrinsically disordered proteins in human 
diseases: introducing the D2 concept. Annu Rev Biophys 37:215-246. 
291. Stenson, P.D., Mort, M., Ball, E.V., Howells, K., Phillips, A.D., Thomas, N.S., and Cooper, D.N. 
2009. The Human Gene Mutation Database: 2008 update. Genome Med 1:13. 
292. Cerami, E., Gao, J., Dogrusoz, U., Gross, B.E., Sumer, S.O., Aksoy, B.A., Jacobsen, A., Byrne, 
C.J., Heuer, M.L., Larsson, E., et al. 2012. The cBio cancer genomics portal: an open platform for 
exploring multidimensional cancer genomics data. Cancer Discov 2:401-404. 
293. Gao, J.J., Aksoy, B.A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S.O., Sun, Y.C., Jacobsen, 
A., Sinha, R., Larsson, E., et al. 2013. Integrative Analysis of Complex Cancer Genomics and 
Clinical Profiles Using the cBioPortal. Science Signaling 6. 
294. Kuntzer, J., Eggle, D., Lenhof, H.P., Burtscher, H., and Klostermann, S. 2010. The Roche Cancer 
Genome Database (RCGDB). Hum Mutat 31:407-413. 
 100 
  
295. Mosca, R., Pache, R.A., and Aloy, P. 2012. The Role of Structural Disorder in the Rewiring of 
Protein Interactions through Evolution. Mol Cell Proteomics 11:M111 014969. 
296. Fernandez, S., Genis, L., and Torres-Aleman, I. 2014. A phosphatase-independent gain-of-function 
mutation in PTEN triggers aberrant cell growth in astrocytes through an autocrine IGF-1 loop. 
Oncogene 33:4114-4122. 
297. Chen, Z., Dempsey, D.R., Thomas, S.N., Hayward, D., Bolduc, D.M., and Cole, P.A. 2016. 
Molecular Features of Phosphatase and Tensin Homolog (PTEN) Regulation by C-terminal 
Phosphorylation. J Biol Chem 291:14160-14169. 
298. Espinoza-Fonseca, L.M. 2012. Aromatic residues link binding and function of intrinsically 
disordered proteins. Molecular BioSystems 8:237-246. 
299. Fong, J.H., Shoemaker, B.A., and Panchenko, A.R. 2012. Intrinsic protein disorder in human 
pathways. Mol Biosyst 8:320-326. 
300. Gao J, X.D. 2012. Correlation between posttranslational modification and intrinsic disorder in 
protein. Pac Symp Biocomput.:94-103. 
301. Iakoucheva, L.M., Radivojac, P., Brown, C.J., O'Connor, T.R., Sikes, J.G., Obradovic, Z., and 
Dunker, A.K. 2004. The importance of intrinsic disorder for protein phosphorylation. Nucleic Acids 
Research 32:1037-1049. 
302. Babu, M.M., van der Lee, R., de Groot, N.S., and Gsponer, J. 2011. Intrinsically disordered 
proteins: regulation and disease. Curr Opin Struct Biol 21:432-440. 
303. Cordier, F., Chaffotte, A.F., Terrien, E., Prehaud, C., Theillet, F.X., Delepierre, M., Lafon, M., 
Buc, H., and Wolff, N. 2012. Ordered phosphorylation events in two independent cascades of the 
PTEN C-tail revealed by NMR. J Am Chem Soc. 
304. Salmena, L., Carracedo, A., and Pandolfi, P.P. 2008. Tenets of PTEN tumor suppression. Cell 
133:403-414. 
305. Rahdar, M. 2011. Understanding the nature of PTEN auto-inhibition by its carboxy-terminal tail. 
In Departments of Cell Biology and Pharmacology and Molecular Sciences. Baltimore: Johns 
Hopkins University School of Medicine. 85. 
306. Dyson, H.J., and Wright, P.E. 2002. Coupling of folding and binding for unstructured proteins. 
Current Opinion in Structural Biology 12:54-60. 
307. Fong, J.H., Shoemaker, B.A., Garbuzynskiy, S.O., Lobanov, M.Y., Galzitskaya, O.V., and 
Panchenko, A.R. 2009. Intrinsic Disorder in Protein Interactions: Insights From a Comprehensive 
Structural Analysis. PLoS Comput Biol 5:e1000316. 
308. Dunker, A.K., Cortese, M.S., Romero, P., Iakoucheva, L.M., and Uversky, V.N. 2005. Flexible 
nets. FEBS Journal 272:5129-5148. 
309. Shimizu, K., and Toh, H. 2009. Interaction between Intrinsically Disordered Proteins Frequently 
Occurs in a Human Protein–Protein Interaction Network. Journal of Molecular Biology 392:1253-
1265. 
310. Mohan, A., Oldfield, C.J., Radivojac, P., Vacic, V., Cortese, M.S., Dunker, A.K., and Uversky, 
V.N. 2006. Analysis of molecular recognition features (MoRFs). J Mol Biol 362:1043-1059. 
311. Diella, F., Haslam, N., Chica, C., Budd, A., Michael, S., Brown, N.P., Trave, G., and Gibson, T.J. 
2008. Understanding eukaryotic linear motifs and their role in cell signaling and regulation. 
Frontiers in Bioscience 13:6580-6603. 
312. Stumpf, M., Blokzijl-Franke, S., and den Hertog, J. 2016. Fine-Tuning of Pten Localization and 
Phosphatase Activity Is Essential for Zebrafish Angiogenesis. Plos One 11. 
313. Nguyen, H.N., Afkari, Y., Senoo, H., Sesaki, H., Devreotes, P.N., and Iijima, M. 2014. Mechanism 
of human PTEN localization revealed by heterologous expression in Dictyostelium. Oncogene 
33:5688-5696. 
314. Nguyen, H.N., Yang, J.M., Rahdar, M., Keniry, M., Swaney, K.F., Parsons, R., Park, B.H., Sesaki, 
H., Devreotes, P.N., and Iijima, M. 2015. A new class of cancer-associated PTEN mutations 
defined by membrane translocation defects. Oncogene 34:3737-3743. 
 101 
  
315. Nguyen, H.N., Yang, J.M., Afkari, Y., Park, B.H., Sesaki, H., Devreotes, P.N., and Iijima, M. 2014. 
Engineering ePTEN, an enhanced PTEN with increased tumor suppressor activities. Proceedings 
of the National Academy of Sciences of the United States of America 111:E2684-E2693. 
316. van Duijn, P.W., Ziel-van der Made, A.C.J., van der Korput, J.A.G., and Trapman, J. 2010. PTEN-
Mediated G1 Cell-Cycle Arrest in LNCaP Prostate Cancer Cells Is Associated With Altered 
Expression of Cell-Cycle Regulators. Prostate 70:135-146. 
317. Vazquez, F., Grossman, S.R., Takahashi, Y., Rokas, M.V., Nakamura, N., and Sellers, W.R. 2001. 
Phosphorylation of the PTEN tail acts as an inhibitory switch by preventing its recruitment into a 
protein complex. Journal of Biological Chemistry 276:48627-48630. 
318. Geng, Y., Eaton, E.N., Picon, M., Roberts, J.M., Lundberg, A.S., Gifford, A., Sardet, C., and 
Weinberg, R.A. 1996. Regulation of cyclin E transcription by E2Fs and retinoblastoma protein. 
Oncogene 12:1173-1180. 
319. Tetsu, O., and McCormick, F. 1999. beta-catenin regulates expression of cyclin D1 in colon 
carcinoma cells. Nature 398:422-426. 
320. Neuman, E., Flemington, E.K., Sellers, W.R., and Kaelin, W.G. 1994. Transcription of the E2f-1 
Gene Is Rendered Cell-Cycle Dependent by E2f DNA-Binding Sites within Its Promoter. 
Molecular and Cellular Biology 14:6607-6615. 
321. Wang, S., Nath, N., Fusaro, G., and Chellappan, S. 1999. Rb and prohibitin target distinct regions 
of E2F1 for repression and respond to different upstream signals. Molecular and Cellular Biology 
19:7447-7460. 
322. Rizwani, W., Schaal, C., Kunigal, S., Coppola, D., and Chellappan, S. 2014. Mammalian Lysine 
Histone Demethylase KDM2A Regulates E2F1-Mediated Gene Transcription in Breast Cancer 
Cells. Plos One 9. 
323. Ho, S.N., Hunt, H.D., Horton, R.M., Pullen, J.K., and Pease, L.R. 1989. Site-Directed Mutagenesis 
by Overlap Extension Using the Polymerase Chain-Reaction. Gene 77:51-59. 
324. Boussif, O., Lezoualch, F., Zanta, M.A., Mergny, M.D., Scherman, D., Demeneix, B., and Behr, 
J.P. 1995. A Versatile Vector for Gene and Oligonucleotide Transfer into Cells in Culture and in-
Vivo - Polyethylenimine. Proceedings of the National Academy of Sciences of the United States of 
America 92:7297-7301. 
325. Pathak, R.R., Grover, A., Malaney, P., Quarni, W., Pandit, A., Allen-Gipson, D., and Dave, V. 
2013. Loss of phosphatase and tensin homolog (PTEN) induces leptin-mediated leptin gene 
expression: feed-forward loop operating in the lung. J Biol Chem 288:29821-29835. 
326. V, D., Childs, T., and Whitsett, J.A. 2004. Nuclear factor of activated T cells regulates transcription 
of the surfactant protein D gene (Sftpd) via direct interaction with thyroid transcription factor-1 in 
lung epithelial cells. Journal of Biological Chemistry 279:34578-34588. 
327. Brunner, E., Ahrens, C.H., Mohanty, S., Baetschmann, H., Loevenich, S., Potthast, F., Deutsch, 
E.W., Panse, C., de Lichtenberg, U., Rinner, O., et al. 2007. A high-quality catalog of the 
Drosophila melanogaster proteome. Nat Biotechnol 25:576-583. 
328. Terzidis, A., Sergentanis, T.N., Antonopoulos, G., Syrigos, C., Efremidis, A., Polyzos, A., 
Dessypris, N., and Petridou, E.T. 2009. Elevated serum leptin levels: a risk factor for non-small-
cell lung cancer? Oncology 76:19-25. 
329. Song, C.-H., Liao, J., Deng, Z.-H., Zhang, J.-Y., Xue, H., Li, Y.-M., Liang, C., Han, M., Zhang, 
K., and Yan, G.-T. 2014. Is leptin a predictive factor in patients with lung cancer? Clinical 
Biochemistry 47:230-232. 
330. Ning, K., Miller, L.C., Laidlaw, H.A., Burgess, L.A., Perera, N.M., Downes, C.P., Leslie, N.R., 
and Ashford, M.L. 2006. A novel leptin signalling pathway via PTEN inhibition in hypothalamic 
cell lines and pancreatic beta-cells. EMBO J 25:2377-2387. 
331. Rankin, S.L., Guy, C.S., and Mearow, K.M. 2009. PTEN downregulates p75NTR expression by 
decreasing DNA-binding activity of Sp1. Biochemical and Biophysical Research Communications 
379:721-725. 
 102 
  
332. Trotman, L.C., Wang, X., Alimonti, A., Chen, Z., Teruya-Feldstein, J., Yang, H., Pavletich, N.P., 
Carver, B.S., Cordon-Cardo, C., Erdjument-Bromage, H., et al. 2007. Ubiquitination regulates 
PTEN nuclear import and tumor suppression. Cell 128:141-156. 
333. Seiler, C.Y., Park, J.G., Sharma, A., Hunter, P., Surapaneni, P., Sedillo, C., Field, J., Algar, R., 
Price, A., Steel, J., et al. 2014. DNASU plasmid and PSI: Biology-Materials repositories: resources 
to accelerate biological research. Nucleic Acids Research 42:D1253-D1260. 
334. Cormier, C.Y., Park, J.G., Fiacco, M., Steel, J., Hunter, P., Kramer, J., Singla, R., and LaBaer, J. 
2011. PSI:Biology-materials repository: a biologist's resource for protein expression plasmids. J 
Struct Funct Genomics 12:55-62. 
335. Cormier, C.Y., Mohr, S.E., Zuo, D., Hu, Y., Rolfs, A., Kramer, J., Taycher, E., Kelley, F., Fiacco, 
M., Turnbull, G., et al. 2010. Protein Structure Initiative Material Repository: an open shared public 
resource of structural genomics plasmids for the biological community. Nucleic Acids Res 
38:D743-749. 
336. JavanMoghadam-Kamrani, S., and Keyomarsi, K. 2008. Synchronization of the cell cycle using 
lovastatin. Cell Cycle 7:2434-2440. 
337. Liu, F.T., Patterson, R.J., and Wang, J.L. 2002. Intracellular functions of galectins. Biochimica Et 
Biophysica Acta-General Subjects 1572:263-273. 
338. Viguier, M., Advedissian, T., Delacour, D., Poirier, F., and Deshayes, F. 2014. Galectins in 
epithelial functions. Tissue Barriers 2:e29103. 
339. Yang, R.Y., Rabinovich, G.A., and Liu, F.T. 2008. Galectins: structure, function and therapeutic 
potential. Expert Rev Mol Med 10:e17. 
340. Cay, T. 2012. Immunhistochemical expression of galectin-3 in cancer: a review of the literature. 
Turk Patoloji Derg 28:1-10. 
341. Camby, I., Le Mercier, M., Lefranc, F., and Kiss, R. 2006. Galectin-1: a small protein with major 
functions. Glycobiology 16:137R-157R. 
342. Carlini, M.J., Roitman, P., Nunez, M., Pallotta, M.G., Boggio, G., Smith, D., Salatino, M., Joffe, 
E.D.B.D., Rabinovich, G.A., and Puricelli, L.I. 2014. Clinical relevance of galectin-1 expression 
in non-small cell lung cancer patients. Lung Cancer 84:73-78. 
343. Zhou, X.F., Li, D., Wang, X.G., Zhang, B., Zhu, H., and Zhao, J.P. 2015. Galectin-1 is 
overexpressed in CD133(+) human lung adenocarcinoma cells and promotes their growth and 
invasiveness. Oncotarget 6:3111-3122. 
344. Hsu, Y.L., Wu, C.Y., Hung, J.Y., Lin, Y.S., Huang, M.S., and Kuo, P.L. 2013. Galectin-1 promotes 
lung cancer tumor metastasis by potentiating integrin alpha 6 beta 4 and Notch1/Jagged2 signaling 
pathway. Carcinogenesis 34:1370-1381. 
345. Lee, M.Y., Lee, S.H., Park, J.H., and Han, H.J. 2009. Interaction of galectin-1 with caveolae 
induces mouse embryonic stem cell proliferation through the Src, ERas, Akt and mTOR signaling 
pathways. Cellular and Molecular Life Sciences 66:1467-1478. 
346. Zhang, P.F., Li, K.S., Shen, Y.H., Gao, P.T., Dong, Z.R., Cai, J.B., Zhang, C., Huang, X.Y., Tian, 
M.X., Hu, Z.Q., et al. 2016. Galectin-1 induces hepatocellular carcinoma EMT and sorafenib 
resistance by activating FAK/PI3K/AKT signaling. Cell Death & Disease 7. 
347. Cheung, L.W.T., Walkiewicz, K.W., Besong, T., Hawke, D., Arold, S.T., and Mills, G.B. 2015. 
Regulation of the PI3K pathway through a p85 alpha monomer-homodimer equilibrium. Cancer 
Research 75. 
348. Maki-Nevala, S., Sarhadi, V.K., Ronty, M., Kettunen, E., Husgafvel-Pursiainen, K., Wolff, H., 
Knuuttila, A., and Knuutila, S. 2016. Hot spot mutations in Finnish non-small cell lung cancers. 
Lung Cancer 99:102-110. 
349. Forgacs, E., Biesterveld, E.J., Sekido, Y., Fong, K., Muneer, S., Wistuba, II, Milchgrub, S., 
Brezinschek, R., Virmani, A., Gazdar, A.F., et al. 1998. Mutation analysis of the PTEN/MMAC1 
gene in lung cancer. Oncogene 17:1557-1565. 
 103 
  
350. Cui, M., Augert, A., Rongione, M., Conkrite, K., Parazzoli, S., Nikitin, A.Y., Ingolia, N., and 
MacPherson, D. 2014. PTEN Is a Potent Suppressor of Small Cell Lung Cancer. Molecular Cancer 
Research 12:654-659. 
351. Hesson, L.B., Packham, D., Pontzer, E., Funchain, P., Eng, C., and Ward, R.L. 2012. A 
reinvestigation of somatic hypermethylation at the PTEN CpG island in cancer cell lines. Biological 
Procedures Online 14. 
352. Zhu, D.Y., Li, X.N., Qi, Y., Liu, D.L., Yang, Y., Zhao, J., Zhang, C.Y., Wu, K., and Zhao, S. 2016. 
MiR-454 promotes the progression of human non-small cell lung cancer and directly targets PTEN. 
Biomed Pharmacother 81:79-85. 
353. Yu, T., Liu, L., Li, J., Yan, M.X., Lin, H.C., Liu, Y., Chu, D.D., Tu, H., Gu, A.Q., and Yao, M. 
2015. MiRNA-10a is upregulated in NSCLC and may promote cancer by targeting PTEN. 
Oncotarget 6:30239-30250. 
354. Xie, X., Liu, H.T., Mei, J., Ding, F.B., Xiao, H.B., Hu, F.Q., Hu, R., and Wang, M.S. 2015. miR-
106a promotes growth and metastasis of non-small cell lung cancer by targeting PTEN. Int J Clin 
Exp Pathol 8:3827-3834. 
355. Wang, H., Guan, X., Tu, Y., Zheng, S., Long, J., Li, S., Qi, C., Xie, X., Zhang, H., and Zhang, Y. 
2015. MicroRNA-29b attenuates non-small cell lung cancer metastasis by targeting matrix 
metalloproteinase 2 and PTEN. J Exp Clin Cancer Res 34:59. 
356. Wang, J., Chen, H., Liao, Y., Chen, N., Liu, T., Zhang, H., and Zhang, H. 2015. Expression and 
clinical evidence of miR-494 and PTEN in non-small cell lung cancer. Tumour Biol 36:6965-6972. 
357. Correia, N.C., Girio, A., Antunes, I., Martins, L.R., and Barata, J.T. 2014. The multiple layers of 
non-genetic regulation of PTEN tumour suppressor activity. Eur J Cancer 50:216-225. 
358. Leslie, N.R., and Foti, M. 2011. Non-genomic loss of PTEN function in cancer: not in my genes. 
Trends in Pharmacological Sciences 32:131-140. 
359. Brito, M.B., Goulielmaki, E., and Papakonstanti, E.A. 2015. Focus on PTEN regulation. Frontiers 
in Oncology 5. 
360. Hoaglin, D.C., Iglewicz, B., and Tukey, J.W. 1986. Performance of Some Resistant Rules for 
Outlier Labeling. Journal of the American Statistical Association 81:991-999. 
361. Hoaglin, D.C., and Iglewicz, B. 1987. Fine-Tuning Some Resistant Rules for Outlier Labeling. 
Journal of the American Statistical Association 82:1147-1149. 
362. Chang, C.J., Mulholland, D.J., Valamehr, B., Mosessian, S., Sellers, W.R., and Wu, H. 2008. PTEN 
nuclear localization is regulated by oxidative stress and mediates p53-dependent tumor 
suppression. Molecular and Cellular Biology 28:3281-3289. 
363. He, J.X., Kang, X., Yin, Y.X., Chao, K.S.C., and Shen, W.H. 2015. PTEN regulates DNA 
replication progression and stalled fork recovery. Nature Communications 6. 
364. Wang, G.X., Li, Y., Wang, P., Liang, H., Cui, M., Zhu, M.L., Guo, L.M., Su, Q., Sun, Y.J., McNutt, 
M.A., et al. 2015. PTEN regulates RPA1 and protects DNA replication forks. Cell Research 
25:1189-1204. 
365. Schlacher, K., Guo, W., Jasin, M., and Wu, H. 2014. Novel Role for PTEN in Regulating Non 
Homologous End-Joining Factor 53BP1 to Suppress Replication Fork Instability. Faseb Journal 
28. 
366. Misra, S., Mukherjee, A., and Karmakar, P. 2014. Phosphorylation of PTEN at STT motif is 
associated with DNA damage response. Mutation Research-Fundamental and Molecular 
Mechanisms of Mutagenesis 770:112-119. 
367. Fumarola, C., Bonelli, M.A., Petronini, P.G., and Alfieri, R.R. 2014. Targeting PI3K/AKT/mTOR 
pathway in non small cell lung cancer. Biochemical Pharmacology 90:197-207. 
368. Sarris, E.G., Saif, M.W., and Syrigos, K.N. 2012. The Biological Role of PI3K Pathway in Lung 
Cancer. Pharmaceuticals (Basel) 5:1236-1264. 
369. Panagiotou, I., Tsiambas, E., Lazaris, A.C., Kavantzas, N., Konstantinou, M., Kalkandi, P., Ragkos, 
V., Metaxas, G.E., Roukas, D.K., Vilaras, G., et al. 2012. PTEN expression in non small cell lung 
carcinoma based on digitized image analysis. Journal of Buon 17:719-723. 
 104 
  
370. Kechagioglou, P., Papi, R.M., Provatopoulou, X., Kalogera, E., Papadimitriou, E., Grigoropoulos, 
P., Nonni, A., Zografos, G., Kyriakidis, D.A., and Gounaris, A. 2014. Tumor Suppressor PTEN in 
Breast Cancer: Heterozygosity, Mutations and Protein Expression. Anticancer Research 34:1387-
1400. 
371. Yang, Z., Yuan, X.G., Chen, J., Luo, S.W., Luo, Z.J., and Lu, N.H. 2013. Reduced expression of 
PTEN and increased PTEN phosphorylation at residue Ser380 in gastric cancer tissues: A novel 
mechanism of PTEN inactivation. Clinics and Research in Hepatology and Gastroenterology 
37:72-79. 
372. Roy, D., and Dittmer, D.P. 2011. Phosphatase and Tensin Homolog on Chromosome 10 Is 
Phosphorylated in Primary Effusion Lymphoma and Kaposi's Sarcoma. American Journal of 
Pathology 179:2108-2119. 
373. Lee, E.J., Kim, N., Kang, K.H., and Kim, J.W. 2011. Phosphorylation/inactivation of PTEN by 
Akt-independent PI3K signaling in retinal pigment epithelium. Biochemical and Biophysical 
Research Communications 414:384-389. 
374. Hua, F., Ha, T.Z., Ma, J., Li, Y., Kelley, J., Gao, X., Browder, I.W., Kao, R.L., Williams, D.L., and 
Li, C.F. 2007. Protection against myocardial ischemia/reperfusion injury in TLR4-deficient mice 
is mediated through a phosphoinositide 3-kinase-dependent mechanism. Journal of Immunology 
178:7317-7324. 
375. Horita, H., Furgeson, S.B., Ostriker, A., Olszewski, K.A., Sullivan, T., Villegas, L.R., Levine, M., 
Parr, J.E., Cool, C.D., Nemenoff, R.A., et al. 2013. Selective Inactivation of PTEN in Smooth 
Muscle Cells Synergizes With Hypoxia to Induce Severe Pulmonary Hypertension. Journal of the 
American Heart Association 2. 
376. Collaud, S., Tischler, V., Atanassoff, A., Wiedl, T., Komminoth, P., Oehlschlegel, C., Weder, W., 
and Soltermann, A. 2015. Lung neuroendocrine tumors: correlation of ubiquitinylation and 
sumoylation with nucleo-cytosolic partitioning of PTEN. Bmc Cancer 15. 
377. Song, M.S., Salmena, L., Carracedo, A., Egia, A., Lo-Coco, F., Teruya-Feldstein, J., and Pandolfi, 
P.P. 2008. The deubiquitinylation and localization of PTEN are regulated by a HAUSP-PML 
network. Nature 455:813-U811. 
378. Tachibana, M., Shibakita, M., Ohno, S., Kinugasa, S., Yoshimura, H., Ueda, S., Fujii, T., Rahman, 
M.A., Dhar, D.K., and Nagasue, N. 2002. Expression and prognostic significance of PTEN product 
protein in patients with esophageal squamous cell carcinoma. Cancer 94:1955-1960. 
379. Whiteman, D.C., Zhou, X.P., Cummings, M.C., Pavey, S., Hayward, N.K., and Eng, C. 2002. 
Nuclear PTEN expression and clinicopathologic features in a population-based series of primary 
cutaneous melanoma. International Journal of Cancer 99:63-67. 
380. Perren, A., Komminoth, P., Saremaslani, P., Matter, C., Feurer, S., Lees, J.A., Heitz, P.U., and Eng, 
C. 2000. Mutation and expression analyses reveal differential subcellular compartmentalization of 
PTEN in endocrine pancreatic tumors compared to normal islet cells. American Journal of 
Pathology 157:1097-1103. 
381. Fridberg, M., Servin, A., Anagnostaki, L., Linderoth, J., Berglund, M., Soderberg, O., Enblad, G., 
Rosen, A., Mustelin, T., Jerkeman, M., et al. 2007. Protein expression and cellular localization in 
two prognostic subgroups of diffuse large B-cell lymphoma: Higher expression of ZAP70 and 
PKC-beta II in the non-germinal center group and poor survival in patients deficient in nuclear 
PTEN. Leukemia & Lymphoma 48:2221-2232. 
382. Dillon, L.M., and Miller, T.W. 2014. Therapeutic targeting of cancers with loss of PTEN function. 
Curr Drug Targets 15:65-79. 
383. Nair, J.S., Sheikh, T., Ho, A.L., and Schwartz, G.K. 2013. PTEN regulates sensitivity of melanoma 
cells to RO4929097, the gamma-secretase inhibitor. Anticancer Res 33:1307-1316. 
384. Peng, W.Y., Chen, J.Q., Liu, C.W., Malu, S., Creasy, C., Tetzlaff, M.T., Xu, C.Y., McKenzie, J.A., 
Zhang, C.L., Liang, X.X., et al. 2016. Loss of PTEN Promotes Resistance to T Cell-Mediated 
Immunotherapy. Cancer Discovery 6:202-216. 
 105 
  
385. Jing, W., Li, M., Zhang, Y., Teng, F., Han, A., Kong, L., and Zhu, H. 2016. PD-1/PD-L1 blockades 
in non-small-cell lung cancer therapy. Onco Targets Ther 9:489-502. 
386. Mendes-Pereira, A.M., Martin, S.A., Brough, R., McCarthy, A., Taylor, J.R., Kim, J.S., Waldman, 
T., Lord, C.J., and Ashworth, A. 2009. Synthetic lethal targeting of PTEN mutant cells with PARP 
inhibitors. Embo Molecular Medicine 1:315-322. 
387. Ni, J., Liu, Q., Xie, S., Carlson, C., Von, T., Vogel, K., Riddle, S., Benes, C., Eck, M., Roberts, T., 
et al. 2012. Functional characterization of an isoform-selective inhibitor of PI3K-p110beta as a 
potential anticancer agent. Cancer Discov 2:425-433. 
388. Edgar, K.A., Wallin, J.J., Berry, M., Lee, L.B., Prior, W.W., Sampath, D., Friedman, L.S., and 
Belvin, M. 2010. Isoform-specific phosphoinositide 3-kinase inhibitors exert distinct effects in 
solid tumors. Cancer Res 70:1164-1172. 
389. Chen, H., Mei, L., Zhou, L., Shen, X., Guo, C., Zheng, Y., Zhu, H., Zhu, Y., and Huang, L. 2011. 
PTEN restoration and PIK3CB knockdown synergistically suppress glioblastoma growth in vitro 
and in xenografts. J Neurooncol 104:155-167. 
390. Mendes-Pereira, A.M., Lord, C.J., and Ashworth, A. 2012. NLK Is a Novel Therapeutic Target for 
PTEN Deficient Tumour Cells. Plos One 7. 
391. Masson, G.R., Burke, J.E., and Williams, R.L. 2016. Methods in the Study of PTEN Structure: X-
Ray Crystallography and Hydrogen Deuterium Exchange Mass Spectrometry. Methods Mol Biol 
1388:215-230. 
392. Shenoy, S.S., Nanda, H., and Losche, M. 2012. Membrane association of the PTEN tumor 
suppressor: electrostatic interaction with phosphatidylserine-containing bilayers and regulatory 
role of the C-terminal tail. J Struct Biol 180:394-408. 
393. Hebbar, P.B., and Archer, T.K. 2008. Altered histone H1 stoichiometry and an absence of 
nucleosome positioning on transfected DNA. Journal of Biological Chemistry 283:4595-4601. 
394. Rastogi, S., Joshi, B., Dasgupta, P., Morris, M., Wright, K., and Chellappan, S. 2006. Prohibitin 
facilitates cellular senescence by recruiting specific corepressors to inhibit E2F target genes. 
Molecular and Cellular Biology 26:4161-4171. 
395. Joshi, B., Ko, D., Ordonez-Ercan, D., and Chellappan, S.P. 2003. A putative coiled-coil domain of 
prohibitin is sufficient to repress E2F1-mediated transcription and induce apoptosis. Biochemical 
and Biophysical Research Communications 312:459-466. 
396. Wang, S., Nath, N., Adlam, M., and Chellappan, S. 1999. Prohibitin, a potential tumor suppressor, 
interacts with RB and regulates E2F function. Oncogene 18:3501-3510. 
397. Giambruno, R., Grebien, F., Stukalov, A., Knoll, C., Planyavsky, M., Rudashevskaya, E.L., 
Colinge, J., Superti-Furga, G., and Bennett, K.L. 2013. Affinity Purification Strategies for 
Proteomic Analysis of Transcription Factor Complexes. Journal of Proteome Research 12:4018-
4027. 
 
 
106 
 
 
 
 
APPENDIX A 
Supplementary Data 
 
Table A1: Interaction interfaces for selected PTEN C-tail binding proteins. 
Name of 
protein 
Interaction interface in PTEN Interaction interface in the 
protein 
   
Neprilysin AA 379-385 of PTEN A triple lysine residue in 
cytoplasmic domain 
NHERF1 PDZ binding motif of PTEN Q37 residue in the PDZ1 domain 
NHERF2 PDZ binding motif of PTEN PDZ1 domain 
MSP58 C-terminal region of PTEN (interaction requires 
Thr366) 
Forkhead Association (FHA) 
Domain 
PREX2 C-terminal region of PTEN (not including the 
PDZ domain) 
Pleckstrin Homology (PH) 
domain 
Sharpin Amino and C-terminus of PTEN Ubiquitin Like (UBL) domain 
MAGI-1b PDZ binding motif 2nd PDZ domain 
MAGI-2 PDZ binding motif 2nd PDZ domain 
MAGI-3 PDZ binding motif 2nd PDZ domain 
MAST1 PDZ binding motif PDZ domain 
MAST2 PDZ binding motif PDZ domain 
MAST3 PDZ binding motif PDZ domain 
DLG1 PDZ binding motif 2nd PDZ domain 
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Figure A1: Sequence conservation in PTEN C-tail interacting proteins reflects functionality. (A-M) 
Thirteen representative proteins use conserved domains to interact with the PTEN C-tail indicating that 
PTEN C-tail has evolved in vertebrates to incorporate features that allow it to interact with these proteins. 
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